

03/29/00



JC780 U.S. PTO

3-31-00

Docket No. 57155-D/JPW

A/Boxed

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

HON. COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

March 29, 2000

S I R:

Transmitted herewith for filing are the specification and claims of the patent application of:

Christophe P.G. Gerald, Kenneth A. Jones, James A. Bonini, Beth E. Borowsky, and for
Inventor(s) Douglas A. Craig

DNA Encoding Mammalian Neuropeptide FF (NPFF) Receptors and Uses Thereof
Title of Invention

Also enclosed are:

X 33 sheet(s) of informal X formal drawings.

3 Oath or declaration of Applicant(s).

3 A power of attorney

3 An assignment of the invention to _____

X A Preliminary Amendment

3 A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27.

The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE	
					SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	17 -20	=	0	X	\$ 9.00	\$ 18.00	= \$	\$ -0-
Independent Claims	5 -3	=	2	X	\$ 39.00	\$ 78.00	= \$	\$ 156
Multiple Dependent Claims Presented: <u>X</u> Yes <u> </u> No					\$ 130.00	\$ 260.00	= \$	\$ 260
*If the different in Col. 1 is less than zero, enter "0" in Col. 2					BASIC FEE		\$ 345	\$ 690
					TOTAL FEE		\$	\$ 1,106



JC530 U.S. PTO

09/538036

03/29/00

☒ A check in the amount of \$ 1,106.00 to cover the filing fee.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the following or credit any over-payment to Account No. 03-3125:

☒ Filing fees under 37 C.F.R. §1.16.

☒ Patent application processing fees under 37 C.F.R. §1.17.


☐ The issue fee set in 37 C.F.R. §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. §1.311(b).

☒ Three copies of this sheet are enclosed.

☐ A certified copy of previously filed foreign application No. _____ filed in _____ on _____.
Applicant(s) hereby claim priority based upon this aforementioned foreign application under 35 U.S.C. §119.

☒ Other (identify) 1 loose set of formal drawings, paper copy of sequence listing, computer readable diskette, Statement in Accordance with 37 C.F.R. §1.821(f), Information Disclosure Statement including form PTO-1449, Express Mail Certificate of Mailing bearing label no. EM 525 891 324 US dated March 29, 2000

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald et al.
Serial No. : Not Yet Known
Filed : Herewith
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE FF
(NPFF) RECEPTORS AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
March 29, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT AND INFORMATION DISCLOSURE STATEMENT

Please amend the subject application as follows:

In the claims:

Please cancel claims 2-8, 10, 12-19, 22-25, 27-83, 87-90, 92-199, 202-211, 215-217 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

REMARKS

Claims 1-217 were pending in the subject application. By this Amendment applicants have canceled claims 2-8, 10, 12-19, 22-25, 27-83, 87-90, 92-199, 202-211, 215-217 without prejudice or disclaimer. Accordingly, upon entry of this Amendment claims 1, 9, 11, 20, 21, 26, 84-86, 91, 200, 201, and 212-214 will be pending.

By this Amendment, applicants submit a paper copy and computer readable copy of the nucleotide and/or amino acid sequences disclosed in the application in order to fulfill the requirements

Christophe P.G. Gerald, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 2

of 37 C.F.R. §§1.821 through 1.825 in connection with this application. Applicants submit herewith twenty seven (27) pages of Sequence Listing, in compliance with the requirements of §§1.821 through 1.825, attached hereto as **Exhibit A**.

Applicants also submit herewith a formatted Sequence Listing in a computer readable form which complies with the requirements of 37 C.F.R. §1.824. In addition, applicants submit a Statement in Accordance with 37 C.F.R. §1.821(f), attached hereto as **Exhibit B**, certifying that the computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. §1.821(e) contains the same information which is submitted as "Sequence Listing".

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. § 1.56 and § 1.97 (a)-(b), applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**Exhibit 1**) and which were previously cited in connection with the prosecution of U.S. Serial Numbers 09/405,558, 09/255,368 and 09/161,113 from which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

1. PCT International Publication WO 00/00606, published January 6, 2000;

Christophe P.G. Gerald, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 3


2. European Patent Application EP 0 884 387, published December 16, 1998;
3. Expressed Sequence Tags Database Accession No. AA 449919, published June 4, 1997;
4. Expressed Sequence Tags Database Accession No. AA 449920, published June 4, 1997;
5. Allard, et al., "Mechanisms Underlying the Cardiovascular Responses to Peripheral Administration of NPFF in the Rat", *J. Pharmacol. Exp. Ther.* 274(1): 577-583 (July 1995);
6. Cikoš, et al., "Sequence and Tissue Distribution of a Novel G-Protein-Coupled Receptor Expressed Prominently in Human Placenta," *Biochem. and Biophysical Res. Comm.*, March 16, 1999, 256: 352-356;
7. Devillers, et al., "Characterization of a Potent Agonist for NPFF Receptors: Binding Study on Rat Spinal Cord Membranes" *Neuropharmacology* 33(5): 661-669 (May 1994);
8. Dupouy, et al., "Species Differences in the Localization of Neuropeptide FF Receptors in Rodent and Lagomorph Brain and Spinal Cord" *Peptides* 17(3): 399-405 (1996);
8. Knapp, et al., "Molecular Biology and Pharmacology of Cloned Opioid Receptors" *FASEB J.* 9(7): 516-525 (April 1995); and
9. Payza, et al., "Modulation of Neuropeptide FF Receptors by Guanine Nucleotides and Cations in Membranes of Rat Brain and Spinal Cord" *J. Neurochem.* 60(5): 1894-1899 (May 1993).

Christophe P.G. Gerald, et al.
Serial No.: Not Yet Known
Filed: Herewith
Page 4

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the \$1,106.00 filing fee enclosed herewith, is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. However, should any additional fee be necessary, authorization is hereby given to charge such fee to Deposit Account No. 03-3125.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "John P. White", written over a horizontal line.

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

**Application
for
United States Letters Patent**

To all whom it may concern:

Be it known that we,

**Christophe P.G. Gerald, Kenneth A. Jones, James A. Bonini, Beth E. Borowsky and
Douglas A. Craig
have invented certain new and useful improvements in**

DNA Encoding Mammalian Neuropeptide FF (NPFF) Receptors and Uses Thereof

of which the following is a full, clear and exact description.

**DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF) RECEPTORS
AND USES THEREOF**

BACKGROUND OF THE INVENTION

5

This application is a continuation-in-part of U.S. Serial No. 09/405,558, filed September 24, 1999, which is a continuation-in-part of U.S. Serial No. 09/255,368, filed February 22, 1999, which is a
10 continuation-in-part of U.S. Serial No. 09/161,113, filed September 25, 1998, the contents of both of which are hereby incorporated by reference into the subject application.

15

Throughout this application, various publications are referenced in parentheses by author and year. Full citations for these references may be found at the end of the specification immediately preceding the sequence listings and the claims. The disclosure of these
20 publications in their entireties are hereby incorporated by reference into this application to describe more fully the art to which this invention pertains.

25

Neuroregulators comprise a diverse group of natural products that subserve or modulate communication in the nervous system. They include, but are not limited to, neuropeptides, amino acids, biogenic amines, lipids and lipid metabolites, and other metabolic byproducts. Many
30 of these neuroregulator substances interact with specific cell surface receptors which transduce signals from the outside to the inside of the cell. G-protein coupled receptors (GPCRs) represent a major class of cell surface receptors with which many
35 neurotransmitters interact to mediate their effects. GPCRs are predicted to have seven membrane-spanning domains and are coupled to their effectors via

G-proteins linking receptor activation with intracellular biochemical sequelae such as stimulation of adenylyl cyclase.

5 Neuropeptide FF (NPFF) is an octapeptide isolated from bovine brain in 1985 by Yang and coworkers (1) using antibodies to the molluscan neuropeptide FMRFamide (FMRFa). FMRFamide-like immunoreactivity was observed in rat brain, spinal cord, and pituitary, suggesting
10 the existence of mammalian homologs of the FMRFa family of invertebrate peptides. The isolation of NPFF, named for its N- and C-terminal phenylalanines (also called F8Famide) and a second mammalian peptide, NPAF (also called A18Famide), confirmed the existence of mammalian
15 family of peptides sharing C-terminal sequence homology with FMRFa (1). Molecular cloning has revealed that NPFF and NPAF are encoded by the same gene and cleaved from a common precursor protein (2). Studies of the localization, radioligand binding, and function of
20 NPFF-like peptides (see below) indicate they are neuromodulatory peptides whose effects are likely to be mediated by G protein-coupled receptors (for review, see 3).

25 NPFF, also called "morphine modulating peptide", is an endogenous modulator of opioid systems with effects on morphine analgesia, tolerance, and withdrawal (for review see 3,4). NPFF appears to represent an endogenous "anti-opioid" system in the CNS acting at
30 specific, high-affinity receptors distinct from opiate receptors (5,6). Endogenous NPFF has been suggested to play a role in morphine tolerance: agonists of NPFF precipitate "morphine abstinence syndrome" (i.e. symptoms of morphine withdrawal) in morphine-dependent
35 animals (7,8), while antagonists and anti-NPFF IgG restore morphine sensitivity and ameliorate symptoms of withdrawal (9-12). NPFF antagonists potentially could

be useful as therapeutic agents to prevent the development of morphine tolerance, and to treat opiate addiction. NPFF has also been suggested to participate in the regulation of pain threshold, showing both
5 "anti-opiate" effects and analgesic effects depending on test system and route of administration (for review, see 4). As an anti-opiate, NPFF has been shown to inhibit morphine- and stress-induced analgesia (1, 13, 14, 15), whereas anti-NPFF IgG (which blocks the
10 biological activity of NPFF) potentiates these two phenomena (16, 17). An NPFF antagonist may be clinically useful in potentiating the analgesic effects of morphine, allowing use of lower doses without the development of tolerance. NPFF agonists may also
15 exhibit analgesic activity in some model systems (14, 18, 19). The analgesia elicited by NPFF is typically sensitive to naloxone, indicating that it is mediated by release of endogenous opioid peptides (19, 20). The interaction of NPFF and opioid systems in regulating
20 pain pathways is thus complex and may involve multiple mechanisms and sites of action. NPFF has additional biological activities in accord with its pattern of expression in the nervous system.

25 NPFF peptide localization in rat CNS was examined using specific antibodies ((21-23); see also (3)). The highest levels of NPFF are found in spinal cord and posterior pituitary; pituitary NPFF is believed to originate in the hypothalamus. In the brain,
30 immunoreactive cell bodies are found in two major cell groups: medial hypothalamus (between dorsomedial and ventromedial) and nucleus of the solitary tract. Immunoreactive fibers are observed in lateral septal nucleus, amygdala, hypothalamus, nucleus of solitary
35 tract, ventral medulla, trigeminal complex, and dorsal horn of spinal cord. This localization pattern is consistent with a role for NPFF in sensory processing

and modulation of opioid systems. In addition, its presence in the hypothalamus and other limbic structures could subserve roles in the regulation of appetitive and affective states. In the periphery, NPFF-like immunoreactivity (as well as NPFF binding) has been observed in the heart (24). In addition, injection of NPFF raises blood pressure in rats (24, 25). These observations, combined with the colocalization of NPFF with catecholaminergic neurons in the nucleus of the solitary tract (26), suggest that NPFF is involved in central and peripheral cardiovascular regulation.

The ability of NPFF peptides to modulate the opioid system raised the possibility that NPFF interacts directly with opiate receptors. However, radioligand binding assays using a tyrosine-substituted NPFF analog [¹²⁵I]Y8Fa demonstrate that NPFF acts through specific high affinity binding sites distinct from opiate receptors (27-30) that are sensitive to inhibition by guanine nucleotides (31). The latter observation indicates that NPFF receptors are likely to belong to the superfamily of G protein-coupled receptors which share common structural motifs. However, no reports of cloning NPFF receptors have appeared as yet.

To address the issue of potential degradation of the peptide radioligand, a more stable NPFF analog (called (1DMe)Y8Fa(18)) has also been radioiodinated and the binding characterized in spinal cord membranes (32). The binding was saturable and of high affinity; inhibition of binding with unlabeled NPFF analogs yielded K_i values of 0.16nM and 0.29nM for (1DMe)Y8Fa and NPFF, respectively, with a B_{max} = 15 fmol/mg protein. No inhibition by various opioid compounds (naloxone, morphine, enkephalins, dynorphins, etc.) or other peptides (NPY, SP, CGRP, for examples) was

observed at a concentration of 10 μ M, confirming the specificity of NPFF receptors. Interestingly, the related molluscan peptide FMRFa inhibited the binding of $[^{125}\text{I}](1\text{DMe})\text{Y8Fa}$ with a $K_i = 30$ nM. The effectiveness of FMRFamide and the C-terminal fragment NPFF(6-8) at NPFF receptors suggests an important role for the common C-terminus. Full activity is retained by NPFF (3-8); it has been suggested that although the C-terminus is important for receptor recognition, the N-terminus is necessary for formation of a high-affinity conformation (33).

Allard et al. (29) examined the distribution of NPFF binding sites in rat brain and spinal cord using $[^{125}\text{I}]\text{Y8Fa}$ ($[^{125}\text{I}]\text{YLFQPQRFamide}$). The highest densities were observed in the external layers of dorsal horn of spinal cord, several brainstem nuclei, the suprachiasmatic nucleus, restricted nuclei of the thalamus, and the presubiculum of the hippocampus. Lower densities were seen in central gray, reticular formation, ventral tegmental area, lateral and anterior hypothalamus, medial preoptic area, lateral septum, the head of caudate-putamen and cingulate cortex. No binding was observed in cortex, nucleus accumbens, hippocampus (except in presubiculum) or cerebellum. The localization of NPFF binding sites is in good agreement with the location of the peptide itself, consistent with the binding sites mediating the biological actions of NPFF in these tissues (29, 34, 35). Less is known about the signal transduction pathways activated by NPFF receptors; NPFF was shown to activate adenylyl cyclase in mouse olfactory bulb membranes (36) but no other reports of functional coupling via G proteins have appeared.

Until now, no direct evidence for NPFF receptor subtypes has been reported in mammals. Recent

physiological data suggest complex (biphasic) effects on nociception and antioiate activity of NPFF (for review, see (3, 4)) that could possibly signal the presence of multiple subtypes. Short term ICV injection of NPFF causes a hyperesthetic effect followed by long lasting analgesic effect. Intrathecal NPFF and FMRFa both produce long-lasting analgesia, but subeffective doses caused different modulatory effects on morphine-induced analgesia (F8Fa potentiated, FMRFa decreased). The analgesic effects of NPFF are sensitive to naloxone, suggesting that NPFF receptors may have distinct presynaptic (possibly associated with increase release of opioids) and postsynaptic (anti-opiate) effects mediated by multiple receptors. Little is known of the biological effects of A18Famide, which shares its C-terminal 4 amino acids with NPFF, but the existence of a family of related peptides often is predictive of multiple receptor subtypes.

No nonpeptide agonists or antagonists of NPFF are available, but several useful peptidic analogs have been developed that exhibit increased agonist stability or antagonist activity. For example, desamino Y8Fa (daY8Fa) can antagonize the behavioral effects of NPFF and restore morphine-sensitivity (tail-flick analgesia) to morphine-tolerant rats at lower doses, although at higher doses it can act as NPFF agonist (10) (see also (3)). (1DMe)Y8Fa, in which L-Phe¹ is replaced by D-Tyr and the second peptidic bond is N-methylated, has been shown to inhibit morphine-induced analgesia (18), and has higher affinity and stability than Y8Fa: (1DMe)Y8Fa was 90% stable after 150 min. incubation with rat spinal cord membranes compared with Y8Fa, which was fully degraded after 30 minutes. These analogs may be useful in predicting the effects of agonist or antagonist drugs that would act at NPFF receptors.

Despite the numerous studies linking NPFF with analgesia (for review, see (4)), only recently has NPFF been observed to play a role in animal models of chronic pain. For example, NPFF has recently been shown to be involved in inflammatory pain (37) and neuropathic pain (38). Importantly, NPFF was shown to attenuate the allodynia associated with neuropathic pain, suggesting that it may be clinically useful in treating this condition. In addition to its potential therapeutic roles in the treatment of pain and morphine tolerance ((4) and above), NPFF and related peptides have a number of other biological activities that may be therapeutically relevant. NPFF and FMRFamide have been shown to reduce deprivation- and morphine-induced feeding in rats (39-41), indicating that NPFF receptors may be important targets in the treatment of eating disorders. FMRFamide has also been shown to produce antipsychotic (42) and antianxiety (85) effects in rats, indicating that NPFF receptors may be valuable targets for the treatment of psychosis and anxiety. There is evidence for a role of NPFF in learning and memory. Kavaliers and Colwell (79) have shown that i.c.v. administered NPFF has a biphasic effect of spatial learning in mice: low doses improve and high doses impair learning. This suggests the possibility that different NPFF receptor subtypes may have opposite roles in some types of learning behavior. NPFF is known to have indirect effects on water and electrolyte balance. Arima et al. (86) have shown that NPFF will reduce increase in vasopressin release produced by salt loading or hypovolemia. Additionally, NPFF may be involved in the control of plasma aldosterone levels (87). These observations raise the possibility that agents targeting NPFF receptors may be of value in the treatment of diuresis or in the treatment of cardiovascular conditions such as hypertension and congestive heart failure. Drugs acting at NPFF

receptors may be of value in the treatment of diabetes, since NPFF and A-18-Famide have been shown to produce significant inhibition of glucose- and arginine-induced insulin release in rats (88). Several investigators have reported effects of NPFF and analogs on intestinal motility in mice (89) and guinea pigs (90, 91). When administered to isolated preparations of guinea pig ileum, the actions of NPFF oppose those of opioids. Conversely, i.c.v. administration of NPFF in mice produces effects similar to those of morphine on intestinal motility. Together, these results indicate a complex modulatory role for NPFF in intestinal motility, but indicate that NPFF receptors are potential targets for drugs to treat GI motility disorders, including irritable bowel syndrome. NPFF has been shown to precipitate nicotine abstinence syndrome in a rodent model (43). These authors have raised the possibility that nicotine dependence may be attenuated by measures which inactivate NPFF. Thus, NPFF receptor antagonists may be of use for this purpose. Finally, NPFF is known to elicit two acute cardiovascular responses when administered peripherally: elevation of blood pressure and heart rate (24, 25). These actions may be mediated peripherally, centrally, or both. Thus, agents acting at NPFF receptors may be of value in the treatment of hypertension (also see above) or hypotension. The cloning of NPFF receptors will facilitate the elucidation of the roles of NPFF and related peptides in these and other important biological functions.

Described herein is the isolation and characterization of a new family of neuropeptide FF (NPFF) receptors, referred to herein as the NPFF receptors. Cloned NPFF receptors will serve as invaluable tools for drug design for pathophysiological conditions such as memory loss, affective disorders, schizophrenia, pain,

hypertension, locomotor problems, circadian rhythm disorders, eating/body weight disorders, sexual/reproductive disorders, nasal congestion, diarrhea, gastrointestinal, and cardiovascular disorders. Also described herein are experimental data which indicate that NPFF receptors will be useful targets for the design of drugs to treat disorders of the lower urinary tract, including incontinence and bladder instability.

SUMMARY OF THE INVENTION

This invention provides an isolated nucleic acid encoding a mammalian NPFF receptor.

5

This invention provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 1 (SEQ ID NO: 1) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement. This invention further provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 4 (SEQ ID NO: 3) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement. This invention also provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 7 (SEQ ID NO: 5) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.

10

15

20

25

30

35

5 This invention further provides a nucleic acid encoding
a mammalian NPFF receptor, wherein the nucleic acid (a)
hybridizes to a nucleic acid having the defined
sequence shown in Figure 11 (SEQ ID NO: 7) under low
stringency conditions or a sequence complementary
thereto and (b) is further characterized by its ability
to cause a change in the pH of a culture of CHO cells
when a NPFF peptide is added to the culture and the CHO
cells express the nucleic acid which hybridized to the
10 nucleic acid having the defined sequence or its
complement.

15 This invention further provides a nucleic acid encoding
a mammalian NPFF receptor, wherein the nucleic acid (a)
hybridizes to a nucleic acid having the defined
sequence shown in Figures 22A-C (SEQ ID NO: 43) under
low stringency conditions or a sequence complementary
thereto and (b) is further characterized by its ability
to cause a change in the pH of a culture of CHO cells
when a NPFF peptide is added to the culture and the CHO
cells express the nucleic acid which hybridized to the
20 nucleic acid having the defined sequence or its
complement.

25 This invention also provides a purified mammalian NPFF
receptor protein.

30 This invention further provides a vector comprising a
nucleic acid encoding a mammalian NPFF receptor,
particularly a vector adapted for expression of the
mammalian NPFF receptor in mammalian or non-mammalian
cells.

35 This invention provides a plasmid designated
pEXJ-rNPFF1 (ATCC Accession No. 203184). This
invention also provides a plasmid designated
pWE15-hNPFF1 (ATCC Accession No. 203183). This

invention further provides a plasmid designated pCDNA3.1-hNPFF2b (ATCC Accession No. 203255). This invention still further provides a plasmid designated pCDNA3.1-hNPFF1 (ATCC Accession No. 203605). This invention still further provides a plasmid designated pCDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).

This invention additionally provides a cell comprising a vector which in turn comprises a nucleic acid encoding a mammalian NPFF receptor as well as a membrane preparation isolated from such a cell.

Moreover, this invention provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within one of the two strands of the nucleic acid encoding the mammalian NPFF1 receptor and contained in plasmid pEXJ-rNPFF1 (ATCC Accession No. 203184), plasmid pWE15-hNPFF1 (ATCC Accession No. 203183), plasmid pCDNA3.1-hNPFF2b (ATCC Accession No. 203255), plasmid pCDNA3.1-hNPFF1 (ATCC Accession No. 203605) or plasmid pCDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).

This invention further provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 1 (SEQ ID NO: 1) or (b) the reverse complement thereto.

This invention further provides a nucleic acid probe comprising at least 15 nucleotides, which probe

specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 4 (SEQ ID NO: 3) or (b) the reverse complement thereto.

This invention further provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 7 (SEQ ID NO: 5) or (b) the reverse complement thereto.

This invention further provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 11 (SEQ ID NO: 7) or (b) the reverse complement thereto.

This invention further provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figures 22A-C (SEQ ID NO: 43) or (b) the reverse complement thereto.

This invention still further provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to RNA encoding the mammalian NPFF receptor, so as to prevent translation of the RNA. This invention also provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to genomic DNA encoding a

mammalian NPFF receptor, so as to prevent transcription thereof.

5 This invention further provides an antibody capable of binding to a mammalian NPFF receptor. This invention also provides an agent capable of competitively inhibiting the binding of the antibody to a mammalian NPFF receptor.

10 In addition, this invention provides a pharmaceutical composition comprising (a) an amount of the oligonucleotide described above capable of passing through a cell membrane and effective to reduce expression of a mammalian NPFF receptor and (b) a
15 pharmaceutically acceptable carrier capable of passing through the cell membrane.

This invention also provides a transgenic, nonhuman mammal expressing DNA encoding a mammalian NPFF
20 receptor. This invention also provides a transgenic, nonhuman mammal comprising a homologous recombination knockout of the native mammalian NPFF receptor. This invention further provides a transgenic, nonhuman mammal whose genome comprises antisense DNA
25 complementary to the DNA encoding a mammalian NPFF receptor so placed within the genome as to be transcribed into antisense mRNA which is complementary to mRNA encoding the mammalian NPFF receptor and which hybridizes to mRNA encoding the mammalian NPFF
30 receptor, thereby reducing its translation.

This invention provides a process for identifying a chemical compound which specifically binds to a
35 mammalian NPFF receptor which comprises contacting cells containing DNA encoding and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF

receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian NPFF receptor.

5 This invention further provides a process for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises contacting a membrane preparation from cells transfected with DNA encoding and expressing on their
10 cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian NPFF receptor.

15 This invention provides a process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises separately contacting cells expressing on
20 their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under
25 conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the mammalian NPFF receptor, a decrease in the binding of the second chemical compound to the mammalian NPFF receptor in the presence of the chemical compound
30 indicating that the chemical compound binds to the mammalian NPFF receptor.

This invention further provides a process involving competitive binding for identifying a chemical compound
35 which specifically binds to a mammalian NPFF receptor which comprises separately contacting a membrane fraction from cells expressing on their cell surface

the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second
5 chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the mammalian NPFF receptor, a decrease in the binding of the second chemical compound to the mammalian NPFF receptor in the
10 presence of the chemical compound indicating that the chemical compound binds to the mammalian NPFF receptor.

This invention provides a method of screening a plurality of chemical compounds not known to bind to a
15 mammalian NPFF receptor to identify a compound which specifically binds to the mammalian NPFF receptor, which comprises (a) contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with a compound known to bind specifically to the
20 mammalian NPFF receptor; (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the mammalian NPFF receptor, under conditions permitting binding of compounds known to bind to the mammalian NPFF receptor; (c) determining
25 whether the binding of the compound known to bind to the mammalian NPFF receptor is reduced in the presence of any compound within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so (d) separately
30 determining the binding to the mammalian NPFF receptor of compounds included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the mammalian NPFF receptor.

35 This invention also provides a method of screening a plurality of chemical compounds not known to bind to a mammalian NPFF receptor to identify a compound which

specifically binds to the mammalian NPFF receptor, which comprises (a) contacting a membrane preparation from cells transfected with and expressing DNA encoding a mammalian NPFF receptor with a compound known to bind to the mammalian NPFF receptor; (b) determining whether the binding of a compound known to bind to the mammalian NPFF receptor is reduced in the presence of any compound within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so (c) separately determining the binding to the mammalian NPFF receptor of compounds included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the mammalian NPFF receptor.

Still further, this invention provides a method of detecting expression of a mammalian NPFF receptor by detecting the presence of mRNA coding for the mammalian NPFF receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with a nucleic acid probe under hybridizing conditions, detecting the presence of mRNA hybridizing to the probe, and thereby detecting the expression of the mammalian NPFF receptor by the cell.

This invention provides a method of detecting the presence of a mammalian NPFF receptor on the surface of a cell which comprises contacting the cell with an antibody under conditions permitting binding of the antibody to the receptor, detecting the presence of the antibody bound to the cell, and thereby detecting the presence of the mammalian NPFF receptor on the surface of the cell.

This invention provides a method of determining the physiological effects of varying levels of activity of mammalian NPFF receptors which comprises producing a

transgenic, nonhuman mammal whose levels of mammalian NPFF receptor activity are varied by use of an inducible promoter which regulates mammalian NPFF receptor expression.

5

This invention also provides a method of determining the physiological effects of varying levels of activity of mammalian NPFF receptors which comprises producing a panel of transgenic, nonhuman mammals each expressing a different amount of mammalian NPFF receptor.

10

This invention further provides a method for identifying an antagonist capable of alleviating an abnormality wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor comprising administering a compound to a transgenic, nonhuman mammal as described above and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic, nonhuman mammal as a result of overactivity of a mammalian NPFF receptor, the alleviation of the abnormality identifying the compound as an antagonist. This invention also provides an antagonist identified by this method. This invention still further provides a pharmaceutical composition comprising an antagonist identified by this method and a pharmaceutically acceptable carrier.

15

20

25

30

35

This invention additionally provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor which comprises administering to the subject an effective amount of the preceding pharmaceutical composition containing a mammalian NPFF receptor antagonist, thereby treating the abnormality.

This invention also provides a method for identifying

an agonist capable of alleviating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor comprising administering a compound to a transgenic, nonhuman mammal, and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic, nonhuman mammal, the alleviation of the abnormality identifying the compound as an agonist. This invention also provides an agonist identified by this method. This invention further provides a pharmaceutical composition comprising an agonist identified by this method and a pharmaceutically acceptable carrier. This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor which comprises administering to the subject an effective amount of the preceding pharmaceutical composition containing a mammalian NPFF receptor agonist, thereby treating the abnormality.

This invention provides a method for diagnosing a predisposition to a disorder associated with the activity of a specific mammalian allele which comprises: (a) obtaining DNA of subjects suffering from the disorder; (b) performing a restriction digest of the DNA with a panel of restriction enzymes; (c) electrophoretically separating the resulting DNA fragments on a sizing gel; (d) contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a mammalian NPFF receptor and labeled with a detectable marker; (e) detecting labeled bands which have hybridized to the DNA encoding a mammalian NPFF receptor labeled with a detectable marker to create a unique band pattern specific to the DNA of subjects

suffering from the disorder; (f) preparing DNA obtained for diagnosis by steps (a)-(e); and (g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step (e) and the DNA
5 obtained for diagnosis from step (f) to determine whether the patterns are the same or different and to diagnose thereby predisposition to the disorder if the patterns are the same.

10 This invention provides a method of preparing a purified mammalian NPFF receptor which comprises: (a)culturing cells which express the mammalian NPFF receptor; (b) recovering the mammalian NPFF receptor from the cells; and (c) purifying the mammalian NPFF
15 receptor so recovered.

This invention provides a method of preparing a purified mammalian NPFF receptor which comprises: (a)inserting a nucleic acid encoding the mammalian NPFF
20 receptor into a suitable vector; (b) introducing the resulting vector into a suitable host cell; (c) placing the resulting cell in suitable condition permitting the production of the mammalian NPFF receptor; (d) recovering the mammalian NPFF receptor produced by the
25 resulting cell; and (e) isolating and/or purifying the mammalian NPFF receptor so recovered.

This invention provides a process for determining whether a chemical compound is a mammalian NPFF
30 receptor agonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the compound under conditions permitting the activation of the mammalian NPFF receptor, and detecting an increase in mammalian
35 NPFF receptor activity, so as to thereby determine whether the compound is a mammalian NPFF receptor agonist. This invention also provides a pharmaceutical

composition which comprises an amount of a mammalian NPFF receptor agonist determined by this process effective to increase activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.

5

This invention provides a process for determining whether a chemical compound is a mammalian NPFF receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the compound in the presence of a known mammalian NPFF receptor agonist, under conditions permitting the activation of the mammalian NPFF receptor, and detecting a decrease in mammalian NPFF receptor activity, so as to thereby determine whether the compound is a mammalian NPFF receptor antagonist. This invention also provides a pharmaceutical composition which comprises an amount of a mammalian NPFF receptor antagonist determined by this process effective to reduce activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.

This invention provides a process for determining whether a chemical compound specifically binds to and activates a mammalian NPFF receptor, which comprises contacting cells producing a second messenger response and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the chemical compound under conditions suitable for activation of the mammalian NPFF receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian NPFF receptor. This invention also provides a compound determined by this process. This invention

further provides a pharmaceutical composition which comprises an amount of the compound (a NPFF receptor agonist) determined by this process effective to increase activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.

This invention provides a process for determining whether a chemical compound specifically binds to and inhibits activation of a mammalian NPFF receptor, which comprises separately contacting cells producing a second messenger response and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to activate the mammalian NPFF receptor, and with only the second chemical compound, under conditions suitable for activation of the mammalian NPFF receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the mammalian NPFF receptor. This invention also provides a compound determined by this process. This invention further provides a pharmaceutical composition which comprises an amount of the compound (a mammalian NPFF receptor antagonist) determined by this effective to reduce activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.

This invention provides a method of screening a plurality of chemical compounds not known to activate a mammalian NPFF receptor to identify a compound which

activates the mammalian NPFF receptor which comprises:
(a) contacting cells transfected with and expressing
the mammalian NPFF receptor with the plurality of
compounds not known to activate the mammalian NPFF
receptor, under conditions permitting activation of the
mammalian NPFF receptor; (b) determining whether the
activity of the mammalian NPFF receptor is increased in
the presence of the compounds; and if so (c) separately
determining whether the activation of the mammalian
NPFF receptor is increased by each compound included in
the plurality of compounds, so as to thereby identify
the compound which activates the mammalian NPFF
receptor. This invention also provides a compound
identified by this method. This invention further
provides a pharmaceutical composition which comprises
an amount of the compound (a mammalian NPFF receptor
agonist) identified by this method effective to
increase activity of a mammalian NPFF receptor and a
pharmaceutically acceptable carrier.

This invention provides a method of screening a
plurality of chemical compounds not known to inhibit
the activation of a mammalian NPFF receptor to identify
a compound which inhibits the activation of the
mammalian NPFF receptor, which comprises: (a)
contacting cells transfected with and expressing the
mammalian NPFF receptor with the plurality of compounds
in the presence of a known mammalian NPFF receptor
agonist, under conditions permitting activation of the
mammalian NPFF receptor; (b) determining whether the
activation of the mammalian NPFF receptor is reduced in
the presence of the plurality of compounds, relative to
the activation of the mammalian NPFF receptor in the
absence of the plurality of compounds; and if so (c)
separately determining the inhibition of activation of
the mammalian NPFF receptor for each compound included
in the plurality of compounds, so as to thereby

identify the compound which inhibits the activation of the mammalian NPFF receptor. This invention also provides a compound identified by this method. This invention further provides a pharmaceutical composition which comprises an amount of the compound (a mammalian NPFF receptor antagonist) identified by this process effective to decrease activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor which comprises administering to the subject an amount of a compound which is a mammalian NPFF receptor agonist effective to treat the abnormality.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor which comprises administering to the subject an amount of a compound which is a mammalian NPFF receptor antagonist effective to treat the abnormality.

This invention provides a process for making a composition of matter which specifically binds to a mammalian NPFF receptor which comprises identifying a chemical compound using any of the processes described herein for identifying a compound which binds to and/or activates or inhibits activation of a mammalian NPFF receptor and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof. This invention further provides a process for preparing a pharmaceutical composition which comprises admixing a pharmaceutically acceptable carrier and a pharmaceutically acceptable amount of a chemical

compound identified by any of the processes described herein for identifying a compound which binds to and/or activates or inhibits activation of a mammalian NPFF receptor or a novel structural and functional analog or homolog thereof.

5

BRIEF DESCRIPTION OF THE FIGURES

Figure 1

Nucleotide sequence encoding a rat neuropeptide FF receptor (NPFF1) (SEQ ID NO: 1). In addition, partial 5' and 3' untranslated sequences are shown. In Figure 1, two start (ATG) codons (at positions 73-75 and 148-150) and the stop (TAG) codon (at positions 1369-1371) are underlined.

Figure 2

Deduced amino acid sequence (SEQ ID NO: 2) of the rat neuropeptide FF receptor (NPFF1) encoded by the nucleotide sequence shown Figures 1 (SEQ ID NO: 1).

Figure 3

Deduced amino acid sequence for rat NPFF1 (SEQ ID NO: 2). Seven solid lines designated I-VII located above portions of the sequence indicate the seven putative transmembrane (TM) spanning regions.

Figure 4

Partial coding sequence of human neuropeptide FF receptor (NPFF1) (SEQ ID NO: 3).

Figure 5

Partial deduced amino acid sequence of the human neuropeptide FF (NPFF1) receptor (SEQ ID NO: 4) encoded by the partial nucleotide sequence of Figure 3.

Figure 6

Partial amino acid alignment of rat and human NPFF1. Vertical lines represent identical residues and dots represent similar residues.

Figure 7

Nucleotide sequence of hNPFF2b (SEQ ID NO: 5). The initiating methionine and the stop codon are underlined.

5

Figure 8

Deduced amino acid sequence of human NPFF2b (hNPFF2) (SEQ ID NO: 6) encoded by the nucleotide sequence shown in Figure 7.

10

Figure 9

Deduced amino acid sequence for human hNPFF2 (SEQ ID NO: 6), with potential transmembrane domains underlined.

15

Figure 10

Amino acid alignment of rat NPFF1 and human NPFF2. Vertical lines represent identical residues and dots represent similar residues.

20

Figure Legends

Figure 11

Nucleotide sequence of a human neuropeptide FF receptor (NPFF1) (SEQ ID NO: 7). The initiating methionine (at positions 1-3) and the stop codon (at positions 1291-1293) are underlined.

25

Figure 12

Deduced amino acid sequence of the human neuropeptide FF receptor (NPFF1) (SEQ ID NO: 8).

30

Figure 13

Deduced amino acid sequence for human NPFF1 (SEQ ID NO: 8). Seven solid lines designated I-VII indicate the seven putative transmembrane (TM) spanning regions.

35

Figure 14

Amino acid alignment of the human NPFF1 and human NPFF2 receptors. Vertical lines represent identical residues and dots represent similar residues.

Figure 15A-15C

Electrophysiological responses to NPFF and related peptides from voltage clamped oocytes expressing NPFF1 and chimeric G-protein.

Figures 16A-16C

Electrophysiological responses in voltage-clamped oocytes expressing NPFF2 mRNA. **Figure 16A:** Oocyte injected with NPFF2 mRNA (from ligation PCR) generates an inward current in response to NPFF at 1 μ M. **Figure 16B:** In a different oocyte, no response is observed when challenged with a mixture of galanin, NPY, orexin A and neurokinin A, each at 1 μ M. A subsequent application of NPFF elicits a response. **Figure 16C:** Oocyte injected with NPFF2 mRNA (from BO89) generates an inward current in response to NPFF at 1 μ M. Oocytes were clamped at a holding potential of -80mV.

Figures 17A and 17B

Microphysiometric response of CHO cells transiently transfected with either NPFF1 (SN2) alone or NPFF1 accompanied by Gq/Gz. **Figure 17A:** Cells expressing either NPFF1 alone or NPFF1+Gq/Gz produced a dose-dependent response to NPFF with an EC50 value of 19.3 nM and 27.7 nM respectively. Mock control cells transfected with empty vector produced little if any response to NPFF even at the highest concentrations used. **Figure 17B:** Cells expressing NPFF1 alone produced a dose-dependent response to A-18-F-amide with an EC50 value of 150nM. In both Figures 17A and 17B

control cells mock transfected with empty vector produced little if any response to drug even at the highest concentrations used. Responses are reported as percentage increase in the acidification rate as observed just prior to drug challenge (immediate prior basal rate).

Figures 18A and 18B

NPFF stimulation of Inositol phosphate release in NPFF-1 transfected Cos-7 cells. **Figure 18A:** Cos-7 cells were transiently transfected with NPFF-1 receptor cDNA. **Figure 18B:** Cos-7 cells were transiently co-transfected with cDNAs for the NPFF-1 receptor and the Gq/Gz chimera. The accumulation of total inositol phosphate release was measured by prelabelling cells with [³H]myoinositol (2μCi/ml) overnight. Cells were washed to remove unincorporated radioactivity and resuspended in medium containing 10mM LiCl. [³H]myoinositol labeled cells were incubated with appropriate drugs for 1hr at 37°C. The reaction was stopped by addition of 5% TCA and IPs were isolated by ion exchange chromatography (Berridge et al., 1982). Columns were washed with water and total [³H] inositol phosphates were then eluted with 1M ammonium formate/0.1 M formic acid. Radioactivity in the final fraction was measured by liquid scintillation spectroscopy. Cells were either treated with vehicle (water, control) or cholera toxin (CTX; 1 μg/ml) or pertussis toxin (PTX, 100 ng/ml) overnight. Data are from one experiment representative of at least one other.

Figure 19

RT-PCR was performed as described on a panel of mRNA extracted from rat tissue as indicated at the bottom of the gel. After amplification, PCR reactions were size

fractionated on 10% polyacrylamide gels, and stained with SYBR Green I. Images were analyzed using a Molecular Dynamics Storm 860 workstation. The amplified band corresponding to NPFF1 (490 base pairs) is indicated (arrow). RT-PCR indicates a broad distribution of mRNA encoding NPFF1 with highest concentrations found in nervous system structures.

Figure 20

Autoradiograph demonstrating hybridization of radiolabeled rat NPFF1 probe to RNA extracted from rat tissue in a solution hybridization/nuclease protection assay using ^{32}P labeled riboprobe. 2 μg of RNA was used in each assay. The single band (arrow) represents mRNA coding for the NPFF1 receptors extracted from the indicated tissue. Highest levels of mRNA coding for NPFF1 are found in: hypothalamus and pituitary gland. The smaller bands representing NPFF1 mRNA from the pituitary, adrenal gland, and ovary (double arrow) may indicate a splice variant present in this tissue. Integrity of RNA was assessed using hybridization to mRNA coding for GAPDH (not shown).

Figure 21

RT-PCR was performed as described on a panel of mRNA extracted from tissue as indicated at the bottom of the gel. After amplification, PCR reactions were size fractionated on 10% polyacrylamide gels, and stained with SYBR Green I. Images were analyzed using a Molecular Dynamics Storm 860 workstation. The amplified band corresponding to NPFF2 receptors (approximately 325 base pairs) is indicated (arrow). RT-PCR indicates a broad distribution of mRNA encoding NPFF2 receptors. The only tissue containing mRNA coding for NPFF2 receptors were HeLa cells and Jurkat cells.

Figures 22A-22C

Nucleotide sequence encoding a rat neuropeptide FF receptor (NPFF2) (SEQ ID NO: 43). In addition, partial 5' and 3' untranslated sequences are shown. Two start (ATG) codons (at positions 26-28 and 128-130) and the stop (TAG) codon (at positions 1277-1279) are underlined.

Figures 23A and 23B

Deduced amino acid sequence of the rat neuropeptide FF receptor (NPFF2) (SEQ ID NO: 44) encoded by the nucleotide sequence shown in Figures 22A-22C. Seven putative transmembrane spanning regions are indicated by underlining.

Figures 24A and 24B

Amino acid alignment of human NPFF2 and rat NPFF2. Vertical lines represent identical residues and dots represent similar residues.

Figures 25A and 25B

Amino acid alignment of rat NPFF1 and rat NPFF2. Vertical lines represent identical residues and dots represent similar residues.

Figure 26

Inhibition of distension-induced rhythmic contractions of the bladder in an anesthetized rat by NPFF (1.0 mg/kg) administered intravenously.

Figure 27

Effect of saline, frog pancreatic polypeptide (fPP), and increasing concentrations of NPFF on the disappearance time of the bladder contractions in the distension-induced rhythmic contraction model of micturition in anesthetized rats. Presented are the

mean values \pm sem from experiments on "n" different rats.

Figure 28

- 5 Inhibition of distension-induced rhythmic contractions of the bladder in an anesthetized rat by frog Pancreatic Polypeptide (fPP) (0.3 mg/kg) administered intravenously.

Figure 28 shows the effect of fPP on the rhythmic contractions of the bladder in an anesthetized rat. The graph displays the amplitude of the contractions over time. The control curve shows a series of rhythmic contractions with a peak amplitude of approximately 1.0. The administration of fPP (0.3 mg/kg) intravenously results in a significant inhibition of the contractions, with the amplitude dropping to near zero.

DETAILED DESCRIPTION OF THE INVENTION

Throughout this application, the following standard abbreviations are used to indicate specific nucleotide bases:

- 5
- A = adenine
- G = guanine
- C = cytosine
- T = thymine
- 10 U = uracil
- M = adenine or cytosine
- R = adenine or guanine
- W = adenine, thymine, or uracil
- S = cytosine or guanine
- 15 Y = cytosine, thymine, or uracil
- K = guanine, thymine, or uracil
- V = adenine, cytosine, or guanine (not thymine or uracil)
- H = adenine, cytosine, thymine, or uracil (not guanine)
- 20 D = adenine, guanine, thymine, or uracil (not cytosine)
- B = cytosine, guanine, thymine, or uracil (not adenine)
- 25 N = adenine, cytosine, guanine, thymine, or uracil (or other modified base such as inosine)
- I = inosine

30 Furthermore, the term "agonist" is used throughout this application to indicate any peptide or non-peptidyl compound which increases the activity of any of the polypeptides of the subject invention. The term "antagonist" is used throughout this application to

35 indicate any peptide or non-peptidyl compound which decreases the activity of any of the polypeptides of the subject invention.

The activity of a G-protein coupled receptor such as the polypeptides disclosed herein may be measured using any of a variety of functional assays in which activation of the receptor in question results in an observable change in the level of some second messenger system, including, but not limited to, adenylate cyclase, calcium mobilization, arachidonic acid release, ion channel activity, inositol phospholipid hydrolysis or guanylyl cyclase. Heterologous expression systems utilizing appropriate host cells to express the nucleic acid of the subject invention are used to obtain the desired second messenger coupling. Receptor activity may also be assayed in an oocyte expression system.

It is possible that the mammalian NPFF receptor genes contain introns and furthermore, the possibility exists that additional introns could exist in coding or non-coding regions. In addition, spliced form(s) of mRNA may encode additional amino acids either upstream of the currently defined starting methionine or within the coding region. Further, the existence and use of alternative exons is possible, whereby the mRNA may encode different amino acids within the region comprising the exon. In addition, single amino acid substitutions may arise via the mechanism of RNA editing such that the amino acid sequence of the expressed protein is different than that encoded by the original gene. (Burns et al., 1996 (82); Chu et al., 1996 (83)). Such variants may exhibit pharmacologic properties differing from the polypeptide encoded by the original gene.

This invention provides splice variants of the mammalian NPFF receptors disclosed herein. This invention further provides for alternate translation initiation sites and alternately spliced or edited

variants of nucleic acids encoding the mammalian NPFF receptors of this invention.

5 The nucleic acids of the subject invention also include nucleic acid analogs of the rat and human NPFF receptor genes, wherein the rat NPFF1 receptor gene comprises the nucleic acid sequence shown in Fig. 1 or contained in plasmid pEXJ-rNPFF1 (ATCC Accession No. 203184); the human NPFF1 receptor gene comprises the nucleic acid
10 shown in Figure 4 and contained in plasmid pWE15-hNPFF1 (ATCC Accession No. 203183); the human NPFF2 receptor gene comprises the nucleic acid shown in Figure 7 and contained in plasmid pCDNA3.1-hNPFF2b (ATCC Accession No.203255); the human NPFF1 receptor gene comprises
15 the nucleic acid shown in Figure 11 and contained in plasmid pCDNA3.1-hNPFF1 (ATCC Accession No.203605); or the rat NPFF2 receptor gene comprises the nucleic acid shown in Figures 22A-22C and contained in plasmid pCDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-
20 535). Nucleic acid analogs of the rat and human NPFF receptor genes differ from the rat and human NPFF receptor genes described herein in terms of the identity or location of one or more nucleic acid bases (deletion analogs containing less than all of the
25 nucleic acid bases shown in Figs. 1, 4, 7, 11 or 22A-C or contained in plasmids pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or pCDNA3.1-rNPFF2-f respectively, substitution analogs wherein one or more nucleic acid bases shown in Figs. 1, 4, 7, 11 or 22A-C
30 or contained in plasmids pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or pCDNA3.1-rNPFF2-f respectively, are replaced by other nucleic acid bases, and addition analogs, wherein one or more nucleic acid bases are added to a terminal or medial portion of the
35 nucleic acid sequence) and which encode proteins which share some or all of the properties of the proteins encoded by the nucleic acid sequences shown in Figs. 1,

4, 7, 11 or 22A-C or contained in plasmids pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or pCDNA3.1-rNPFF2-f respectively. In one embodiment of the present invention, the nucleic acid analog encodes
5 a protein which has an amino acid sequence identical to that shown in Fig. 2, 5 8, 12 or 23A-B or encoded by the nucleic acid sequence contained in plasmids pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or pCDNA3.1-rNPFF2-f respectively. In
10 another embodiment, the nucleic acid analog encodes a protein having an amino acid sequence which differs from the amino acid sequences shown in Fig. 2, 5, 8, 12 or 23A-B or encoded by the nucleic acid contained in plasmids pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f respectively. In
15 a further embodiment, the protein encoded by the nucleic acid analog has a function which is the same as the function of the receptor proteins having the amino acid sequence shown in Fig. 2, 5, 8, 12 or 23A-B. In another embodiment, the function of the protein encoded by the nucleic acid analog differs from the function of the receptor protein having the amino acid sequence shown in Fig. 2, 5, 8, 12 or 23A-B. In another embodiment, the variation in the nucleic acid sequence occurs within the transmembrane (TM) region of the protein. In a further embodiment, the variation in the
20 nucleic acid sequence occurs outside of the TM region.

This invention provides the above-described isolated
30 nucleic acid, wherein the nucleic acid is DNA. In an embodiment, the DNA is cDNA. In another embodiment, the DNA is genomic DNA. In still another embodiment, the nucleic acid is RNA. Methods for production and manipulation of nucleic acid molecules are well known
35 in the art.

This invention further provides nucleic acid which is

degenerate with respect to the DNA encoding any of the polypeptides described herein. In an embodiment, the nucleic acid comprises a nucleotide sequence which is degenerate with respect to the nucleotide sequence shown
5 in Figures 1 (SEQ ID NO: 1), 4 (SEQ ID NO: 3), 7 (SEQ ID NO: 5), 11 (SEQ ID NO: 7) or 22A-C (SEQ ID NO: 43) or the nucleotide sequence contained in the plasmids pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or pCDNA3.1-rNPFF2-f respectively,
10 that is, a nucleotide sequence which is translated into the same amino acid sequence.

This invention also encompasses DNAs and cDNAs which encode amino acid sequences which differ from those of
15 the polypeptides of this invention, but which should not produce phenotypic changes. Alternately, this invention also encompasses DNAs, cDNAs, and RNAs which hybridize to the DNA, cDNA, and RNA of the subject invention. Hybridization methods are well known to
20 those of skill in the art.

The nucleic acids of the subject invention also include nucleic acid molecules coding for polypeptide analogs, fragments or derivatives of antigenic polypeptides
25 which differ from naturally-occurring forms in terms of the identity or location of one or more amino acid residues (deletion analogs containing less than all of the residues specified for the protein, substitution analogs wherein one or more residues specified are
30 replaced by other residues and addition analogs wherein one or more amino acid residues is added to a terminal or medial portion of the polypeptides) and which share some or all properties of naturally-occurring forms. These molecules include: the incorporation of codons
35 "preferred" for expression by selected non-mammalian hosts; the provision of sites for cleavage by restriction endonuclease enzymes; and the provision of

additional initial, terminal or intermediate DNA sequences that facilitate construction of readily expressed vectors. The creation of polypeptide analogs is well known to those of skill in the art (R.F. Spurney et al. (1997); Fong, T.M. et al. (1995); Underwood, D.J. et al. (1994); Graziano, M.P. et al. (1996); Guam X.M. et al. (1995)).

The modified polypeptides of this invention may be transfected into cells either transiently or stably using methods well-known in the art, examples of which are disclosed herein. This invention also provides for binding assays using the modified polypeptides, in which the polypeptide is expressed either transiently or in stable cell lines. This invention further provides a compound identified using a modified polypeptide in a binding assay such as the binding assays described herein.

The nucleic acids described and claimed herein are useful for the information which they provide concerning the amino acid sequence of the polypeptide and as products for the large scale synthesis of the polypeptides by a variety of recombinant techniques. The nucleic acid molecule is useful for generating new cloning and expression vectors, transformed and transfected prokaryotic and eukaryotic host cells, and new and useful methods for cultured growth of such host cells capable of expression of the polypeptide and related products.

This invention provides an isolated nucleic acid encoding a mammalian NPFF receptor. In one embodiment, the nucleic acid is DNA. In another embodiment, the DNA is cDNA. In another embodiment, the DNA is genomic DNA. In another embodiment, the nucleic acid is RNA.

In one embodiment, the mammalian NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF1 receptor is a human NPFF1 receptor. In a further embodiment, the mammalian NPFF receptor is a NPFF2 receptor. In one embodiment, the mammalian NPFF2 receptor is a human NPFF2 receptor. In another embodiment, the mammalian NPFF2 receptor is a rat NPFF2 receptor.

This invention also provides an isolated nucleic acid encoding species homologs of the NPFF receptors encoded by the nucleic acid sequence shown in Figs. 1 (SEQ ID NO: 1), 4 (SEQ ID NO: 3), 7 (SEQ ID NO: 5), 11 (SEQ ID NO: 7) or 22A-C (SEQ ID NO: 43) encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or pCDNA3.1-rNPFF2-f respectively. In one embodiment, the nucleic acid encodes a mammalian NPFF receptor homolog which has substantially the same amino acid sequence as does the NPFF receptor encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f. In another embodiment, the nucleic acid encodes a mammalian NPFF receptor homolog which has above 65% amino acid identity to the NPFF receptor encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f; preferably above 75% amino acid identity to the NPFF receptor encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f; more preferably above 85% amino acid identity to the NPFF receptor encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f; most preferably above 95% amino acid identity to the NPFF receptor encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1, or

pcDNA3.1-rNPFF2-f. In another embodiment, the mammalian NPFF receptor homolog has above 70% nucleic acid identity to the NPFF receptor gene contained in plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pcDNA3.1-hNPFF2b, 5 pcDNA3.1-hNPFF1 or pcDNA3.1-rNPFF2-f; preferably above 80% nucleic acid identity to the NPFF receptor gene contained in the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pcDNA3.1-hNPFF2b, pcDNA3.1-hNPFF1 or pcDNA3.1-rNPFF2-f; more preferably above 90% nucleic acid identity to the NPFF receptor gene contained in 10 the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pcDNA3.1-hNPFF2b, pcDNA3.1-hNPFF1 or pcDNA3.1-rNPFF2-f. Examples of methods for isolating and purifying species homologs are described elsewhere (e.g., U.S. Patent No. 5,602,024, WO94/14957, 15 WO97/26853, WO98/15570).

In separate embodiments of the present invention, the nucleic acid encodes a NPFF receptor which has an amino acid sequence identical to that encoded by the plasmid 20 pEXJ-rNPFF1, pWE15-hNPFF1, pcDNA3.1-hNPFF2b, pcDNA3.1-hNPFF1 or pcDNA3.1-rNPFF2-f. In further embodiments, the NPFF receptor has a sequence substantially the same as the amino acid sequence shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO: 4), 25 Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8) or Figure 23A-B (SEQ ID NO: 44). In other embodiments, the NPFF receptor has an amino acid sequence identical to the amino acid sequence shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO: 4), Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8) or Figure 23A-B (SEQ ID NO: 44). 30

This invention provides an isolated nucleic acid 35 encoding a modified mammalian NPFF receptor, which differs from a mammalian NPFF receptor by having an amino acid(s) deletion, replacement, or addition in the

third intracellular domain.

5 This invention provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 1 (SEQ ID No: 1) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement. This invention further provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 4 (SEQ ID NO: 3) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement. This invention also provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 7 (SEQ ID NO: 5) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.

35 This invention further provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined

sequence shown in Figure 11 (SEQ ID NO: 7) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.

This invention further provides a nucleic acid encoding a mammalian NPFF receptor, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figures 22A-22C (SEQ ID NO: 43) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.

In one embodiment, the mammalian NPFF receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF receptor is a human NPFF1 receptor. In a further embodiment, the mammalian NPFF receptor is a human NPFF2 receptor. In a further embodiment, the mammalian NPFF receptor is a rat NPFF2 receptor. For purpose of the invention hybridization under low stringency conditions means hybridization performed at 40°C in a hybridization buffer containing 25% formamide, 5X SCC, 7mM Tris, 1X Denhardt's, 25µl/ml salmon sperm DNA. Wash at 40°C in 0.1X SCC, 0.1% SDS. Changes in pH are measured through microphysiometric measurement of receptor mediated extracellular acidification rates. Because cellular metabolism is intricately involved in a broad range of cellular events (including receptor activation of multiple messenger pathways), the use of

microphysiometric measurements of cell metabolism can in principle provide a generic assay of cellular activity arising from the activation of any receptor regardless of the specifics of the receptor's signaling pathway. General guidelines for transient receptor expression, cell preparation and microphysiometric recording are described elsewhere (Salon, J.A. and Owicki, J.A., 1996). Receptors and/or control vectors are transiently expressed in CHO-K1 cells, by liposome mediated transfection according to the manufacturers recommendations (LipofectAMINE, GibcoBRL, Gaithersburg, MD), and maintained in Ham's F-12 complete (10% serum). A total of 10 μ g of DNA is used to transfect each 75cm² flask which had been split 24 hours prior to the transfection and judged to be 70-80% confluent at the time of transfection. 24 hours post transfection, the cells are harvested and 3 x 10⁵ cells seeded into microphysiometer capsules. Cells are allowed to attach to the capsule membrane for an additional 24 hours; during the last 16 hours, the cells are switched to serum-free F-12 complete to minimize ill-defined metabolic stimulation caused by assorted serum factors. On the day of the experiment the cell capsules are transferred to the microphysiometer and allowed to equilibrate in recording media (low buffer RPMI 1640, no bicarbonate, no serum (Molecular Devices Corporation, Sunnyvale, CA) containing 0.1% fatty acid free BSA), during which a baseline measurement of basal metabolic activity is established. A standard recording protocol specifies a 100 μ l/min flow rate, with a 2 min total pump cycle which includes a 30 sec flow interruption during which the acidification rate measurement is taken. Ligand challenges involve a 1 min 20 sec exposure to the sample just prior to the first post challenge rate measurement being taken, followed by two additional pump cycles for a total of 5 min 20 sec sample exposure. Typically, drugs in a

primary screen are presented to the cells at 10 μ M final concentration. Ligand samples are then washed out and the acidification rates reported are expressed as a percentage increase of the peak response over the baseline rate observed just prior to challenge. Endogenous NPFF peptides include rat NPFF (FLFQPQRF-NH₂) (SEQ ID NO: 45) and rat A18Fa (AGEGLSSPFWSLAAPQRF-NH₂) (SEQ ID NO: 46).

This invention provides a purified mammalian NPFF receptor protein. In one embodiment, the purified mammalian NPFF receptor protein is a human NPFF1 receptor protein. In another embodiment, the purified mammalian NPFF receptor protein is a rat NPFF1 receptor protein. In a further embodiment, the purified mammalian NPFF receptor protein is a human NPFF2 receptor protein. In a further embodiment, the purified mammalian NPFF receptor protein is a rat NPFF2 receptor protein.

This invention provides a vector comprising nucleic acid encoding a mammalian NPFF receptor. In one embodiment, the mammalian NPFF receptor protein is a NPFF1 receptor protein. In another embodiment of the present invention the mammalian NPFF receptor protein is a NPFF2 receptor protein. In one embodiment, the mammalian NPFF receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF receptor is a human NPFF1 receptor. In a further embodiment, the mammalian NPFF receptor is a human NPFF2 receptor. In a further embodiment, the purified mammalian NPFF receptor protein is a rat NPFF2 receptor.

In an embodiment, the vector is adapted for expression in a cell which comprises the regulatory elements necessary for expression of the nucleic acid in the cell operatively linked to the nucleic acid encoding

the mammalian NPFF receptor as to permit expression thereof. In separate embodiments, the cell is a bacterial cell, an amphibian cell, a yeast cell, an insect cell or a mammalian cell. In another embodiment, the vector is a baculovirus. In one embodiment, the vector is a plasmid.

This invention provides a plasmid designated pEXJ-rNPFF1 (ATCC Accession No. 203184). This plasmid comprises the regulatory elements necessary for expression of DNA in a mammalian cell operatively linked to DNA encoding the mammalian NPFF1 receptor so as to permit expression thereof. This invention also provides a plasmid designated pWE15-hNPFF1 (ATCC Accession No. 203183). This invention further provides a plasmid designated pCDNA3.1-hNPFF2b (ATCC Accession No. 203255). This invention additionally provides a plasmid designated pCDNA3.1-hNPFF1 (ATCC Accession No. 203605). This invention additionally provides a plasmid designated pCDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).

These plasmids (pEXJ-rNPFF1 and pWE15-hNPFF1) were deposited on September 9, 1998, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and were accorded ATCC Accession Nos. 203184 and 203183, respectively. Plasmid pCDNA3.1-hNPFF2b was deposited on September 22, 1998, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Accession No. 203255. Plasmid

pcDNA3.1-hNPFF1 was deposited on January 21, 1999, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and was accorded ATCC Accession No. 203605. Plasmid pcDNA3.1-rNPFF2-f was deposited on August 17, 1999, with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, Virginia 20110-2209, U.S.A. under the provisions of the Budapest Treaty for the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and was accorded Patent Deposit Designation No. PTA-535.

15

This invention further provides for any vector or plasmid which comprises modified untranslated sequences, which are beneficial for expression in desired host cells or for use in binding or functional assays. For example, a vector or plasmid with untranslated sequences of varying lengths may express differing amounts of the polypeptide depending upon the host cell used. In an embodiment, the vector or plasmid comprises the coding sequence of the polypeptide and the regulatory elements necessary for expression in the host cell.

25

This invention provides a cell comprising a vector comprising a nucleic acid encoding the mammalian NPFF receptor. In an embodiment, the cell is a non-mammalian cell. In a further embodiment, the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell. In another embodiment, the cell is a mammalian cell. In a further embodiment, the mammalian cell is a COS-7 cell, a 293 human embryonic kidney cell (HEK-293 cell), a NIH-3T3 cell, a LM(tk-)

35

cell, a mouse Y1 cell, or a CHO cell.

5 This invention provides an insect cell comprising a vector adapted for expression in an insect cell which comprises a nucleic acid encoding a mammalian NPFF receptor. In another embodiment, the insect cell is an Sf9 cell, an Sf21 cell or a Trichoplusia ni 5B1-4 (HighFive) cell.

10 This invention provides a membrane preparation isolated from any one of the cells described above.

15 This invention provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within one of the two strands of the nucleic acid encoding the mammalian NPFF receptor and are contained in plasmid pEXJ-rNPFF1, 20 plasmid pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f. This invention also provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe 25 has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 1 (SEQ ID NO: 1) or (b) the reverse complement thereto. This invention also provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a 30 mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 4 (SEQ ID NO: 3) or (b) the reverse complement thereto. This 35 invention also provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian

NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figure 7 (SEQ ID NO: 5) or (b) the reverse complement thereto. This invention
5 also provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor, wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid
10 sequence shown in Figure 11 (SEQ ID NO: 7) or (b) the reverse complement thereto. This invention also provides a nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian NPFF receptor,
15 wherein the probe has a unique sequence corresponding to a sequence present within (a) the nucleic acid sequence shown in Figures 22A-22C (SEQ ID NO: 43) or (b) the reverse complement thereto. In one embodiment, the nucleic acid is DNA. In another embodiment, the
20 nucleic acid is RNA.

As used herein, the phrase "specifically hybridizing" means the ability of a nucleic acid molecule to recognize a nucleic acid sequence complementary to its
25 own and to form double-helical segments through hydrogen bonding between complementary base pairs.

Nucleic acid probe technology is well known to those skilled in the art who will readily appreciate that
30 such probes may vary greatly in length and may be labeled with a detectable label, such as a radioisotope or fluorescent dye, to facilitate detection of the probe. DNA probe molecules may be produced by insertion of a DNA molecule which encodes the
35 polypeptides of this invention into suitable vectors, such as plasmids or bacteriophages, followed by transforming into suitable bacterial host cells,

replication in the transformed bacterial host cells and harvesting of the DNA probes, using methods well known in the art. Alternatively, probes may be generated chemically from DNA synthesizers.

5

RNA probes may be generated by inserting the DNA molecule which encodes the polypeptides of this invention downstream of a bacteriophage promoter such as T3, T7, or SP6. Large amounts of RNA probe may be produced by incubating the labeled nucleotides with the linearized fragment where it contains an upstream promoter in the presence of the appropriate RNA polymerase.

15 This invention provides an antisense oligonucleotide having a sequence capable of specifically hybridizing to RNA encoding a mammalian NPFF receptor, so as to prevent translation of the RNA. This invention also provides an antisense oligonucleotide having a sequence
20 capable of specifically hybridizing to genomic DNA encoding a mammalian NPFF receptor, so as to prevent translation of the genomic DNA. In one embodiment, the oligonucleotide comprises chemically modified nucleotides or nucleotide analogues.

25

This invention provides an antibody capable of binding to a mammalian NPFF receptor encoded by a nucleic acid encoding a mammalian NPFF receptor. In one embodiment, the mammalian NPFF receptor is a rat NPFF1 receptor.
30 In another embodiment, the mammalian NPFF receptor is a human NPFF1 receptor. In a further embodiment, the mammalian NPFF receptor is a human NPFF2 receptor. In a further embodiment, the mammalian NPFF receptor is a rat NPFF2 receptor. This invention also provides an agent capable of competitively inhibiting the binding
35 of the antibody to a mammalian NPFF receptor. In one embodiment, the antibody is a monoclonal antibody or

antisera.

5 This invention provides a pharmaceutical composition comprising (a) an amount of the oligonucleotide capable of passing through a cell membrane and effective to reduce expression of a mammalian NPFF receptor and (b) a pharmaceutically acceptable carrier capable of passing through the cell membrane. In an embodiment, the oligonucleotide is coupled to a
10 substance which inactivates mRNA. In a further embodiment, the substance which inactivates mRNA is a ribozyme. In another embodiment, the pharmaceutically acceptable carrier comprises a structure which binds to a mammalian NPFF receptor on a cell capable of being
15 taken up by the cells after binding to the structure. In a further embodiment, the pharmaceutically acceptable carrier is capable of binding to a mammalian NPFF receptor which is specific for a selected cell type.

20 This invention provides a pharmaceutical composition which comprises an amount of an antibody effective to block binding of a ligand to a human NPFF receptor and a pharmaceutically acceptable carrier.

25 As used herein, the phrase "pharmaceutically acceptable carrier" means any of the standard pharmaceutically acceptable carriers. Examples include, but are not limited to, phosphate buffered saline, physiological
30 saline, water, and emulsions, such as oil/water emulsions.

35 This invention provides a transgenic, nonhuman mammal expressing DNA encoding a mammalian NPFF receptor. This invention also provides a transgenic, nonhuman mammal comprising a homologous recombination knockout of the native mammalian NPFF receptor. This invention

further provides a transgenic, nonhuman mammal whose genome comprises antisense DNA complementary to the DNA encoding a mammalian NPFF receptor so placed within the genome as to be transcribed into antisense mRNA which is complementary to mRNA encoding the mammalian NPFF receptor and which hybridizes to mRNA encoding the mammalian NPFF receptor, thereby reducing its translation. In an embodiment, the DNA encoding the mammalian NPFF receptor additionally comprises an inducible promoter. In another embodiment, the DNA encoding the mammalian NPFF receptor additionally comprises tissue specific regulatory elements. In a further embodiment, the transgenic, nonhuman mammal is a mouse.

Animal model systems which elucidate the physiological and behavioral roles of the polypeptides of this invention are produced by creating transgenic animals in which the activity of the polypeptide is either increased or decreased, or the amino acid sequence of the expressed polypeptide is altered, by a variety of techniques. Examples of these techniques include, but are not limited to: 1) Insertion of normal or mutant versions of DNA encoding the polypeptide, by microinjection, electroporation, retroviral transfection or other means well known to those in the art, into appropriate fertilized embryos in order to produce a transgenic animal or 2) Homologous recombination of mutant or normal, human or animal versions of these genes with the native gene locus in transgenic animals to alter the regulation of expression or the structure of these polypeptide sequences. The technique of homologous recombination is well known in the art. It replaces the native gene with the inserted gene and so is useful for producing an animal that cannot express native polypeptides but does express, for example, an inserted mutant

polypeptide, which has replaced the native polypeptide in the animal's genome by recombination, resulting in underexpression of the transporter. Microinjection adds genes to the genome, but does not remove them, and so is useful for producing an animal which expresses its own and added polypeptides, resulting in overexpression of the polypeptides.

One means available for producing a transgenic animal, with a mouse as an example, is as follows: Female mice are mated, and the resulting fertilized eggs are dissected out of their oviducts. The eggs are stored in an appropriate medium such as M2 medium. DNA or cDNA encoding a polypeptide of this invention is purified from a vector by methods well known in the art. Inducible promoters may be fused with the coding region of the DNA to provide an experimental means to regulate expression of the trans-gene. Alternatively, or in addition, tissue specific regulatory elements may be fused with the coding region to permit tissue-specific expression of the trans-gene. The DNA, in an appropriately buffered solution, is put into a microinjection needle (which may be made from capillary tubing using a pipet puller) and the egg to be injected is put in a depression slide. The needle is inserted into the pronucleus of the egg, and the DNA solution is injected. The injected egg is then transferred into the oviduct of a pseudopregnant mouse (a mouse stimulated by the appropriate hormones to maintain pregnancy but which is not actually pregnant), where it proceeds to the uterus, implants, and develops to term. As noted above, microinjection is not the only method for inserting DNA into the egg cell, and is used here only for exemplary purposes.

This invention provides a process for identifying a chemical compound which specifically binds to a

mammalian NPFF receptor which comprises contacting cells containing DNA encoding and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian NPFF receptor. This invention also provides a process for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises contacting a membrane fraction from a cell extract of cells containing DNA encoding and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian NPFF receptor. In one embodiment, the NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF1 receptor is a human NPFF1 receptor. In one embodiment, the mammalian NPFF receptor is a NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a human NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a rat NPFF2 receptor. In another embodiment, the mammalian NPFF receptor has substantially the same amino acid sequence as the NPFF receptor encoded by plasmid pEXJ-rNPFF1, plasmid pWE15-hNPFF1, plasmid pCDNA3.1-hNPFF2b, plasmid pCDNA3.1-hNPFF1, or plasmid pCDNA3.1-rNPFF2-f. In a further embodiment, the mammalian NPFF receptor has substantially the same amino acid sequence as that shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO: 4), Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8) or Figures 23A-23B (SEQ ID NO: 44). In another embodiment, the mammalian NPFF receptor has the amino acid sequence shown in Figure 2 (SEQ ID NO: 2), Figure

5 (SEQ ID NO: 4) Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8) or Figure 23A-23B (SEQ ID NO: 44). In one embodiment, the compound is not previously known to bind to a mammalian NPFF receptor. This invention further provides a compound identified by the above-described processes.

In one embodiment of the above-described processes, the cell is an insect cell. In another embodiment, the cell is a mammalian cell. In a further embodiment, the cell is nonneuronal in origin. In a further embodiment, the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell. In an embodiment, the compound is a compound not previously known to bind to a mammalian NPFF receptor. This invention also provides a compound identified by the above-described process.

This invention provides a process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises separately contacting cells expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the mammalian NPFF receptor, a decrease in the binding of the second chemical compound to the mammalian NPFF receptor in the presence of the chemical compound indicating that the chemical compound binds to the mammalian NPFF receptor.

This invention also provides a process involving

competitive binding for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises separately contacting a membrane preparation from cells expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the mammalian NPFF receptor, a decrease in the binding of the second chemical compound to the mammalian NPFF receptor in the presence of the chemical compound indicating that the chemical compound binds to the mammalian NPFF receptor.

In an embodiment of the present invention, the second chemical compound is NPFF or a homolog or analog of NPFF.

In one embodiment, the mammalian NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF1 receptor is a human NPFF1 receptor. In another embodiment, the mammalian NPFF receptor is a NPFF2 receptor. In a further embodiment, the NPFF2 receptor is a human NPFF2 receptor. In a further embodiment, the NPFF2 receptor is a rat NPFF2 receptor. In another embodiment, the mammalian NPFF receptor has substantially the same amino acid sequence as the NPFF receptor encoded by plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f. In a further embodiment, the mammalian NPFF receptor has substantially the same amino acid sequence as that shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO: 4), Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8)

or Figures 23A-B (SEQ ID NO: 44). In another embodiment, the mammalian NPFF receptor has the amino acid sequence shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO: 4), Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8) or Figures 23A-B (SEQ ID NO: 44).

In one embodiment, the cell is an insect cell. In another embodiment, the cell is a mammalian cell. In a further embodiment, the cell is nonneuronal in origin. In another embodiment, the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell. In one embodiment, the compound is not previously known to bind to a mammalian NPFF receptor.

This invention provides a compound identified by the above-described processes.

This invention provides a method of screening a plurality of chemical compounds not known to bind to a mammalian NPFF receptor to identify a compound which specifically binds to the mammalian NPFF receptor, which comprises (a) contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with a compound known to bind specifically to the mammalian NPFF receptor; (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the mammalian NPFF receptor, under conditions permitting binding of compounds known to bind the mammalian NPFF receptor; (c) determining whether the binding of the compound known to bind to the mammalian NPFF receptor is reduced in the presence of the compounds within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so (d) separately determining the binding to the mammalian NPFF receptor of compounds included in the plurality of compounds, so

as to thereby identify the compound which specifically binds to the mammalian NPFF receptor.

5 This invention provides a method of screening a plurality of chemical compounds not known to bind to a mammalian NPFF receptor to identify a compound which specifically binds to the mammalian NPFF receptor, which comprises (a) contacting a membrane preparation from cells transfected with and expressing DNA encoding
10 the mammalian NPFF receptor with the plurality of compounds not known to bind specifically to the mammalian NPFF receptor under conditions permitting binding of compounds known to bind to the mammalian NPFF receptor; (b) determining whether the binding of
15 a compound known to bind to the mammalian NPFF receptor is reduced in the presence of any compound within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so (c) separately determining the binding to the
20 mammalian NPFF receptor of compounds included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the mammalian NPFF receptor.

25 This invention provides a method of screening a plurality of chemical compounds not known to bind to a mammalian NPFF receptor to identify a compound which specifically binds to the mammalian NPFF receptor, which comprises (a) contacting a membrane preparation
30 from cells transfected with and expressing the mammalian NPFF receptor with a compound known to bind specifically to the mammalian NPFF receptor; (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically
35 to the mammalian NPFF receptor, under conditions permitting binding of compounds known to bind the mammalian NPFF receptor; (c) determining whether the

binding of the compound known to bind to the mammalian NPFF receptor is reduced in the presence of the compounds within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so (d) separately determining the binding to the mammalian NPFF receptor of compounds included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the mammalian NPFF receptor.

In one embodiment of the above-described methods, the mammalian NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF1 receptor is a human NPFF1 receptor. In another embodiment, the mammalian NPFF receptor is a NPFF2 receptor. In a further embodiment the NPFF2 receptor is a human NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a rat NPFF2 receptor. In another embodiment, the cell is a mammalian cell. In a further embodiment, the mammalian cell is non-neuronal in origin. In another embodiment, the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk-) cell, a CHO cell, a mouse Y1 cell, or an NIH-3T3 cell.

This invention also provides a method of detecting expression of a mammalian NPFF receptor by detecting the presence of mRNA coding for the mammalian NPFF receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained from a nucleic acid probe under hybridizing conditions, detecting the presence of mRNA hybridizing to the probe, and thereby detecting the expression of the mammalian NPFF receptor by the cell.

This invention further provides a method of detecting

the presence of a mammalian NPFF receptor on the surface of a cell which comprises contacting the cell with an antibody under conditions permitting binding of the antibody to the receptor, detecting the presence of the antibody bound to the cell, and thereby detecting the presence of the mammalian NPFF receptor on the surface of the cell.

This invention provides a method of determining the physiological effects of varying levels of activity of mammalian NPFF receptors which comprises producing a transgenic, nonhuman mammal whose levels of mammalian NPFF receptor activity are varied by use of an inducible promoter which regulates mammalian NPFF receptor expression.

This invention also provides a method of determining the physiological effects of varying levels of activity of mammalian NPFF receptors which comprises producing a panel of transgenic, nonhuman mammals each expressing a different amount of mammalian NPFF receptor.

This invention provides a method for identifying an antagonist capable of alleviating an abnormality wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor comprising administering a compound to a transgenic, nonhuman mammal, and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic, nonhuman mammal as a result of overactivity of a mammalian NPFF receptor, the alleviation of the abnormality identifying the compound as an antagonist. This invention also provides an antagonist identified by the above-described method. This invention further provides a pharmaceutical composition comprising an antagonist identified by the above-described method and a pharmaceutically

acceptable carrier. This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor which comprises administering to the subject an effective amount of this pharmaceutical composition, thereby treating the abnormality.

This invention provides a method for identifying an agonist capable of alleviating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor comprising administering a compound to transgenic, nonhuman mammal, and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic, nonhuman mammal, the alleviation of the abnormality identifying the compound as an agonist. This invention also provides an agonist identified by the above-described method. This invention further provides a pharmaceutical composition comprising an agonist identified by the above-described method and a pharmaceutically acceptable carrier. This invention further provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor which comprises administering to the subject an effective amount of this pharmaceutical composition, thereby treating the abnormality.

This invention provides a method for diagnosing a predisposition to a disorder associated with the activity of a specific mammalian allele which comprises: (a) obtaining DNA of subjects suffering from the disorder; (b) performing a restriction digest of the DNA with a panel of restriction enzymes; (c) electrophoretically separating the resulting DNA fragments on a sizing gel; (d) contacting the resulting

gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a mammalian NPFF receptor and labeled with a detectable marker; (e) detecting labeled bands which have hybridized to the DNA encoding a mammalian NPFF receptor labeled with a detectable marker to create a unique band pattern specific to the DNA of subjects suffering from the disorder; (f) preparing DNA obtained for diagnosis by steps (a)-(e); and (g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step (e) and the DNA obtained for diagnosis from step (f) to determine whether the patterns are the same or different and to diagnose thereby predisposition to the disorder if the patterns are the same. In one embodiment, a disorder associated with the activity of a specific mammalian allele is diagnosed.

This invention provides a method of preparing the purified mammalian NPFF receptor which comprises: (a) inducing cells to express the mammalian NPFF receptor; (b) recovering the mammalian NPFF receptor from the induced cells; and (c) purifying the mammalian NPFF receptor so recovered.

This invention provides a method of preparing the purified mammalian NPFF receptor which comprises: (a) inserting nucleic acid encoding the mammalian NPFF receptor in a suitable vector; (b) introducing the resulting vector in a suitable host cell; (c) placing the resulting cell in suitable condition permitting the production of the isolated mammalian NPFF receptor; (d) recovering the mammalian NPFF receptor produced by the resulting cell; and (e) purifying the mammalian NPFF receptor so recovered.

This invention provides a process for determining whether a chemical compound is a mammalian NPFF receptor agonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the compound under conditions permitting the activation of the mammalian NPFF receptor, and detecting an increase in mammalian NPFF receptor activity, so as to thereby determine whether the compound is a mammalian NPFF receptor agonist. This invention also provides a process for determining whether a chemical compound is a mammalian NPFF1 receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the compound in the presence of a known mammalian NPFF receptor agonist, under conditions permitting the activation of the mammalian NPFF receptor, and detecting a decrease in mammalian NPFF receptor activity, so as to thereby determine whether the compound is a mammalian NPFF receptor antagonist. In one embodiment, the mammalian NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF1 receptor is a human NPFF1 receptor. In one embodiment, the mammalian NPFF receptor is a NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a human NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a rat NPFF2 receptor.

This invention further provides a pharmaceutical composition which comprises an amount of a mammalian NPFF receptor agonist determined by the above-described process effective to increase activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier. In one embodiment, the mammalian NPFF receptor agonist is not previously known.

This invention provides a pharmaceutical composition which comprises an amount of a mammalian NPFF receptor antagonist determined by the above-described process effective to reduce activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier. In one embodiment, the mammalian NPFF receptor antagonist is not previously known.

This invention provides a process for determining whether a chemical compound specifically binds to and activates a mammalian NPFF receptor, which comprises contacting cells producing a second messenger response and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the chemical compound under conditions suitable for activation of the mammalian NPFF receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian NPFF receptor. In one embodiment, the second messenger response comprises chloride channel activation and the change in second messenger is an increase in the level of inward chloride current.

This invention also provides a process for determining whether a chemical compound specifically binds to and inhibits activation of a mammalian NPFF receptor, which comprises separately contacting cells producing a second messenger response and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to activate the mammalian NPFF receptor, and with only the second chemical compound, under conditions suitable for activation of the mammalian

NPFF receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the mammalian NPFF receptor. In one embodiment, the second messenger response comprises chloride channel activation and the change in second messenger response is a smaller increase in the level of inward chloride current in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound. This invention also provides the above-described processes performed with membrane preparations from cells producing a second messenger response and transfected with and expressing the mammalian NPFF receptor.

In one embodiment of the above-described processes, the mammalian NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a rat NPFF1 receptor. In another embodiment, the mammalian NPFF1 receptor is a human NPFF1 receptor. In another embodiment, the mammalian NPFF receptor is a NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a human NPFF2 receptor. In a further embodiment, the mammalian NPFF2 receptor is a rat NPFF2 receptor. In another embodiment, the mammalian NPFF receptor has substantially the same amino acid sequence as encoded by the plasmid pEXJ-rNPFF1, pWE15-hNPFF1, pCDNA3.1-hNPFF2b, pCDNA3.1-hNPFF1 or pCDNA3.1-rNPFF2-f. In a further embodiment, the mammalian NPFF receptor has substantially the same amino acid sequence as that shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO:

4), Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8)
or Figures 23A-B (SEQ ID NO: 44). In another
embodiment, the mammalian NPFF receptor has an amino
acid sequence identical to the amino acid sequence
5 shown in Figure 2 (SEQ ID NO: 2), Figure 5 (SEQ ID NO:
4), Figure 8 (SEQ ID NO: 6), Figure 12 (SEQ ID NO: 8)
or Figures 23A-B (SEQ ID NO: 44). In an embodiment,
the cell is an insect cell. In a further embodiment,
the cell is a mammalian cell. In a still further
10 embodiment, the mammalian cell is nonneuronal in
origin. In another embodiment, the nonneuronal cell is
a COS-7 cell, CHO cell, 293 human embryonic kidney
cell, NIH-3T3 cell or LM(tk-) cell. In an embodiment,
the compound is not previously known to bind to a
15 mammalian NPFF receptor. This invention also provides
a compound determined by the above-described processes.

This invention also provides a pharmaceutical
composition which comprises an amount of a mammalian
NPFF receptor agonist determined by the above-described
20 processes effective to increase activity of a mammalian
NPFF receptor and a pharmaceutically acceptable
carrier. In one embodiment, the mammalian NPFF
receptor agonist is not previously known.

25 This invention further provides a pharmaceutical
composition which comprises an amount of a mammalian
NPFF receptor antagonist determined by the
above-described processes effective to reduce activity
30 of a mammalian NPFF receptor and a pharmaceutically
acceptable carrier. In one embodiment, the mammalian
NPFF receptor antagonist is not previously known.

35 This invention provides a method of screening a
plurality of chemical compounds not known to activate
a mammalian NPFF receptor to identify a compound which
activates the mammalian NPFF receptor which comprises:

(a) contacting cells transfected with and expressing the mammalian NPFF receptor with the plurality of compounds not known to activate the mammalian NPFF receptor, under conditions permitting activation of the mammalian NPFF receptor; (b) determining whether the activity of the mammalian NPFF receptor is increased in the presence of the compounds; and if so (c) separately determining whether the activation of the mammalian NPFF receptor is increased by each compound included in the plurality of compounds, so as to thereby identify the compound which activates the mammalian NPFF receptor. In one embodiment, the mammalian NPFF receptor is a human NPFF receptor. In a further embodiment the human NPFF receptor is a human NPFF1 receptor or a human NPFF2 receptor.

This invention provides a method of screening a plurality of chemical compounds not known to inhibit the activation of a mammalian NPFF receptor to identify a compound which inhibits the activation of the mammalian NPFF receptor, which comprises: (a) contacting cells transfected with and expressing the mammalian NPFF receptor with the plurality of compounds in the presence of a known mammalian NPFF receptor agonist, under conditions permitting activation of the mammalian NPFF receptor; (b) determining whether the activation of the mammalian NPFF receptor is reduced in the presence of the plurality of compounds, relative to the activation of the mammalian NPFF receptor in the absence of the plurality of compounds; and if so (c) separately determining the inhibition of activation of the mammalian NPFF receptor for each compound included in the plurality of compounds, so as to thereby identify the compound which inhibits the activation of the mammalian NPFF receptor. In one embodiment, the mammalian NPFF receptor is a NPFF1 receptor. In a further embodiment, the mammalian NPFF1 receptor is a

rat NPFF1 receptor. In another embodiment, the NPFF1
receptor is a human NPFF1 receptor. In another
embodiment, the mammalian NPFF receptor is a NPFF2
receptor. In a further embodiment, the NPFF2 receptor
5 is a human NPFF2 receptor. In a further embodiment,
the mammalian NPFF2 receptor is a rat NPFF2 receptor.

10 In one embodiment of the above-described methods, the
cell is a mammalian cell. In another embodiment, the
mammalian cell is non-neuronal in origin. In a further
embodiment, the non-neuronal cell is a COS-7 cell, a
293 human embryonic kidney cell, a LM(tk-) cell or an
NIH-3T3 cell.

15 This invention provides a pharmaceutical composition
comprising a compound identified by the above-described
methods effective to increase mammalian NPFF receptor
activity and a pharmaceutically acceptable carrier.

20 This invention also provides a pharmaceutical
composition comprising a compound identified by the
above-described methods effective to decrease mammalian
NPFF receptor activity and a pharmaceutically
25 acceptable carrier.

This invention further provides a method of measuring
polypeptide activation in an oocyte expression system
such as a Xenopus oocyte expression system or
30 melanophore. In an embodiment, polypeptide activation
is determined by measurement of ion channel activity.
In another embodiment, polypeptide activation is
measured by aequorin luminescence.

35 Expression of genes in Xenopus oocytes is well known in
the art (Coleman, A., 1984; Masu, Y., et al., 1994) and
is performed using microinjection of native mRNA or in

vitro synthesized mRNA into frog oocytes. The preparation of in vitro synthesized mRNA can be performed by various standard techniques (Sambrook, et al. 1989) including using T7 polymerase with the mCAP RNA mapping kit (Stratagene).

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated diseases. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data (McKusick, V.A., 1998). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). The difference in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor which comprises administering to the subject an amount of a compound which is a mammalian NPFF receptor agonist effective to treat the abnormality. In separate embodiments, the abnormality is a lower urinary tract disorder such as interstitial cystitis or urinary incontinence such as urge

incontinence or stress incontinence particularly stress incontinence, a regulation of a steroid hormone disorder, an epinephrine release disorder, a gastrointestinal disorder, irritable bowel syndrome, a cardiovascular disorder, an electrolyte balance disorder, diuresis, hypertension, hypotension, diabetes, hypoglycemia, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, a serotonergic function disorder, an appetite disorder, obesity, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, pain, psychotic behavior, morphine tolerance, nicotine addiction, opiate addiction, or migraine.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor which comprises administering to the subject an amount of a compound which is a mammalian NPFF receptor antagonist effective to treat the abnormality. In separate embodiments, the abnormality is a lower urinary tract disorder such as interstitial cystitis or urinary incontinence such as urge incontinence or stress incontinence particularly stress incontinence, a regulation of a steroid hormone disorder, an epinephrine release disorder, a gastrointestinal disorder, irritable bowel syndrome, a cardiovascular disorder, an electrolyte balance disorder, diuresis, hypertension, hypotension, diabetes, hypoglycemia, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder,

an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, a serotonergic function disorder, an appetite disorder, obesity, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, pain, psychotic behavior, morphine tolerance, nicotine addiction, opiate addiction, or migraine.

This invention provides a method of treating urinary incontinence which comprises administering to a subject an amount of an antagonist of a human NPFF2 receptor effective to inhibit activation of the receptor and thereby treat incontinence, such as urge incontinence or stress incontinence.

This invention provides a method of treating urinary retention which comprises administering to a subject an amount of an agonist of a human NPFF2 receptor effective to activate the receptor and thereby treat retention.

This invention provides a method of treating hypertension which comprises administering to a subject an amount of an antagonist of a human NPFF1 receptor effective to inhibit activation of the receptor and thereby treat hypertension.

This invention provides a method of treating hypotension which comprises administering to a subject an amount of an agonist of a human NPFF1 receptor effective to activate the receptor and thereby treat hypotension.

This invention provides a method of modifying the feeding behavior of a subject which comprises administering the subject an amount of a compound which is a NPFF2 receptor agonist effective to decrease the consumption of food by the subject so as to thereby modify the feeding behavior of the subject.

In one embodiment of the above-described method the subject is a vertebrate. In another embodiment, the subject is a mammal. In a further embodiment, the subject is a human. In another embodiment, the subject is a canine.

This invention also provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound which is NPFF2 receptor agonist effective to activate the receptor and thereby treat the feeding disorder. In separate embodiments, the feeding disorder is bulimia, bulimia nervosa or obesity.

In one embodiment of the above-described method the subject is a vertebrate. In another embodiment, the subject is a mammal. In a further embodiment, the subject is a human. In another embodiment, the subject is a canine.

This invention further provides a method of inhibiting feeding which comprises administering to a subject an amount of an agonist of a human NPFF2 receptor effective to activate the receptor and thereby inhibit feeding.

This invention also provides the use of mammalian NPFF receptors for analgesia.

This invention provides a process for making a

composition of matter which specifically binds to a mammalian NPFF receptor which comprises identifying a chemical compound using any of the processes described herein for identifying a compound which binds to and/or
5 activates or inhibits activation of a mammalian NPFF receptor and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof. In one embodiment, the mammalian NPFF receptor is a human NPFF1 receptor. In another
10 embodiment, the mammalian NPFF receptor is a human NPFF2 receptor.

This invention further provides a process for preparing a pharmaceutical composition which comprises admixing
15 a pharmaceutically acceptable carrier and a pharmaceutically acceptable amount of a chemical compound identified by any of the processes described herein for identifying a compound which binds to and/or activates or inhibits activation of a mammalian NPFF
20 receptor or a novel structural and functional analog or homolog thereof. In one embodiment, the mammalian NPFF receptor is a human NPFF1 receptor. In another embodiment, the mammalian NPFF receptor is a human NPFF2 receptor.

25 This invention provides for use of a human NPFF2 receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence, such as urge incontinence or stress
30 incontinence. This invention provides for use of a human NPFF2 receptor agonist for the preparation of a pharmaceutical composition for treating urinary retention.

35 This invention provides for use of a human NPFF1 receptor antagonist for the preparation of a pharmaceutical composition for treating hypertension.

This invention provides for use of a human NPFF1 receptor agonist for the preparation of a pharmaceutical composition for treating hypotension.

5 This invention also provides the use of a human NPFF2 receptor agonist for the preparation of a pharmaceutical composition for inhibiting feeding. This invention provides the use of a human NPFF2
10 receptor agonist for the preparation of a pharmaceutical composition for treating a feeding disorder.

Thus, once the gene for a targeted receptor subtype is cloned, it is placed into a recipient cell which then
15 expresses the targeted receptor subtype on its surface. This cell, which expresses a single population of the targeted human receptor subtype, is then propagated resulting in the establishment of a cell line. This cell line, which constitutes a drug discovery system,
20 is used in two different types of assays: binding assays and functional assays. In binding assays, the affinity of a compound for both the receptor subtype that is the target of a particular drug discovery program and other receptor subtypes that could be
25 associated with side effects are measured. These measurements enable one to predict the potency of a compound, as well as the degree of selectivity that the compound has for the targeted receptor subtype over other receptor subtypes. The data obtained from
30 binding assays also enable chemists to design compounds toward or away from one or more of the relevant subtypes, as appropriate, for optimal therapeutic efficacy. In functional assays, the nature of the response of the receptor subtype to the compound is
35 determined. Data from the functional assays show whether the compound is acting to inhibit or enhance the activity of the receptor subtype, thus enabling

pharmacologists to evaluate compounds rapidly at their ultimate human receptor subtypes targets permitting chemists to rationally design drugs that will be more effective and have fewer or substantially less severe side effects than existing drugs.

Approaches to designing and synthesizing receptor subtype-selective compounds are well known and include traditional medicinal chemistry and the newer technology of combinatorial chemistry, both of which are supported by computer-assisted molecular modeling. With such approaches, chemists and pharmacologists use their knowledge of the structures of the targeted receptor subtype and compounds determined to bind and/or activate or inhibit activation of the receptor subtype to design and synthesize structures that will have activity at these receptor subtypes.

Combinatorial chemistry involves automated synthesis of a variety of novel compounds by assembling them using different combinations of chemical building blocks. The use of combinatorial chemistry greatly accelerates the process of generating compounds. The resulting arrays of compounds are called libraries and are used to screen for compounds ("lead compounds") that demonstrate a sufficient level of activity at receptors of interest. Using combinatorial chemistry it is possible to synthesize "focused" libraries of compounds anticipated to be highly biased toward the receptor target of interest.

Once lead compounds are identified, whether through the use of combinatorial chemistry or traditional medicinal chemistry or otherwise, a variety of homologs and analogs are prepared to facilitate an understanding of the relationship between chemical structure and biological or functional activity. These studies

define structure activity relationships which are then
used to design drugs with improved potency, selectivity
and pharmacokinetic properties. Combinatorial
chemistry is also used to rapidly generate a variety of
5 structures for lead optimization. Traditional
medicinal chemistry, which involves the synthesis of
compounds one at a time, is also used for further
refinement and to generate compounds not accessible by
automated techniques. Once such drugs are defined the
10 production is scaled up using standard chemical
manufacturing methodologies utilized throughout the
pharmaceutical and chemistry industry.

This invention will be better understood from the
15 Experimental Details which follow. However, one
skilled in the art will readily appreciate that the
specific methods and results discussed are merely
illustrative of the invention as described more fully
in the claims which follow thereafter.

EXPERIMENTAL DETAILS

Materials and methods

5 Cloning of rat and human NPFF1 receptor

MOPAC (Mixed Oligonucleotide Primed Amplification of cDNA

100ng of rat genomic DNA (Clontech, Palo Alto, CA) was
used for degenerate MOPAC PCR using Taq DNA polymerase
10 (Boehringer-Mannheim, Indianapolis, IN) and the
following degenerate oligonucleotides: JAB126, designed
based on an alignment of the sixth transmembrane domain
of more than 180 members of the rhodopsin superfamily
of G protein-coupled receptors; and JAB108, designed
15 based on an alignment of the seventh transmembrane
domain of the same rhodopsin superfamily.

The conditions for the MOPAC PCR reaction were as
follows: 3 minute hold at 94°C; 10 cycles of 1 minute
20 at 94°C, 1 minute 45 seconds at 44°C, 2 minutes at 72°C;
30 cycles of 94°C for 1 minute, 49°C for 1 minute 45
seconds, 2 minutes at 72°C; 4 minute hold at 72°C; 4°C
until ready for agarose gel electrophoresis.

25 The products were run on a 1% agarose TAE gel and bands
of the expected size (~150bp) were cut from the gel,
purified using the QIAQUICK gel extraction kit (QIAGEN,
Chatsworth, CA), and subcloned into the TA cloning
vector (Invitrogen, San Diego, CA). White
30 (insert-containing) colonies were picked and subjected
to PCR using pCR2.1 vector primers JAB1 and JAB2 using
the Expand Long Template PCR System and the following
protocol: 94°C hold for 3 minutes; 35 cycles of 94°C for
1 minute, 68°C for 1 minute 15 seconds; 2 minute hold
35 at 68°C, 4°C hold until products were ready for
purification. PCR products were purified by
isopropanol precipitation (10 µl PCR product, 18 µl low

TE, 10.5 μ l 2M NaClO₄ and 21.5 μ l isopropanol) and sequenced using the ABI Big Dye cycle sequencing protocol and ABI 377 sequencers (ABI, Foster City, CA). Nucleotide and amino acid sequence analyses were performed using the Wisconsin Package (GCG, Genetics Computer Group, Madison, WI). Two PCR products produced from rat genomic cDNA (MPR3-RGEN-31 and MPR3-RGEN-45) were determined to be identical clones of a novel G protein-coupled receptor-like sequence based on database searches and its homology to other known G protein-coupled receptors (~30-40% amino acid identity to dopamine D₂, orexin, galanin, angiotensin 1 and 5-HT_{2b} receptors). This novel sequence was designated SNORF2.

Cloning of the full-length coding sequence of SNORF2 (rat NPFF1)

Pools of the rat hypothalamic cDNA library "I" were screened by PCR with SNORF2-specific primers JAB208 and JAB209 and the Expand Long Template PCR system (Boehringer-Mannheim, Indianapolis, IN) with the following PCR protocol: 94°C hold for 3 minutes; 40 cycles of 94°C for 1 minute, 68°C for 2 minutes; 4 minute hold at 68°C; 4°C hold until the samples are run on a gel. This screen yielded a positive pool I36E and a positive sub-pool I36E-17. High stringency hybridization of isolated colonies from I36E-17 with the SNORF2-specific oligonucleotide probe JAB211 and subsequent PCR testing of positive colonies indicated that the isolated clone I36E-17-1B-1 contained at least a partial clone of SNORF2. Sequencing of I36E-17-1B-1 revealed that this insert contained the coding region from the TMIII-TMIV loop through the stop codon, including some 3' untranslated sequence. From this sequence, a new forward primer, JAB221, was designed in TMV. PCR screening of a second rat hypothalamic cDNA library "J" with primers JAB221 and JAB209, and

subsequent colony hybridization with the JAB211 probe on a low complexity positive sub-pool resulted in the isolation of a SNORF2 clone J-13-16-A1. Full-length double-stranded sequence of SNORF2 was determined by sequencing both strands of the J-13-16-A1 plasmid using an ABI 377 sequencer as described above. This insert is about 2.8 kb in length with an approximately 200 bp 5' untranslated region, a 1296 bp coding region, and a 1.3 kb 3'untranslated region. The clone is also in the correct orientation for expression in the mammalian expression vector pEXJ.T7. This construct of SNORF2 in pEXJ.T7 was designated BN-6. The full length SNORF2 was determined to be most like the orexin 1 receptor (45% DNA identity, 35% amino acid identity), orexin 2 receptor (40% DNA identity, 32% amino acid identity), and NPY2 receptor (47% DNA identity, 29% amino acid identity), although several other G protein-coupled receptors also displayed significant homology. There were no sequences in the Genbank databases (genembl, sts, est, gss, or swissprot) that were identical to SNORF2. SNORF2 also showed significant homology (85% nucleotide identity, 93% amino acid identity) to a partial G protein-coupled receptor fragment in the Synaptic Pharmaceutical Corporation in-house database, designated PLC29b. PLC29b, which includes part of the amino terminus through TMIII, was originally isolated from a human genomic library using oligonucleotide probes for NPY4. Subsequent screening of a human hippocampal cDNA library yielded an overlapping sequence extending into TMIV. Based on sequence similarity, this human sequence appears to be a partial clone of the human homolog of SNORF2.

The following is a list of primers and their associated sequences which were used in the cloning of these receptors:

JAB126: 5'-GYNTWYRYNNTNWSNTGGHTNCC-3' (SEQ ID NO: 9)
JAB108: 5'-AVNADNGBRWAVANNANNGGRTT-3' (SEQ ID NO: 10)
JAB1: 5'-TTATGCTTCCGGCTCGTATGTTGTG-3' (SEQ ID NO: 11)
JAB2: 5'-ATGTGCTGCAAGGCGATTAAGTTGGG-3' (SEQ ID NO: 12)
5 JAB208: 5'-GGTGCTGCTGCTGCTCATCGACTATG-3' (SEQ ID NO: 13)
JAB209: 5'-TTGGCGCTGCTGTGGAAGAAGGCCAG-3' (SEQ ID NO: 14)
JAB221: 5'-CGGTGCTCTTCGCGCACATCTACC-3' (SEQ ID NO: 15)
JAB211: 5'-TGCCAAGGGGAAGGCGTAGACCGACAGCAGGTGCAGTTGCA
GCTCGATCAGCTCCCCATA-3' (SEQ ID NO: 16)

10 Isolation of the full-length human SNORF2 receptor gene
(human NPFF1)

The full-length, intronless version of the human NPFF1
receptor gene may be isolated using standard molecular
15 biology techniques and approaches such as those briefly
described below:

Approach #1: To obtain a full-length human NPFF1
receptor, a human cosmid library was screened with a
20 ³²P-labeled oligonucleotide probe, BB609, corresponding
to the 2/3 loop of the PLC29b clone. A positive clone
was isolated and partially sequenced, revealing part of
the amino terminus and TMs I and II.

25 The full-length sequence may be obtained by sequencing
this cosmid clone with additional sequencing primers.
Since at least two introns are present in this gene,
one in the amino terminus and one just after the third
transmembrane domain, the full-length intronless gene
30 may be obtained from cDNA using standard molecular
biology techniques. For example, a forward PCR primer
designed in the 5'UT and a reverse PCR primer designed
in the 3'UT may be used to amplify a full-length,
intronless gene from cDNA. RT-PCR localization has
35 identified several human tissues which could be used
for this purpose, including cerebellum, spinal cord,
hippocampus, lung and kidney. Standard molecular

biology techniques could be used to subclone this gene into a mammalian expression vector.

5 Approach #2: Standard molecular biology techniques could be used to screen commercial human cDNA phage libraries by hybridization under high stringency with a ³²P-labeled oligonucleotide probe, BB609, corresponding to the 2/3 loop of the PLC29b clone. One may isolate a full-length human NPFF1 by obtaining a
10 plaque purified clone from the lambda libraries and then subjecting the clone to direct DNA sequencing using primers from the PLC29b sequence. Alternatively, standard molecular biology techniques could be used to screen in-house human cDNA plasmid libraries by PCR
15 amplification of library pools using primers to the human NPFF1 sequence (BB629, forward primer in TMI, and A71, reverse primer in TMIV). A full-length clone could be isolated by Southern hybridization of colony lifts of positive pools with a ³²P-labeled
20 oligonucleotide probe, BB609, corresponding to the 2/3 loop of the PLC29b clone.

Approach #3: As yet another alternative method, one could utilize 3' and 5' RACE to generate PCR products
25 from human cDNA expressing human NPFF1 (for example, cerebellum, spinal cord, hippocampus, lung and kidney), which contain the additional sequences of human NPFF1. For 5' RACE, a reverse primer derived from PLC29b between the amino terminus and TM IV could be used to
30 amplify the additional amino terminus sequence for hNPFF1. For 3' RACE, a forward primer derived from PLC29b between the amino terminus and TM IV could be used to amplify the additional 3' sequence for hNPFF1, including TMs 5-7 and the COOH terminus. These RACE
35 PCR product could then be sequenced to determine the missing sequence. This new sequence could then be used to design a forward PCR primer in the 5'UT and a

reverse primer in the 3'UT. These primers could then be used to amplify a full-length hNPFF1 clone from human cDNA sources known to express NPFF1 (for example, cerebellum, spinal cord, hippocampus, lung and kidney).

5

BB609: 5'-CCACCCTTGTGGACAACCTCATCACTGGGTGGCCCTTCGACA
ATGCCACATGC-3' (SEQ ID NO: 17)

10

BB629: 5'-CTGCTCTGCATGGTGGGCAACACC-3' (SEQ ID NO: 18)

A71: 5'-GACGGCGATGGTGACGAGCGC-3' (SEQ ID NO: 19)

Cloning of human NPFF1 receptor

15

The sequence of the human NPFF1 (hNPFF1) receptor from the initiating methionine to TMIV was determined to be present in a partial clone, plc29b, found in a Synaptic Pharmaceutical Corporation in-house database.

20

In order to isolate the full-length hNPFF1 receptor cDNA, a human cosmid library (Stratagene) was screened with a ³²P-labeled probe (BB609) corresponding to the II/III loop of plc29b. Partial DNA sequencing of one positive clone from this library, COS28a revealed

25

similar sequence as had been previously shown for plc29b, with an intron downstream of TMIII. In order to obtain sequence in the 3' end of hNPFF1, COS28a was amplified with a vector primer and BB702, BB703 or BB704, forward primers in TMIV. DNA sequencing of these PCR products resulted in the identification of

30

TMIV through the stop codon.

35

Next, an in-house human spinal cord library was screened by PCR using a forward primer in the region of the initiating methionine (BB729) and a reverse primer corresponding to TMIV (BB728). One positive pool, W4, was subdivided and a positive sub-pool was screened by colony hybridization with a ³²P-labeled probe from TMII,

BB676. Plasmid DNA was isolated for clone W4-18-4, renamed B098, and DNA sequencing revealed that it was full-length but in the wrong orientation for expression in the expression vector pEXJ. To obtain a full-length hNPFF1 construct in the correct orientation, B098 was amplified with BB757, a forward primer at the initiating methionine which contained an upstream *Bam*HI site, and BB758, a reverse primer at the stop codon which contained a *Eco*RI site. The products from 3 independent PCR reactions were ligated into pcDNA3.1+ and transformed into DH5 α cells. The sequence of one of these transformants, 3.3, was identical to the hNPFF1 sequence previously determined from the consensus of B098, COS28a and plc29b. Clone 3.3 was renamed B0102.

The hNPFF1 clone contains an open reading frame with 1293 nucleotides and predicts a protein of 430 amino acids (Figures 11 and 12). Hydrophobicity analysis reveals seven hydrophobic domains which are presumed to be transmembrane domains (Figure 13). The sequence of hNPFF1 was determined to be most similar to the rat NPFF1 (86% nucleotide identity, 87% amino acid identity) and human NPFF2 (56% nucleotide identity, 49% amino acid identity (Figure 14)). The human NPFF1 receptor also shares homology with human orexin₁ (53% nucleotide identity, 35% amino acid identity), human orexin₂ (43% nucleotide identity, 33% amino acid identity), human NPY₂ (47% nucleotide identity, 31% amino acid identity), human CCK_A (46% nucleotide identity, 32% amino acid identity), and human CCK_B (46% nucleotide identity, 26% amino acid identity).

The following primers and probes were used in the cloning of hNPFF1:

BB676: 5'-GTCACCAACATGTTTCATCCTCAACCTGGCTGTCAGTGACCTGCT

GGTGGGCATCTTCTGCATGCC-3' (SEQ ID NO: 20)
BB702: 5'-GCGAGAAGCTGACCCTGCGGAAGG-3' (SEQ ID NO: 21)
BB703: 5'-TCGTCACCATCGCCGTCATCTGGG-3' (SEQ ID NO: 22)
BB704: 5'-CGTCATCTGGGCCGAGGGACACAG-3' (SEQ ID NO: 23)
5 BB728: 5'-TGACGGCGATGGTGACGAGCGCC-3' (SEQ ID NO: 24)
BB729: 5'-CAGCCTCCCAACAGCAGTTGGCC-3' (SEQ ID NO: 25)
BB757: 5'-TAGCAAGGATCCGCATATGGAGGGGGAGCCCTCCC-3' (SEQ
ID NO: 26)
BB758: 5'-CTTCATGAATTCATCGCCTGCATGTATCTCGTGTCC-3' (SEQ
10 ID NO: 27)

Cloning of human NPFF2 receptor

Discovery of an expressed sequence tag (EST) AA449919 in GENEMBL homologous to rNPFF1 (hNPFF2)

15 A FASTA search of GENEMBL with the full-length sequence
of rat NPFF1 (rNPFF1) resulted in the identification of
an EST (Accession number AA449919) with a high degree
of homology to NPFF1 (57% identity at the DNA level).
20 AA449919 is a 532 bp sequence annotated in Genbank as
"Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone
788698 5' similar to SW:NYR_DROME P25931 NEUROPEPTIDE
Y RECEPTOR," which when translated corresponds to the
region between the first extracellular loop and the
25 beginning of the sixth transmembrane domain of rNPFF1.
GAP analysis of AA449919 with rNPFF1 indicated that
there is 57% DNA identity and a 50% amino acid identity
between the two receptor sequences over this region.
AA449919 displays 60% DNA identity and 59% amino acid
30 identity over the region that overlaps with the known
sequence for hNPFF1 (first extracellular loop to TM4),
while over the same range rNPFF1 is 62% and 61%
identical to AA449919 at the DNA and amino acid levels,
respectively. In comparison, hNPFF1 and rNPFF1 share
35 86% DNA identity and 92 % amino acid identity over this
region. Given the strong degree of identity between
AA449919 and rNPFF1, AA449919 was given the name

NPFF-like (hNPFF2).

Cloning the full-length sequence of (NPFF-like) hNPFF2

To determine the full-length coding sequence of
5 AA449919, 5'/3' Rapid Amplification of cDNA ends (RACE)
was performed on Clontech Human Spleen Marathon-Ready
cDNA (Clontech, Palo Alto, CA). For 5' RACE, 5 μ l
template (human spleen Marathon-Ready cDNA was
10 amplified with oligonucleotide primers JAB256 and AP1,
the Expand Long DNA Template PCR System
(Boehringer-Mannheim, Indianapolis, IN) and the
following PCR protocol were used: 94°C hold for 3
minutes; 5 cycles of 94°C for 30 seconds, 72°C for 4
15 minutes; 5 cycles of 94°C for 30 seconds, 70°C for 4
minutes; 30 cycles of 94°C for 30 seconds, 68°C for 4
minutes; 68°C hold for 4 minutes; 4°C hold until
products were ready to be loaded on a gel. 1 μ l of this
reaction was subjected to a second round of
amplification with primers JAB260 and AP2 and the same
20 PCR protocol. For 3' RACE, 5 μ l human spleen
Marathon-Ready cDNA was subjected to PCR with primers
JAB257 and AP1 with the same PCR protocol that was used
for 5' RACE. 1 μ l of this reaction was subjected to
another round of amplification using AP2 and JAB258 and
25 the same PCR conditions.

The products were run on a 1% agarose TAE gel and bands
greater than 500 bp were extracted from the gel using
the QIAQUICK gel extraction kit (QIAGEN, Chatsworth,
30 CA). 5 μ l of each purified band from the 5' and 3'
RACE reactions were directly sequenced with primers
JAB261 (5' products) and JAB259 (3' products) using the
ABI Big Dye cycle sequencing protocol and ABI377
sequencers (ABI, Foster City, CA). The Wisconsin
35 Package (GCG, Genetics Computer Group, Madison, WI) and
Sequencer 3.0 (Gene Codes Corporation, Ann Arbor, MI)
were used to put together the full-length contiguous

sequence of hNPFF2 from the AA449919 EST and the RACE products.

To attain the full-length hNPFF-like (hNPFF2) coding
sequence for expression, human spinal cord cDNA was
amplified in eight independent PCR reactions using the
Expand Long Template PCR System with buffer I (four of
the eight reactions) or buffer 3 (4 reactions) and two
oligonucleotide primers with restriction sites
incorporated into their 5' ends: BB675 is a forward
primer upstream of the initiating methionine and
contains a BamHI site, and BB663. The PCR conditions
for this reaction were as follows: 94°C hold for 5
minutes; 37 cycles of 94°C for 30 seconds, 64°C for 30
seconds, 68°C for 2 minutes; a 7 minute hold at 68°C,
and a 4°C hold until products were ready to be loaded
on a gel. The products were electrophoresed on a 1%
agarose TAE gel, and a band of approximately 1.35 kb
was cut and purified using the QIAQUICK gel extraction
kit. The purified bands of seven of the eight
reactions were cut with BamHI and EcoRI, gel purified
again using the same method, and ligated into
pcDNA3.1(+) (Invitrogen, Carlsbad, CA). Eighteen
colonies from the subsequent transformations were
picked and determined to be positive for NPFF-like by
PCR. Eight of these 18 clones were fully sequenced,
and one of these, B089, was determined to be a full
length clone with no point mutations. This construct
was renamed pcDNA3.1-hNPFF2b.

For expression of NPFF-like in oocytes, one ul of each
of these eight ligations of the BB675-BB663 PCR product
into pcDNA3.1(+) was subjected to PCR with AN35, a
pcDNA3.1 primer at the CMV promoter site, and the 3'
NPFF-like primer BB663 using the Expand Long Template
PCR System and the following PCR protocol: 94°C hold
for 3 minutes; 37 cycles of 94°C for 30 seconds, 65°C

for 30 seconds, 68°C for 2 minutes; a 7 minute hold at 68°C, and a 4°C hold until products were ready for in vitro transcription. Of the seven PCR reactions, six yielded products of the expected size.

5

The following is a list of primers and their associated sequences which were used in the cloning of this receptor (hNPFF2):

- 10 AN35: 5'-CGTGACGGTGGGAGGTCTATATAAGCAGAG-3' (SEQ ID NO: 28)
- AP1: 5'-CCATCCTAATACGACTCACTATAGGGC-3' (SEQ ID NO: 29)
- AP2: 5'-ACTCACTATAGGGCTCGAGCGGC-3' (SEQ ID NO: 30)
- 15 JAB256: 5'-TGATAGTGAGCTTTGGTTTAAAAGGG-3' (SEQ ID NO: 31)
- JAB257: 5'-GAAGATCTACACCACTGTGCTGTTTG-3' (SEQ ID NO: 32)
- JAB258: 5'-AACATCTACCTGGCTCCCCTCTCCC-3' (SEQ ID NO: 33)
- JAB259: 5'-TTGTCATCATGTATGGAAGGATTGG-3' (SEQ ID NO: 34)
- JAB260: 5'-GACCACACACTGGAACCTATCTAC-3' (SEQ ID NO: 35)
- 20 JAB261: 5'-GCAATTGCAACTAACGTAAAGACTG-3' (SEQ ID NO: 36)
- BB675: 5'-TAGCAAGGATCCGAGGTTTCATCATGAATGAGAAATGG-3' (SEQ ID NO: 37)
- BB663: 5'-CTTCATGAATTCGCGTAGTAGAGTTAGGATTATCAC-3' (SEQ ID NO: 38)

25

For expression of NPFF2, mRNA transcripts were generated as described for NPFF1, using PCR products from ligation reactions or linearized DNA from BO89 as DNA templates. Oocytes were injected with 5-50 ng NPFF2 mRNA and incubated as previously described.

30

Isolation of the Rat Homologue of NPFF2

35

To obtain a fragment of the rat homologue of NPFF2, rat genomic DNA (Clontech, Palo Alto, CA), rat hypothalamic cDNA or rat spinal cord cDNA was amplified with a forward PCR primer corresponding to TMIV of human NPFF2

(JAB307) and a reverse primer corresponding to TMVI of human NPFF2 (JAB 306). PCR was performed with the Expand Long Template PCR System (Roche Molecular Biochemicals, Indianapolis, IN) under the following conditions: 1 minute at 94°C, 2 minutes at 50°C, 2 minutes at 68°C for 40 cycles, with a pre- and post-incubation of 3 minutes at 94°C and 4 minutes at 68°C respectively. Bands of 368 bp from 3 independent PCR reactions were isolated from a TAE gel, purified using the QIAQUICK gel extraction kit (QIAGEN, Chatsworth, CA), and sequenced on both strands as described above. The sequences of these 3 PCR products were identical.

To obtain additional sequence for rat NPFF2, reduced stringency PCR was performed using primers designed against the human NPFF2 NH₂ and COOH termini along with PCR primers designed against the rat NPFF2 fragment. For the NH₂ terminal sequence, PCR was performed on rat spinal cord cDNA with BB665, a sense primer just upstream of TMI in human NPFF2, and BB795, an antisense primer in the second extracellular loop of the rat NPFF2. For the COOH terminal sequence, PCR was performed on rat spinal cord cDNA with BB793, a sense primer from the third intracellular loop in rat NPFF2, and BB668, an antisense primer just downstream from TMVII in human NPFF2. PCR was performed using the Expand Long Template PCR System (Roche Biochemicals, Indianapolis, IN) with buffer 2 (NH₂ terminal) or buffer 1 (COOH terminal) and the following conditions: 30 seconds at 94°C, 30 seconds at 42°C (NH₂ terminal) or 50°C (COOH terminal), 1.5 minutes at 68°C for 40 cycles, with a pre- and post-incubation of 3 minutes at 94°C and 4 minutes at 68°C respectively. A 500 bp band from the NH₂ terminal PCR and a 300 bp band from the COOH terminal PCR were isolated from a TAE gel, purified using the QIAQUICK gel extraction kit (QIAGEN,

Chatsworth, CA), and sequenced on both strands as described above.

5 A rat liver genomic phage library (2.75 million recombinants, Stratagene, LaJolla, CA) was screened using a ³²P-labeled oligonucleotide probe, BB712, corresponding to the second extracellular loop and TMV of the rat NPFF2 fragment above. Hybridization of nitrocellulose filter overlays of the plates was performed at high stringency: 42°C in a solution containing 50% formamide, 5x SSC (1x SSC is 0.15M sodium chloride, 0.015M sodium citrate), 1x Denhardt's solution (0.02% polyvinylpyrrolidone, 0.02% Ficoll, 0.02% bovine serum albumin), 7 mM Tris and 25 µg/ml sonicated salmon sperm DNA. The filters were washed at 15 55°C in 0.1x SSC containing 0.1% sodium dodecyl sulfate and exposed at -70°C to Kodak BioMax MS film in the presence of an intensifying screen.

20 Three positive signals, rNPFF2-1, rNPFF2-4 and rNPFF2-6 were isolated on a tertiary plating. A 3.5 kb fragment, from a BglIII/EcoRI digest of DNA isolated from rNPFF2-6, was identified by Southern blot analysis with BB712, subcloned into pcDNA3.1 (Invitrogen, San Diego, CA) and used to transform *E. coli* DH5α cells (Gibco 25 BRL, Gaithersburg MD). Plasmid DNA from one transformant was sequenced using an ABI 377 sequencer as described above. Sequencing with HK137, a sense primer from TMV of the rat NPFF2 fragment revealed the sequence for TMVII, the COOH terminus and some 3'UT. 30 Sequencing with HK139, an antisense primer from TMII of rNPFF2, revealed the presence an intron upstream of TMII.

35 To determine if any of the three positive plaques contained sequence upstream of this intron, DNA from each of the clones were spotted onto nitrocellulose and

hybridized with HK140, an oligonucleotide probe corresponding to TMI of the rat NPFF2 fragment. The rNPFF2-1 and rNPFF2-4 clones were positive. A 2.1 kb fragment, from a *Hind*III digest of DNA isolated from rNPFF2-4, was identified by Southern blot analysis with HK140, subcloned into pcDNA3.1 (Invitrogen, San Diego, CA) and used to transform *E.coli* DH5 α cells (Gibco BRL, Gaithersburg MD). Sequencing of this fragment with HK138, an antisense primer from TMI of rat NPFF2, revealed the NH₂ terminus and 5'UT of the rat NPFF2 receptor.

The full-length NPFF2 was amplified from rat spinal cord cDNA using a sense primer in the 5'UT (HK146, also incorporating a *Bam*HI restriction site) and an antisense primer from the 3'UT (HK147, also incorporating a *Bst*XI restriction site) and the Expand Long Template PCR System (Roche Molecular Biochemicals, Indianapolis, IN) using buffer 2 and the following PCR conditions: 30 seconds at 94°C, 2.5 minutes at 68°C for 32 cycles, with a pre- and post-incubation of 5 minutes at 94°C and 7 minutes at 68°C, respectively. Products from 5 independent PCR reactions were gel-purified. 1 μ l of each reaction was used as a template to re-amplify the product using the same PCR conditions. The products were digested with *Bam*HI and *Bst*XI and ligated into a modified pcDNA3.1 vector (Invitrogen, San Diego, CA). Products from each PCR reaction were sequenced as above. While a consensus amino acid sequence was determined among the PCR products, there was some ambiguity in the nucleotide sequence at 4 positions. To determine if this represented PCR-induced errors or allelic variations, the areas in question were amplified from several lots of genomic DNA. Sequencing of these genomic products revealed the same ambiguities, suggesting allelic variations at

these residues. One construct, KO31, was renamed BO119 and later renamed pcDNA3.1-rNPFF2-f.

5 Oligonucleotide primers and probes used in the identification and isolation of the rat NPFF2:

JAB307: 5'-TTTGTCAATTATTATGATCATCTGG-3' (SEQ ID NO: 47)
JAB306: 5'-AATAAAAAGCAGGGCCACAATCAG-3' (SEQ ID NO: 48)
BB665: 5'-TCATTATTTCTACTTTCTGATC-3' (SEQ ID NO: 49)
10 BB795: 5'-CTCATTTCTGTTTGGCCAATCC-3' (SEQ ID NO: 50)
BB793: 5'-TCTTCAAGACCTCAGCACACAGC-3' (SEQ ID NO: 51)
BB668: 5'-GAGCTGGAAAGCTTCTTGGAAACC-3' (SEQ ID NO: 52)
BB712: 5'-CTGGTGTCTGGGAGGATTGGCCAAACCAGGAAATGAGGAGGAT
CTACACC-3' (SEQ ID NO: 53)
15 HK137: 5'-GCAGTGTCAACCCCATCATTTATGG-3' (SEQ ID NO: 54)
HK138: 5'-CAAAGCAAACGACAGTGTTCCTCCACC-3' (SEQ ID NO: 55)
HK139: 5'-AGTGACCGTGTGCATGTACCTATTCC-3' (SEQ ID NO: 56)
HK140: 5'-GGTGGGAAACACTGTCGTTTGCTTTGTTGTAATAAGGAATA
GGTACATGCACACGGTCAC -3' (SEQ ID NO: 57)
20 HK146: 5'-GTCACGGATCCAGCCTCTCCTTTGATAAGGTCCACC -3'
(SEQ ID NO: 58)
HK147: 5'-GTCAGCCATCGAGTTGGCTTCGTATGCTATATAACA
TTGGATAGC-3' (SEQ ID NO: 59)

25 Isolation of other species homologs of NPFF1 or NPFF2
receptor cDNA

A nucleic acid sequence encoding a NPFF1 or NPFF2
30 receptor cDNA from other species may be isolated using
standard molecular biology techniques and approaches
such as those described below:

Approach #1: A genomic library (e.g., cosmid, phage,
P1, BAC, YAC) generated from the species of interest
35 may be screened with a ³²P-labeled oligonucleotide probe
corresponding to a fragment of the human or rat NPFF1
or NPFF2 receptors whose sequence is shown in Figures

1, 7, 11 and 22A-C to isolate a genomic clone. The full-length sequence may be obtained by sequencing this genomic clone. If one or more introns are present in the gene, the full-length intronless gene may be
5 obtained from cDNA using standard molecular biology techniques. For example, a forward PCR primer designed in the 5'UT and a reverse PCR primer designed in the 3'UT may be used to amplify a full-length, intronless receptor from cDNA. Standard molecular biology
10 techniques could be used to subclone this gene into a mammalian expression vector.

Approach #2: Standard molecular biology techniques may be used to screen commercial cDNA phage libraries of
15 the species of interest by hybridization under reduced stringency with a ³²P-labeled oligonucleotide probe corresponding to a fragment of the sequences shown in Figures 1, 7, 11 and 22A-C. One may isolate a full-length NPFF1 or NPFF2 receptor by obtaining a
20 plaque purified clone from the lambda libraries and then subjecting the clone to direct DNA sequencing. Alternatively, standard molecular biology techniques could be used to screen cDNA plasmid libraries by PCR amplification of library pools using primers designed
25 against a partial species homolog sequence. A full-length clone may be isolated by Southern hybridization of colony lifts of positive pools with a ³²P-labeled oligonucleotide probe.

30 Approach #3: 3' and 5' RACE may be utilized to generate PCR products from cDNA derived from the species of interest expressing NPFF1 or NPFF2 which contain the additional sequence of NPFF1 or NPFF2. These RACE PCR products may then be sequenced to
35 determine the additional sequence. This new sequence is then used to design a forward PCR primer in the 5'UT and a reverse primer in the 3'UT. These primers are

then used to amplify a full-length NPFF1 or NPFF2 clone from cDNA.

5 Examples of other species include, but are not limited to, mouse, dog, monkey, hamster and guinea pig.

Cell culture

10 COS-7 cells are grown on 150 mm plates in DMEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 μ g/ml streptomycin) at 37°C, 5% CO₂. Stock plates of COS-7 cells are trypsinized and split 1:6 every 3-4 days.

15 Human embryonic kidney 293 cells (HEK-293 cells) are grown on 150 mm plates in DMEM with supplements (10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 μ g/ml streptomycin) at 37°C, 5% CO₂. Stock plates of 293 cells are trypsinized and split 1:6
20 every 3-4 days.

Mouse fibroblast LM(tk-) cells are grown on 150 mm plates in D-MEM with supplements (Dulbecco's Modified Eagle Medium with 10% bovine calf serum, 4 mM
25 glutamine, 100 units/ml penicillin/100 μ g/ml streptomycin) at 37°C, 5% CO₂. Stock plates of LM(tk-) cells are trypsinized and split 1:10 every 3-4 days.

30 Chinese hamster ovary (CHO) cells were grown on 150 mm plates in HAM's F-12 medium with supplements (10% bovine calf serum, 4 mM L-glutamine and 100 units/ml penicillin/ 100 ug/ml streptomycin) at 37°C, 5% CO₂. Stock plates of CHO cells are trypsinized and split 1:8 every 3-4 days.

35 Mouse embryonic fibroblast NIH-3T3 cells are grown on 150 mm plates in Dulbecco's Modified Eagle Medium

(DMEM) with supplements (10% bovine calf serum, 4 mM glutamine, 100 units/ml penicillin/100 µg/ml streptomycin) at 37°C, 5% CO₂. Stock plates of NIH-3T3 cells are trypsinized and split 1:15 every 3-4 days.

5

Sf9 and Sf21 cells are grown in monolayers on 150 mm tissue culture dishes in TMN-FH media supplemented with 10% fetal calf serum, at 27°C, no CO₂. High Five insect cells are grown on 150 mm tissue culture dishes in Ex-Cell 400™ medium supplemented with L-Glutamine, also at 27°C, no CO₂.

10

Transient transfection

15

Receptors studied may be transiently transfected into COS-7 cells by the DEAE-dextran method using 1 µg of DNA /10⁶ cells (Cullen, 1987). In addition, Schneider 2 Drosophila cells may be cotransfected with vectors containing the receptor gene under control of a promoter which is active in insect cells, and a selectable resistance gene, eg., the G418 resistant neomycin gene, for expression of the polypeptides disclosed herein.

20

Stable transfection

25

DNA encoding the human receptor disclosed herein may be co-transfected with a G-418 resistant gene into the human embryonic kidney 293 cell line by a calcium phosphate transfection method (Cullen, 1987). Stably transfected cells are selected with G-418.

30

Membrane preparations

35

LM(tk-) cells stably transfected with the DNA encoding the human receptor disclosed herein may be routinely converted from an adherent monolayer to a viable suspension. Adherent cells are harvested with trypsin at the point of confluence, resuspended in a minimal volume of complete DMEM for a cell count, and further

diluted to a concentration of 10^6 cells/ml in suspension media (10% bovine calf serum, 10% 10X Medium 199 (Gibco), 9 mM NaHCO_3 , 25 mM glucose, 2 mM L-glutamine, 100 units/ml penicillin/100 $\mu\text{g/ml}$ streptomycin, and 0.05% methyl cellulose). Cell suspensions are maintained in a shaking incubator at 37°C , 5% CO_2 for 24 hours. Membranes harvested from cells grown in this manner may be stored as large, uniform batches in liquid nitrogen. Alternatively, cells may be returned to adherent cell culture in complete DMEM by distribution into 96-well microtiter plates coated with poly-D-lysine (0.01 mg/ml) followed by incubation at 37°C , 5% CO_2 for 24 hours.

Generation of baculovirus

The coding region of DNA encoding the human receptors disclosed herein may be subcloned into pBlueBacIII into existing restriction sites or sites engineered into sequences 5' and 3' to the coding region of the polypeptides. To generate baculovirus, 0.5 μg of viral DNA (BaculoGold) and 3 μg of DNA construct encoding a polypeptide may be co-transfected into 2×10^6 *Spodoptera frugiperda* insect Sf9 cells by the calcium phosphate co-precipitation method, as outlined by Pharmingen (in "Baculovirus Expression Vector System: Procedures and Methods Manual"). The cells then are incubated for 5 days at 27°C .

The supernatant of the co-transfection plate may be collected by centrifugation and the recombinant virus plaque purified. The procedure to infect cells with virus, to prepare stocks of virus and to titer the virus stocks are as described in Pharmingen's manual.

Radioligand binding assays

Cells may be screened for the presence of endogenous human receptor using radioligand binding or functional

assays (described in detail in the following experimental description). Cells with either no or a low level of the endogenous human receptors disclosed herein present may be transfected with the human receptors.

Transfected cells from culture flasks are scraped into 5 ml of 20 mM Tris-HCl, 5mM EDTA, pH 7.5, and lysed by sonication. The cell lysates are centrifuged at 1000 rpm for 5 min. at 4°C, and the supernatant is centrifuged at 30,000 x g for 20 min. at 4°C. The pellet is suspended in binding buffer (50 mM Tris-HCl, 60 mM NaCl, 1 mM MgCl, 33μM EDTA, 33 μM EGTA at pH 7.4 supplemented with 0.2% BSA, 2 μg/ml aprotinin, and 20 μM bestatin). Optimal membrane suspension dilutions, defined as the protein concentration required to bind less than 10% of the added radioligand, are added to 96-well polpropylene microtiter plates containing ³H-labeled compound, unlabeled compounds, and binding buffer to a final volume of 250 μl. In equilibrium saturation binding assays membrane preparations are incubated in the presence of increasing concentrations of [³H]-labeled compound. The binding affinities of the different compounds are determined in equilibrium competition binding assays, using [¹²⁵I]-labeled compound in the presence of ten to twelve different concentrations of the displacing ligands. Competition assay: 50pM radioligand, 10 - 12 points. Binding reaction mixtures are incubated for 2 hr at 25°C, and the reaction stopped by filtration through a double layer of GF filters treated with 0.1% polyethyleneimine, using a cell harvester. Wash buffer: 50mM Tris-HCl, 0.1% BSA. Radioactivity may be measured by scintillation counting and data are analyzed by a computerized non-linear regression program. Non-specific binding is defined as the amount of radioactivity remaining after incubation of membrane

protein in the presence of $1\mu\text{M}$ final concentration unlabeled. Protein concentration may be measured by the Bradford method using Bio-Rad Reagent, with bovine serum albumin as a standard.

5

Functional assays

Cells may be screened for the presence of endogenous mammalian receptor using radioligand binding or functional assays (described in detail in the above or following experimental description, respectively). Cells with no or a low level of endogenous receptor present may be transfected with the mammalian receptor for use in the following functional assays.

15 A wide spectrum of assays can be employed to screen for the presence of receptor ligands. These range from traditional measurements of phosphatidyl inositol, cAMP, Ca^{++} , and K^{+} , for example; to systems measuring these same second messengers but which have been modified or adapted to be higher throughput, more generic, and more sensitive; to cell based platforms reporting more general cellular events resulting from receptor activation such as metabolic changes, differentiation, and cell division/proliferation, for example; to high level organism assays which monitor complex physiological or behavioral changes thought to be involved with receptor activation including cardiovascular, analgesic, orexigenic, anxiolytic, and sedation effects, for example.

30

Cyclic AMP (cAMP) formation assay

The receptor-mediated inhibition of cyclic AMP (cAMP) formation may be assayed in transfected cells expressing the mammalian receptors. Cells are plated in 96-well plates and incubated in Dulbecco's phosphate buffered saline (PBS) supplemented with 10 mM HEPES, 5mM theophylline, 2 $\mu\text{g/ml}$ aprotinin, 0.5 mg/ml

35

leupeptin, and 10 $\mu\text{g/ml}$ phosphoramidon for 20 min at 37°C, in 5% CO_2 . Test compounds are added and incubated for an additional 10 min at 37°C. The medium is then aspirated and the reaction stopped by the addition of 100 mM HCl. The plates are stored at 4°C for 15 min, and the cAMP content in the stopping solution measured by radioimmunoassay. Radioactivity may be quantified using a gamma counter equipped with data reduction software.

Arachidonic acid release assay

Cells stably transfected with the mammalian receptor are seeded into 96 well plates and grown for 3 days in HAM's F-12 with supplements. ^3H -arachidonic acid (specific activity = 0.75 $\mu\text{Ci/ml}$) is delivered as a 100 μL aliquot to each well and samples were incubated at 37° C, 5% CO_2 for 18 hours. The labeled cells are washed three times with 200 μL HAM's F-12. The wells are then filled with medium (200 μL) and the assay is initiated with the addition of peptides or buffer (22 μL). Cells are incubated for 30 min at 37°C, 5% CO_2 . Supernatants are transferred to a microtiter plate and evaporated to dryness at 75°C in a vacuum oven. Samples are then dissolved and resuspended in 25 μL distilled water. Scintillant (300 μL) is added to each well and samples are counted for ^3H in a Trilux plate reader. Data are analyzed using nonlinear regression and statistical techniques available in the GraphPAD Prism package (San Diego, CA).

Intracellular calcium mobilization assay

The intracellular free calcium concentration may be measured by microspectrofluorimetry using the fluorescent indicator dye Fura-2/AM (Bush et al, 1991). Stably transfected cells are seeded onto a 35 mm culture dish containing a glass coverslip insert. Cells are washed with HBS and loaded with 100 μL of

Fura-2/AM (10 μ M) for 20 to 40 min. After washing with HBS to remove the Fura-2/AM solution, cells are equilibrated in HBS for 10 to 20 min. Cells are then visualized under the 40X objective of a Leitz Fluovolt FS microscope and fluorescence emission is determined at 510 nm with excitation wavelengths alternating between 340 nm and 380 nm. Raw fluorescence data are converted to calcium concentrations using standard calcium concentration curves and software analysis techniques.

Alternatively, cells expressing the mammalian receptor DNA are plated in 96-well plates and grown to confluence. Cells are incubated with a cell permeant fluorescent calcium indicator such as, but not restricted to, Fluo-3/AM. After washing with HBS to remove the Fluo-3/AM solution, cells are equilibrated for 20 min. The fluorescence emission due to intracellular calcium mobilization elicited by agonists of the expressed mammalian receptor, is determined with a fluorescence imaging plate reader (FLIPR, Molecular Devices Corporation, Sunnyvale, CA).

25 Phosphoinositide metabolism assay

Cells stably expressing the mammalian receptor cDNA are plated in 96-well plates and grown to confluence. The day before the assay the growth medium is changed to 100 μ l of medium containing 1% serum and 0.5 μ Ci [3H]myo-inositol, and the plates are incubated overnight in a CO₂ incubator (5% CO₂ at 37°C). Alternatively, arachidonic acid release may be measured if [3H]arachidonic acid is substituted for the [3H]myo-inositol. Immediately before the assay, the medium is removed and replaced by 200 μ L of PBS containing 10 mM LiCl, and the cells are equilibrated with the new medium for 20 min. During this interval

cells are also equilibrated with the antagonist, added as a 10 μ L aliquot of a 20-fold concentrated solution in PBS. The [3 H]inositol-phosphates accumulation from inositol phospholipid metabolism may be started by adding 10 μ L of a solution containing the agonist. To the first well 10 μ L may be added to measure basal accumulation, and 11 different concentrations of agonist are assayed in the following 11 wells of each plate row. All assays are performed in duplicate by repeating the same additions in two consecutive plate rows. The plates are incubated in a CO₂ incubator for 1 hr. The reaction may be terminated by adding 15 μ L of 50% v/v trichloroacetic acid (TCA), followed by a 40 min. incubation at 4 $^{\circ}$ C. After neutralizing TCA with 40 μ L of 1 M Tris, the content of the wells may be transferred to a Multiscreen HV filter plate (Millipore) containing Dowex AG1-X8 (200-400 mesh, formate form). The filter plates are prepared adding 200 μ L of Dowex AG1-X8 suspension (50% v/v, water: resin) to each well. The filter plates are placed on a vacuum manifold to wash or elute the resin bed. Each well is washed 2 times with 200 μ L of water, followed by 2 x 200 μ L of 5 mM sodium tetraborate/60 mM ammonium formate. The [3 H]IPs are eluted into empty 96-well plates with 200 μ L of 1.2 M ammonium formate/0.1 formic acid. The content of the wells is added to 3 ml of scintillation cocktail, and the radioactivity is determined by liquid scintillation counting.

30 GTP γ S functional assay

Membranes from cells transfected with the mammalian receptors are suspended in assay buffer (50 mM Tris, 100 mM NaCl, 5 mM MgCl₂, pH 7.4) supplemented with 0.1% BSA, 0.1% bacitracin and 10 μ M GDP. Membranes are incubated on ice for 20 minutes, transferred to a 96-well Millipore microtiter GF/C filter plate and mixed with GTP γ ³⁵S (e.g., 250,000 cpm/sample, specific

activity ~1000 Ci/mmol) plus or minus GTP γ S (final concentration = 100 μ M). Final membrane protein concentration \approx 90 μ g/ml. Samples are incubated in the presence or absence of porcine galanin (final concentration = 1 μ M) for 30 min. at room temperature, then filtered on a Millipore vacuum manifold and washed three times with cold assay buffer. Samples collected in the filter plate are treated with scintillant and counted for 35 S in a Trilux (Wallac) liquid scintillation counter. It is expected that optimal results are obtained when the mammalian receptor membrane preparation is derived from an appropriately engineered heterologous expression system, i.e., an expression system resulting in high levels of expression of the mammalian receptor and/or expressing G-proteins having high turnover rates (for the exchange of GDP for GTP). GTP γ S assays are well-known in the art, and it is expected that variations on the method described above, such as are described by e.g., Tian et al. (1994) or Lazareno and Birdsall (1993), may be used by one of ordinary skill in the art.

MAP kinase assay

MAP kinase (mitogen activated kinase) may be monitored to evaluate receptor activation. MAP kinase is activated by multiple pathways in the cell. A primary mode of activation involves the ras/raf/MEK/MAP kinase pathway. Growth factor (tyrosine kinase) receptors feed into this pathway via SHC/Grb-2/SOS/ras. Gi coupled receptors are also known to activate ras and subsequently produce an activation of MAP kinase. Receptors that activate phospholipase C (Gq and G11) produce diacylglycerol (DAG) as a consequence of phosphatidyl inositol hydrolysis. DAG activates protein kinase C which in turn phosphorylates MAP kinase.

MAP kinase activation can be detected by several approaches. One approach is based on an evaluation of the phosphorylation state, either unphosphorylated (inactive) or phosphorylated (active). The phosphorylated protein has a slower mobility in SDS-PAGE and can therefore be compared with the unstimulated protein using Western blotting. Alternatively, antibodies specific for the phosphorylated protein are available (New England Biolabs) which can be used to detect an increase in the phosphorylated kinase. In either method, cells are stimulated with the mitogen and then extracted with Laemmli buffer. The soluble fraction is applied to an SDS-PAGE gel and proteins are transferred electrophoretically to nitrocellulose or Immobilon. Immunoreactive bands are detected by standard Western blotting technique. Visible or chemiluminescent signals are recorded on film and may be quantified by densitometry.

Another approach is based on evaluation of the MAP kinase activity via a phosphorylation assay. Cells are stimulated with the mitogen and a soluble extract is prepared. The extract is incubated at 30°C for 10 min with gamma-³²P-ATP, an ATP regenerating system, and a specific substrate for MAP kinase such as phosphorylated heat and acid stable protein regulated by insulin, or PHAS-I. The reaction is terminated by the addition of H₃PO₄ and samples are transferred to ice. An aliquot is spotted onto Whatman P81 chromatography paper, which retains the phosphorylated protein. The chromatography paper is washed and counted for ³²P in a liquid scintillation counter. Alternatively, the cell extract is incubated with gamma-³²P-ATP, an ATP regenerating system, and biotinylated myelin basic protein bound by streptavidin to a filter support. The myelin basic protein is a

substrate for activated MAP kinase. The phosphorylation reaction is carried out for 10 min at 30°C. The extract can then be aspirated through the filter, which retains the phosphorylated myelin basic protein. The filter is washed and counted for ^{32}P by liquid scintillation counting.

Cell proliferation assay

Receptor activation of a G protein coupled receptor may lead to a mitogenic or proliferative response which can be monitored via ^3H -thymidine uptake. When cultured cells are incubated with ^3H -thymidine, the thymidine translocates into the nuclei where it is phosphorylated to thymidine triphosphate. The nucleotide triphosphate is then incorporated into the cellular DNA at a rate that is proportional to the rate of cell growth. Typically, cells are grown in culture for 1-3 days. Cells are forced into quiescence by the removal of serum for 24 hrs. A mitogenic agent is then added to the media. 24 hrs later, the cells are incubated with ^3H -thymidine at specific activities ranging from 1 to 10 uCi/ml for 2-6 hrs. Harvesting procedures may involve trypsinization and trapping of cells by filtration over GF/C filters with or without a prior incubation in TCA to extract soluble thymidine. The filters are processed with scintillant and counted for ^3H by liquid scintillation counting. Alternatively, adherant cells are fixed in MeOH or TCA, washed in water, and solubilized in 0.05% deoxycholate/0.1 N NaOH. The soluble extract is transferred to scintillation vials and counted for ^3H by liquid scintillation counting.

Promiscuous second messenger assays

It is possible to coax receptors of different functional classes to signal through a pre-selected pathway through the use of promiscuous G_q subunits. For

example, by providing a cell based receptor assay system with an endogenously supplied promiscuous G_α subunit such as $G_{\alpha 16}$ or a chimeric G_α subunit such as $G_{\alpha zq}$, a GPCR, which might normally prefer to couple through a specific signaling pathway (e.g., G_q , G_i , G_q , G_0 , etc.), can be made to couple through the pathway defined by the promiscuous G_α subunit and upon agonist activation produce the second messenger associated with that subunit's pathway. In the case of $G_{\alpha 16}$ and/or $G_{\alpha zq}$ this would involve activation of the G_q pathway and production of the second messenger phosphatidylinositol. Through the use of similar strategies and tools, it is possible to bias receptor signaling through pathways producing other second messengers such as Ca^{++} , cAMP, and K^+ currents, for example.

Microphysiometric measurement of receptor mediated extracellular acidification rates

Because cellular metabolism is intricately involved in a broad range of cellular events (including receptor activation of multiple messenger pathways), the use of microphysiometric measurements of cell metabolism can in principle provide a generic assay of cellular activity arising from the activation of any receptor regardless of the specifics of the receptor's signaling pathway.

General guidelines for transient receptor expression, cell preparation and microphysiometric recording are described elsewhere (Salon, J.A. and Owicki, J.A., 1996). Receptors and/or control vectors are transiently expressed in CHO-K1 cells, by liposome mediated transfection according to the manufacturers recommendations (LipofectAMINE, GibcoBRL, Gaithersburg, MD), and maintained in Ham's F-12 complete (10% serum). A total of $10\mu g$ of DNA is used to transfect each $75cm^2$ flask which had been split 24 hours prior to the

transfection and judged to be 70-80% confluent at the time of transfection. 24 hours post transfection, the cells are harvested and 3×10^5 cells seeded into microphysiometer capsules. Cells are allowed to attach to the capsule membrane for an additional 24 hours; during the last 16 hours, the cells are switched to serum-free F-12 complete to minimize ill-defined metabolic stimulation caused by assorted serum factors. On the day of the experiment the cell capsules are transferred to the microphysiometer and allowed to equilibrate in recording media (low buffer RPMI 1640, no bicarbonate, no serum (Molecular Devices Corporation, Sunnyvale, CA) containing 0.1% fatty acid free BSA), during which a baseline measurement of basal metabolic activity is established.

A standard recording protocol specifies a $100\mu\text{l}/\text{min}$ flow rate, with a 2 min total pump cycle which includes a 30 sec flow interruption during which the acidification rate measurement is taken. Ligand challenges involve a 1 min 20 sec exposure to the sample just prior to the first post challenge rate measurement being taken, followed by two additional pump cycles for a total of 5 min 20 sec sample exposure. Typically, drugs in a primary screen are presented to the cells at $10\mu\text{M}$ final concentration. Follow up experiments to examine dose-dependency of active compounds is then done by sequentially challenging the cells with a drug concentration range that exceeds the amount needed to generate responses ranging from threshold to maximal levels. Peptides included in the microphysiometric screen included rat NPFF (FLFQPQRF-NH₂) (SEQ ID NO: 45) and rat A-18-F-amide (AGEGLSSPFWSLAAPQRF-NH₂) (SEQ ID NO: 46). Ligand samples are then washed out and the acidification rates reported are expressed as a percentage increase of the peak response over the

baseline rate observed just prior to challenge.

Receptor/G protein co-transfection studies

5 A strategy for determining whether NPFF can couple preferentially to selected G proteins involves co-transfection of NPFF receptor cDNA into a host cell together with the cDNA for a G protein alpha sub-unit. Examples of G alpha sub-units include members of the $G_{\alpha i}/G_{\alpha o}$ class (including $G_{\alpha t2}$ and $G_{\alpha z}$), the $G_{\alpha q}$ class, 10 the $G_{\alpha s}$ class, and the $G_{\alpha 12/13}$ class. A typical procedure involves transient transfection into a host cell such as COS-7. Other host cells may be used. A key consideration is whether the cell has a downstream effector (a particular adenylate cyclase, phospholipase C, or channel isoform, for example) to support a functional response through the G protein under investigation. G protein beta gamma sub-units native 15 to the cell are presumed to complete the G protein heterotrimer; otherwise specific beta and gamma sub-units may be co-transfected as well. Additionally, any individual or combination of alpha, beta, or gamma subunits may be co-transfected to optimize the functional signal mediated by the receptor.

20

25 The receptor/G alpha co-transfected cells are evaluated in a binding assay, in which case the radioligand binding may be enhanced by the presence of the optimal G protein coupling or in a functional assay designed to test the receptor/G protein hypothesis. In one 30 example, the NPFF receptor may be hypothesized to inhibit cAMP accumulation through coupling with G alpha sub-units of the $G_{\alpha i}/G_{\alpha o}$ class. Host cells co-transfected with the NPFF receptor and appropriate G alpha sub-unit cDNA are stimulated with forskolin +/- NPFF agonist, as described above in cAMP methods. 35 Intracellular cAMP is extracted for analysis by radioimmunoassay. Other assays may be substituted for

cAMP inhibition, including GTP γ ³⁵S binding assays and inositol phosphate hydrolysis assays. Host cells transfected with NPFF minus G alpha or with G alpha minus NPFF would be tested simultaneously as negative controls. NPFF receptor expression in transfected cells may be confirmed in ¹²⁵I-NPFF protein binding studies using membranes from transfected cells. G alpha expression in transfected cells may be confirmed by Western blot analysis of membranes from transfected cells, using antibodies specific for the G protein of interest.

The efficiency of the transient transfection procedure is a critical factor for signal to noise in an inhibitory assay, much more so than in a stimulatory assay. If a positive signal present in all cells (such as forskolin-stimulated cAMP accumulation) is inhibited only in the fraction of cells successfully transfected with receptor and G alpha, the signal to noise ratio will be poor. One method for improving the signal to noise ratio is to create a stably transfected cell line in which 100% of the cells express both the receptor and the G alpha subunit. Another method involves transient co-transfection with a third cDNA for a G protein-coupled receptor which positively regulates the signal which is to be inhibited. If the co-transfected cells simultaneously express the stimulatory receptor, the inhibitory receptor, and a requisite G protein for the inhibitory receptor, then a positive signal may be elevated selectively in transfected cells using a receptor-specific agonist. An example involves co-transfection of COS-7 cells with 5-HT₄, NPFF1, and a G alpha sub-unit. Transfected cells are stimulated with a 5-HT₄ agonist +/- NPFF1 protein. Cyclic AMP is expected to be elevated only in the cells also expressing NPFF1 and the G alpha subunit of interest, and a NPFF-dependent inhibition may be measured with an

improved signal to noise ratio.

It is to be understood that the cell lines described herein are merely illustrative of the methods used to evaluate the binding and function of the mammalian receptors of the present invention, and that other suitable cells may be used in the assays described herein.

Electrophysiology

Methods for recording currents in *Xenopus* oocytes

Oocytes were harvested from *Xenopus laevis* and injected with mRNA transcripts as previously described (Quick and Lester, 1994; Smith et al., 1997). NPFF receptors and $G\alpha_{q/z}$ chimera synthetic RNA transcripts were synthesized using the T7 polymerase ("Message Machine," Ambion) from linearized plasmids or PCR products containing the complete coding region of the genes. Oocytes were injected with 10 ng NPFF receptors synthetic RNA and incubated for 3-8 days at 17 degrees. Three to eight hours prior to recording, oocytes were injected with 500 pg $G\alpha_{q/z}$ mRNA in order to observe coupling to Ca^{++} activated Cl^{-} currents. Dual electrode voltage clamp (Axon Instruments Inc.) was performed using 3 M KCl-filled glass microelectrodes having resistances of 1-2 Mohm. Unless otherwise specified, oocytes were voltage clamped at a holding potential of -80 mV. During recordings, oocytes were bathed in continuously flowing (1-3 ml/min) medium containing 96 mM NaCl, 2 mM KCl, 1.8 mM $CaCl_2$, 1 mM $MgCl_2$, and 5 mM HEPES, pH 7.5 (ND96). Drugs were applied either by local perfusion from a 10 ml glass capillary tube fixed at a distance of 0.5 mm from the oocyte, or by switching from a series of gravity fed perfusion lines.

Other oocytes may be injected with a mixture of receptor mRNAs and synthetic mRNA encoding the genes

for G-protein-activated inward rectifiers (GIRK1 and GIRK4, U.S. Patent Nos. 5,734,021 and 5,728,535). Genes encoding G-protein inwardly rectifying K⁺ (GIRK) channels 1 and 4 (GIRK1 and GIRK4) may be obtained by
5 PCR using the published sequences (Kubo et al., 1993; Dascal et al., 1993; Krapivinsky et al., 1995 and 1995b) to derive appropriate 5' and 3' primers. Human heart cDNA may be used as template together with appropriate primers.

10 Heterologous expression of GPCRs in *Xenopus* oocytes has been widely used to determine the identity of signaling pathways activated by agonist stimulation (Gundersen et al., 1983; Takahashi et al., 1987). Activation of the
15 phospholipase C (PLC) pathway is assayed by applying test compound in ND96 solution to oocytes previously injected with mRNA for the mammalian receptor and observing inward currents at a holding potential of -80 mV. The appearance of currents that reverse at -25 mV and display other properties of the Ca⁺⁺-activated Cl⁻ (chloride) channel is indicative of mammalian
20 receptor-activation of PLC and release of IP3 and intracellular Ca⁺⁺. Such activity is exhibited by GPCRs that couple to G_q.

25 Measurement of inwardly rectifying K⁺ (potassium) channel (GIRK) activity may be monitored in oocytes that have been co-injected with mRNAs encoding the mammalian receptor, GIRK1, and GIRK4. The two GIRK
30 gene products co-assemble to form a G-protein activated potassium channel known to be activated (i.e., stimulated) by a number of GPCRs that couple to G_i or G_o (Kubo et al., 1993; Dascal et al., 1993). Oocytes expressing the mammalian receptor plus the two GIRK
35 subunits are tested for test compound responsivity by measuring K⁺ currents in elevated K⁺ solution containing 49 mM K⁺. Activation of inwardly rectifying currents

that are sensitive to 300 μM Ba^{++} signifies the mammalian receptor coupling to a G_i or G_o pathway in the oocytes.

5 **Localization of mRNA coding for rat NPFF1 receptors**

Development of probes for NPFF1: To facilitate the production of radiolabeled, antisense RNA probes a fragment of the gene encoding rat NPFF1 was subcloned into a plasmid vector containing RNA polymerase promoter sites. The full length cDNA encoding the rat NPFF1 was digested with Sph I (nucleotides 766-1111), and this 345 nucleotide fragment was cloned into the Sph I site of pGEM 3z, containing both sp6 and T7 RNA polymerase promoter sites. The construct was sequenced to confirm sequence identity and orientation. To synthesize antisense strands of RNA, this construct was linearized with Hind III and T7 RNA polymerase was used to incorporate radiolabeled nucleotide as described below.

20 A probe coding for the rat glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, a constitutively expressed protein, was used concurrently. GAPDH is expressed at a relatively constant level in most tissue and its detection is used to compare expression levels of the rat NPFF1 receptors genes in different regions.

30 **Synthesis of probes:** NPFF1 and GAPDH cDNA sequences preceded by phage polymerase promoter sequences were used to synthesize radiolabeled riboprobes. Conditions for the synthesis of riboprobes were: 0.25-1.0 μg linearized DNA plasmid template, 1.5 μl of ATP, GTP, UTP (10 mM each), 3 μl dithiothreitol (0.1M), 30 units RNasin RNase inhibitor, 0.5-1.0 μl (15-20 units/ μl) RNA polymerase, 7.0 μl transcription buffer (Promega Corp.), and 12.5 μl $\alpha^{32}\text{P}$ -CTP (specific activity 3,000Ci/mmol). 0.1 mM CTP (0.02-1.0 μl) was added to

the reactions, and the volumes were adjusted to 35 μ l with DEPC-treated water. Labeling reactions were incubated at 37°C for 60 minutes, after which 3 units of RQ1 RNase-free DNase (Promega Corp.) were added to digest the template. Riboprobes were separated from unincorporated nucleotides using Microspin S-300 columns (Pharmacia Biotech). TCA precipitation and liquid scintillation spectrometry were used to measure the amount of label incorporated into the probe. A fraction of all riboprobes synthesized was size-fractionated on 0.25 mm thick 7M urea, 4.5% acrylamide sequencing gels. These gels were apposed to screens and the autoradiograph scanned using a phosphorimager (Molecular Dynamics) to confirm that the probes synthesized were full-length and not degraded.

Solution hybridization/ribonuclease protection assay

(RPA): For solution hybridization 2.0 μ g of mRNA isolated from tissues were used. Negative controls consisted of 30 μ g transfer RNA (tRNA) or no tissue blanks. All mRNA samples were placed in 1.5 ml microfuge tubes and vacuum dried. Hybridization buffer (40 μ l of 400 mM NaCl, 20 mM Tris, pH 6.4, 2 mM EDTA, in 80% formamide) containing 0.25-2.0 E⁶ counts of each probe were added to each tube. Samples were heated at 95°C for 15 min, after which the temperature was lowered to 55°C for hybridization.

After hybridization for 14-18 hr, the RNA/probe mixtures were digested with RNase A (Sigma) and RNase T1 (Life Technologies). A mixture of 2.0 μ g RNase A and 1000 units of RNase T1 in a buffer containing 330 mM NaCl, 10 mM Tris (pH 8.0) and 5 mM EDTA (400 μ l) was added to each sample and incubated for 90 min at room temperature. After digestion with RNases, 20 μ l of 10% SDS and 50 μ g proteinase K were added to each tube and incubated at 37°C for 15 min. Samples were extracted

with phenol/chloroform:isoamyl alcohol and precipitated
in 2 volumes of ethanol for 1 hr at -70°C. Pellet
Paint (Novagen) was added to each tube (2.0 µg) as a
carrier to facilitate precipitation. Following
5 precipitation, samples were centrifuged, washed with
cold 70% ethanol, and vacuum dried. Samples were
dissolved in formamide loading buffer and
size-fractionated on a urea/acrylamide sequencing gel
(7.0 M urea, 4.5% acrylamide in Tris-borate-EDTA).
10 Gels were dried and apposed to storage phosphor screens
and scanned using a phosphorimager (Molecular Dynamics,
Sunnydale, CA).

RT-PCR

15 For the detection of low levels of RNA encoding rat
NPFF1, RT-PCR was carried out on mRNA extracted from
rat tissue. Reverse transcription and PCR reactions
were carried out in 50 µl volumes using EzrTth DNA
polymerase (Perkin Elmer). Primers with the following
20 sequences were used:

RA Rsnorf2/NPFF F1:

CTCCTACTACCAACACTCCTCTCC (SEQ ID NO: 39)

RA RSNORF2/NPFF1 B1:

25 ACGGGTTACGAGCATCCAG (SEQ ID NO: 40)

These primers will amplify 490 base pair fragment from
nucleotide 574 to 1064.

30 Each reaction contained 0.2 µg mRNA and 0.3µM of each
primer. Concentrations of reagents in each reaction
were: 300µM each of dGTP, dATP, dCTP, dTTP; 2.5mM
Mn(OAc)₂; 50mM Bicine; 115 mM K acetate, 8% glycerol and
5 units EzrTth DNA polymerase. All reagents for PCR
35 (except mRNA and oligonucleotide primers) were obtained
from Perkin Elmer. Reactions were carried out under
the following conditions: 65°C, 60 min; 94°C, 2 min;

(94°C, 1 min; 65°C, 1 min) 35 cycles, 72°C, 10 min. PCR reactions were size fractionated by agarose gel electrophoresis using 10% polyacrylamide. DNA was stained with SYBR Green I (Molecular Probes, Eugene, OR) and scanned on a Molecular Dynamics (Sunnyvale, CA) Storm 860 in blue fluorescence mode at 450 nm.

Positive controls for PCR reactions consisted of amplification of the target sequence from a plasmid construct, as well as reverse transcribing and amplifying a known sequence. Negative controls consisted of mRNA blanks as well as primer blanks. To confirm that the mRNA was not contaminated with genomic RNA, samples were digested with RNases before reverse transcription. Integrity of RNA was assessed by amplification of mRNA coding for GAPDH.

Localization of mRNA coding for NPFF-like receptors (hNPFF2) using RT-PCR

For the detection of low levels of RNA encoding hNPFF2 RT-PCR was carried out on mRNA extracted from tissue. Reverse transcription and PCR reactions were carried out in 50 µl volumes using EzrTh DNA polymerase (Perkin Elmer). Primers with the following sequences were used:

JB 249: 5'-GATCAGTGGATTGGTCCAGGGAATATC-3' (SEQ ID NO: 41)

JB 250: 5'-CCAGGTAGATGTTGGCAAACAGCAC-3' (SEQ ID NO: 42)

These primers will amplify a 332 base pair fragment from TMIII to TMV.

Each reaction contained 0.1 ug mRNA and 0.3uM of each primer. Concentrations of reagents in each reaction were 300uM each of dGTP, dATP, dCTP, dTTP, 2.5mM Mn(OAc)2, 50mM Bicine, 115 mM potassium acetate, 8%

glycerol and 5 units EzrTth DNA polymerase. All reagents for PCR (except mRNA and oligonucleotide primers) were obtained from Perkin Elmer. Reactions were carried out under the following conditions: 65°C 60 min., 94°C 2 min, (94°C, 1 min, 65°C 1 min) 35 cycles, 72°C 10 min. PCR reactions were size fractionated by gel electrophoresis using 10% polyacrylamide. DNA was stained with SYBR Green I (Molecular Probes, Eugene OR) and scanned on a Molecular Dynamics (Sunnyvale, CA) Strom 860 in blue fluorescence mode at 450 nm.

Positive controls for PCR reactions consisted of amplification of the target sequence from a plasmid construct, as well as reverse transcribing and amplifying a known sequence. Negative controls consisted of mRNA blanks and primer blanks. To confirm that the mRNA was not contaminated with genomic DNA, samples were digested with RNases before reverse transcription. Integrity of RNA was assessed by amplification of mRNA coding for GAPDH.

Localization of mRNA coding for human and rat NPFF Receptors

Materials and Methods

Quantitative RT-PCR using a fluorogenic probe with real time detection: Quantitative RT-PCR using fluorogenic probes and a panel of mRNA extracted from human and rat tissue was used to characterize the localization of NPFF rat and human RNA. This assay utilizes two oligonucleotides for conventional PCR amplification and a third specific oligonucleotide probe that is labeled with a reporter at the 5' end and a quencher at the 3' end of the oligonucleotide. In the instant invention, FAM (6-carboxyfluorescein) and JOE (6 carboxy-4,5-dichloro-2,7-dimethoxyfluorescein) were the

two reporters that were utilized and TAMRA (6-carboxy-4,7,2,7'-tetramethylrhodamine) was the quencher. As amplification progresses, the labeled oligonucleotide probe hybridizes to the gene sequence between the two oligonucleotides used for amplification. The nuclease activity of Taq, or rTth thermostable DNA polymerases is utilized to cleave the labeled probe. This separates the quencher from the reporter and generates a fluorescent signal that is directly proportional to the amount of amplicon generated. This labeled probe confers a high degree of specificity. Non-specific amplification is not detected as the labeled probe does not hybridize. All experiments were conducted in a PE7700 Sequence Detection System (Perkin Elmer, Foster City CA).

Quantitative RT-PCR: For the detection of RNA encoding NPFF receptors, quantitative RT-PCR was performed on mRNA extracted from tissue. Reverse transcription and PCR reactions were carried out in 50 μ l volumes using rTth DNA polymerase (Perkin Elmer). Primers with the following sequences were used:

NPFF1 human:

Forward primer:
NPFF1h-913F
5'-CTGGTCACCGTCTACGCCTT-3' (SEQ ID NO: 60)

Reverse primer:
NPFF1h-1016R
5'-CCGCGGCGGAAGTTCT-3' (SEQ ID NO: 61)

Fluorogenic oligonucleotide probe:
NPFF1h-962T
5' (6-FAM)-ACAGCAGCGCCAACCCCATCAT- (TAMRA) 3' (SEQ ID NO:

62)

NPFF2 human:

5 Forward primer:

NPFF2h-828F

5'-CCTGATTGTGGCCCTGCT-3' (SEQ ID NO: 63)

Reverse primer:

10 NPFF2h-916R

5'-CATTTGGAGAAAGGTCAGCGTAG-3' (SEQ ID NO: 64)

Fluorogenic oligonucleotide probe:

NPFF2h-855T

15 5' (6-FAM)-CTCATGGCTGCCCCCTGTGGACTCAAT-(TAMRA)3' (SEQ ID
NO: 65)

NPFF1 rat

20 Forward primer:

NPFF1r-412F

5'-GCTGTGGAAAGGTTCCGCT-3' (SEQ ID NO: 66)

Reverse primer:

25 NPFF1r-474R

5'-CGCCTTCCGAAGGGTCA-3' (SEQ ID NO: 67)

Fluorogenic oligonucleotide probe:

NPFF1r-433T

30 5' (6-FAM)-ATCGTGCACCCTTTCCGCGAGAA-(TAMRA)3' (SEQ ID NO:
68)

NPFF2 rat

35 Forward primer:

NPFF2r deg-690F

5'-GAGGATCTACACCACCGTGCTATT-3' (SEQ ID NO: 69)

Reverse primer:

NPFF2r deg-776R

5'-GAAGCCCCAATCCTTGCATAC-3' (SEQ ID NO: 70)

Fluorogenic oligonucleotide probe:

NPFF2r-722T

5'-(6-FAM)-TCTACCTGGCTCCACTCTCCCTCATTGTT-(TAMRA)3' (SEQ
ID NO: 71)

Using these primer pairs, amplicon length is 103 bp for human NPFF1, 88 bp for human NPFF2, 62 bp for rat NPFF1, and 86 bp for rat NPFF2. Each human RT-PCR reaction contained 50 ng mRNA and each rat RT-PCR reaction contained 100 ng total RNA. Oligonucleotide concentrations were: 500 nM of forward and reverse primers, and 200 nM of fluorogenic probe. Concentrations of reagents in each reaction were: 300 μ M each of dGTP; dATP; dCTP; 600 μ M UTP; 3.0mM Mn(OAc)₂; 50 mM Bicine; 115 mM potassium acetate, 8% glycerol, 5 units rTth DNA polymerase, and 0.5 units of uracil N-glycosylase. Buffer for RT-PCR reactions also contained a fluor used as a passive reference (ROX: Perkin Elmer proprietary passive reference I). All reagents for RT-PCR (except mRNA and oligonucleotide primers) were obtained from Perkin Elmer (Foster City, CA). Reactions were carried using the following thermal cycler profile: 50°C 2 min., 60°C 30 min., 95°C 5 min., followed by 40 cycles of: 94°C, 20 sec., 62°C 1 min.

Positive controls for PCR reactions consisted of amplification of the target sequence from a plasmid construct when available. Standard curves for quantitation of human and rat NPFF1 and NPFF2 were constructed using RNA extracted from whole brain.

Negative controls consisted of mRNA blanks, as well as primer and mRNA blanks. To confirm that the mRNA was not contaminated with genomic DNA, PCR reactions were carried out without reverse transcription using Taq DNA polymerase. Integrity of RNA was assessed by amplification of RNA coding for cyclophilin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Following reverse transcription and PCR amplification, data was analyzed using Perkin Elmer sequence detection software. The fluorescent signal from each well was normalized using an internal passive reference, and data was fitted a standard curve to obtain relative quantities of NPFF mRNA expression.

Receptor Autoradiographic Experiments Localizing NPFF Receptor Subtypes in the Rat CNS

Animals

Male Sprague-Dawley rats (Charles Rivers, Rochester, NY) were euthanized using CO₂, decapitated, and their brains and peripheral tissues were immediately removed and rapidly frozen on crushed dry ice. Coronal sections of brain tissues were cut at 20μm using a cryostat, thaw-mounted onto gelatin-coated slides then stored at -20°C until binding assay.

Materials

[¹²⁵I] [D-Tyr¹- (NMe) Phe³]NPFF (specific activity 2200 Ci/mmol was synthesized by iodination with chloramine-T from NEN (Boston, MA). BIBP 3226 was from RBI (Natick, MA). Frog pancreatic polypeptide (frog PP) (Rana Temporaria) was from Peninsula (Belmont, CA), and Neuropeptide FF (NPFF) was from (Bachem, King of Prussia, PA).

In vitro autoradiography

Tissue sections were allowed to equilibrate to room temperature for one hour. Sections were then incubated at 25°C for 2 hours in 50 mM Tris-HCl buffer, pH 7.4, containing 1 mM NaCl, 1 mM MgCl₂, 0.1% Bovine Serum Albumin (Boehringer Mannheim, Indianapolis, IN) and 0.05 nM [¹²⁵I][D-Tyr¹-(NMe)Phe³]NPFF. Adjacent sections were incubated in the presence of 300 nM BIBP 3226 to selectively displace binding to NPFF1 or 300 nM frog PP to selectively displace binding to NPFF2. Nonspecific binding was determined by including 1 μM unlabeled NPFF in the incubation buffer. Sections were then washed four times, 5 minutes each, in 4°C 50 mM Tris-buffer pH 7.4 then rapidly dipped in ice-cold distilled water to remove salts. Tissues were then dried under a stream of cold air. The sections were subsequently apposed together with ¹²⁵I-plastic standard scales, to Kodak BIOMAX MS Scientific Imaging Film (Eastman Kodak Company, Rochester, NY) for three days at room temperature. Films were developed using a Kodak M35A X-OMAT Processor (Eastman Kodak Company, Rochester, NY). Specific [¹²⁵I][D-Tyr¹-(NMe)Phe³]NPFF binding to NPFF1 and NPFF2 receptors was interpreted by observation of the remaining optical density on the autoradiogram in the various regions of rat brain in the presence of the appropriate displacers.

In Vivo Experiments

Effects of NPFF on Blood Pressure in Normotensive Rats

It has been demonstrated that the intravenous administration of NPFF produces an increase in mean arterial blood pressure (MAP) (71). The following experiments were designed to determine which subtype of NPFF receptor mediates this effect.

Experimental Methods

Rats were anesthetized with urethane and PE50 cannulae were placed in the femoral artery and vein for blood pressure monitoring and drug administration, respectively. After stabilization, rats were administered 200 μ l saline vehicle; the agonists NPFF, frog pancreatic polypeptide (fPP), or the NPY-Y₁-selective agonist pLeu, Pro-NPY [(Leu³¹, Pro³⁴)-neuropeptide Y (porcine)]; or the NPY-Y₁ receptor antagonist BIBP 3226.

Effects of NPFF on the Micturition Reflex in Anesthetized Rats

The effects of compounds on the micturition reflex were assessed in the "distension-induced rhythmic contraction" (DIRC) model in rats. This model of the micturition reflex has been described in previous publications (e.g. 72, 73).

DIRC Model

Female Sprague Dawley rats weighing approximately 300g were anesthetized with subcutaneous urethane (1.2g/kg). The trachea was cannulated with PE240 tubing to provide a clear airway throughout the experiment. A midline abdominal incision was made and the left and right ureters were isolated. The ureters were ligated distally (to prevent escape of fluids from the bladder) and cannulated proximally with PE10 tubing. The incision was closed using 4-0 silk sutures, leaving the PE10 lines routed to the exterior for the elimination of urine. The bladder was canulated via the transurethral route using PE50 tubing inserted 2.5cm beyond the urethral opening. This cannula was secured to the tail using tape and connected to a pressure transducer. To prevent leakage from the bladder, the cannula was tied tightly to the exterior urethral opening using 4-0 silk.

To initiate the micturition reflex, the bladder was first emptied by applying pressure to the lower abdomen, and then filled with normal saline in 100 μ l increments (maximum = 2ml) until spontaneous bladder contractions occurred (typically 20-40 mmHg at a rate of one contraction every 2 to 3 minutes. Once a regular rhythm was established, vehicle (saline) or test compounds were administered intravenously to examine their effects on bladder activity. The effect of a compound which inhibited the micturition reflex was expressed as its "disappearance time", defined as the time between successive bladder contractions in the presence of the test compound minus the time between contractions before compound administration.

Chromosomal localization of human NPFF1 and NPFF2 receptor genes.

Chromosomal localization for human NPFF1 and NPFF2 receptor genes was established using a panel of radiation hybrids prepared by the Stanford Human Genome Center (SHGC) and distributed by Research Genetics, Inc. The "Stanford G3" panel of 83 radiation hybrids was analyzed by PCR using the same primers, probes and thermal cycler profiles as used for localization. 20 ng of DNA was used in each PCR reaction. Data was submitted to the RH Server (SHGC) which linked the NPFF1 and NPFF2 gene sequences to specific markers. NCBI LocusLink and NCBI GeneMap '99 were used for further analysis of gene localization.

Results and Discussion

Cloning and Sequencing

rNPFF1 and hNPFF1

100 ng genomic DNA was subjected to MOPAC PCR with two
5 degenerate primers designed based on the sixth and
seventh transmembrane domains of over 180 receptors
from the rhodopsin superfamily of G protein-coupled
receptors. Two products from this reaction,
MPR3-RGEN-31 and MPR3-RGEN-45 were found to be
10 identical clones of a novel DNA sequence not found in
the Genbank databases (Genembl, STS, EST, GSS), which
had 30-40% amino acid identity with the known receptors
dopamine D2, orexin 1, GALR1, angiotensin 1B and
5HT-2b. This novel clone was given the name SNORF2.

15 The full-length SNORF2 sequence was acquired by
screening rat hypothalamic cDNA libraries by PCR using
specific SNORF2 oligonucleotide primers. Pools of the
rat hypothalamic cDNA library "I" were screened by PCR
20 with SNORF2-specific primers JAB208 and JAB209. This
screen yielded a positive pool I36. Successive PCR
screening of sub-pools of this pool followed by high
stringency hybridization of isolated colonies from the
positive sub-pool I36-17 with the SNORF2-specific
25 oligonucleotide probe indicated that the isolated clone
I36E-17-1B-1 contained at least a partial clone of
SNORF2. Sequencing of I36E-17-1B-1 revealed that this
insert contained the coding region from the TMIII-TMIV
loop through the stop codon, including some 3'
30 untranslated sequence. From this sequence, a new
forward primer, JAB221, was designed in TMV. PCR
screening of a second rat hypothalamic cDNA library "J"
with primers JAB221 and JAB209, and subsequent colony
hybridization with the JAB211 probe on a low complexity
35 positive sub-pool resulted in the isolation of a SNORF2
clone J-13-16-A1. This clone contained the full-length
coding sequence of SNORF2 (1296bp) with approximately

200 bp 5'untranslated sequence and 1.3 kb 3'
untranslated sequence. The nucleotide sequence of
SNORF2 and its translated amino acid sequence are
represented in Figures 1 and 2, respectively. As shown
5 in Figure 1, SNORF2 contains two potential initiating
methionines upstream of TMI.

Hydrophobicity (Kyte-Doolittle) analysis of the amino
acid sequence of the full-length clone indicates the
10 presence of seven hydrophobic regions, which is
consistent with the seven transmembrane domains of a G
protein-coupled receptor. The seven expected
transmembrane domains are mapped out in Figure 3. A
comparison of nucleotide and peptide sequences of
15 SNORF2 with sequences contained in the
Genbank/EMBL/SwissProtPlus databases reveals that the
amino acid sequence of this clone is most related to
the orexin 1 and 2 receptors (45% and 40% identity,
respectively) as well as the neuropeptide Y receptors
20 Y1, Y2 and Y4 (~30% identity). Further homology
analysis of SNORF2 against the Synaptic Pharmaceutical
Corporation in-house database revealed that SNORF2 has
a very high degree of identity with a proprietary
Synaptic Pharmaceutical Corporation human partial GPCR
25 clone named PLC29b (85% nucleotide identity, 93% amino
acid identity). PLC29b was originally isolated from a
human genomic library using oligonucleotide probes for
NPY4, and includes part of the amino terminus and TMs
I to IV. Partial nucleotide and amino acid sequence of
30 PLC29b (human SNORF2) is represented in Figures 4 and
5, respectively. Based on sequence similarity, PLC29b
appears to be a partial clone of the human homologue of
SNORF2. Therefore, this human homolog of SNORF2 has
been named hNPFF1. A GAP alignment demonstrating the
35 high homology between these species homologues is
represented in Figure 6.

SNORF2 has several potential protein kinase C (PKC) phosphorylation motifs throughout its amino acid sequence: threonine 154 in the second intracellular loop, threonine 263 and serine 264 in the third intracellular loop, and serine 363 in the intracellular carboxy-terminal tail. It also has four potential N-linked glycosylation sites at asparagines 10 and 18 in the amino-terminal tail and at asparagines 113 and 195 in the first and second extracellular loops, respectively.

hNPFF2

In analyzing the sequence of rNPFF1 and its homology to other sequences in GenBank, a 532 bp EST with the accession number AA449919 was identified which had a high degree of identity to rNPFF1. The translation of this sequence indicated that it coded for the region between the first extracellular loop and the beginning of the sixth transmembrane domain of a G protein-coupled receptor (GPCR). Although AA449919 was documented as being similar to the *Drosophila melanogaster* NPY receptor (accession number P25931), it was found that the amino acid sequence encoded by this EST was much more similar to NPFF1. The predicted amino acid sequence of AA449919 and rNPFF1 are 50% identical, while the amino acid sequence of the *Drosophila* NPY receptor is only 31% identical to the translation of AA449919. Because of the high degree of identity between AA449919 and rNPFF1, AA449919 was given the name hNPFF2, representing a member of a novel family of NPFF receptors of which there is currently only one member, NPFF1.

The full length sequence of NPFF-like (hNPFF2) was acquired by 5'/3' RACE using human spleen cDNA as a template, as described above, demonstrating that the coding region of hNPFF-like (hNPFF2) is 1260 bp, coding

for a protein of 420 amino acids. Sequencing of clones from several independent PCR reactions using spleen, heart, and spinal cord cDNA as templates and subsequent alignment of these clones with Sequencher 3.0 was used to confirm the sequence of hNPFF-like (hNPFF2). The full-length nucleotide sequence of human NPFF2 is shown in Figure 7, and its translated amino acid sequence is shown in Figure 8. The seven putative transmembrane domains of hNPFF-like (hNPFF2) are defined in Figure 9.

Like the original EST AA449919, the amino acid sequence encoded by the full-length DNA sequence of hNPFF2 is most similar to rNPFF1 (48% identity), as shown in the GAP alignment between the two receptors in Figure 10. The next-best matches in SWPLUS to full-length hNPFF2 are the *Drosophila* NPYR (accession number P25931, 34% identity) and TLR2 (accession number P30975, 32% identity), human orexin 1 and 2 receptors (O43613, 31% and O43614, 29%, respectively) and human NPY1 and Y4 receptors (P25929, 31% and P50391, 32%, respectively). A Blast search of the EST database using the full-length nucleotide sequence of hNPFF2 revealed an EST (Accession number AA449920) that is identical to hNPFF2 from the end of TM7 through the stop codon. ESTs AA44919 and AA44920 are the same clone sequenced from 5' end or the 3' end, respectively.

hNPFF2 contains several potential N-linked glycosylation sites. The first three sites, asparagines 8, 20, and 31 are in the N-terminal extracellular domain. Another potential N-linked glycosylation site, at position 198, is in the second extracellular loop. This receptor also contains one potential PKC phosphorylation site at threonine 156 in the second intracellular loop, and two potential PKC phosphorylation sites in the third intracellular loop at threonine 254 and serine 266.

hNPFF1

The sequence of hNPFF1 from the initiating methionine to TMIV was determined to be present in a partial clone, plc29b, found in a Synaptic Pharmaceutical Corporation in-house database. Additional sequence, including TMIV through the stop codon, was determined by sequencing a vector-anchored PCR product from a human cosmid library clone identified by hybridization with a ³²P-labeled probe (BB609) corresponding to the II/III loop of plc29b. Next, a human spinal cord library was screened by PCR using primers designed against the partial hNPFF1 sequence, BB729 and BB728. One positive pool, W4, was subdivided and a positive sub-pool was screened by colony hybridization with a ³²P-labeled probe from TMII of hNPFF1, BB676. Plasmid DNA was isolated for clone W4-18-4, renamed B098, and DNA sequencing revealed that it was full-length but in the wrong orientation for expression in the expression vector pEXJ. To obtain a full-length hNPFF1 construct in the correct orientation, B098 was amplified with BB757 and BB758, and the resulting product ligated into pcDNA3.1 and transformed into DH5α cells. The sequence of one of these transformants was identical to the hNPFF1 sequence previously determined from the consensus of B098 and the two cosmid clones. This human NPFF1 construct in pcDNA3.1 in the correct orientation was renamed B0102.

The hNPFF1 clone contains an open reading frame with 1293 nucleotides and predicts a protein of 430 amino acids (Figures 11 and 12). Seven transmembrane domains predicted by hydrophobicity analysis are indicated in Figure 13. The sequence of hNPFF1 was determined to be most similar to the rat NPFF1 (86% nucleotide identity, 87% amino acid identity) and human NPFF2 (56% nucleotide identity, 49% amino acid identity (Figure 14)). The human NPFF1 receptor also shares homology

with human orexin₁ (53% nucleotide identity, 35% amino acid identity), human orexin₂ (43% nucleotide identity, 33% amino acid identity), human NPY₂ (47% nucleotide identity, 31% amino acid identity), human CCK_A (46% nucleotide identity, 32% amino acid identity), and human CCK_B (46% nucleotide identity, 26% amino acid identity).

Isolation of the Rat NPFF2 Homologue

A fragment of the rat homologue of NPFF2, from TMIV to TMVI, was amplified from rat genomic DNA, rat hypothalamic cDNA and rat spinal cord cDNA by reduced stringency PCR using oligonucleotide primers designed against the human NPFF2. Additional sequence was obtained by amplifying rat spinal cord cDNA under reduced stringency using PCR primers designed against the rat NPFF2 fragment along with primers corresponding to the NH₂- and COOH-termini of the human NPFF2 receptor. This resulted in the identification of a rat NPFF2 fragment from TMI to TMVII.

The remaining sequence of the rat NPFF2 receptor was acquired by screening a rat genomic phage library with an oligonucleotide probe corresponding to the second extracellular loop and TMV of rat NPFF2. Southern blot analysis of three isolated plaques with this same probe identified a 3.5 kb fragment which was subcloned and sequenced, revealing the COOH terminus and some 3'UT. A subsequent Southern blot analysis using an oligonucleotide probe corresponding to TMI of rat NPFF2 identified a 2.1 kb fragment which was subcloned and sequenced, revealing the NH₂ terminus and some 5'UT.

The full-length rat NPFF2 clone was amplified from rat spinal cord cDNA using a sense PCR primer corresponding to the 5'UT and an antisense primer corresponding to the 3'UT, and subcloned into pcDNA3.1. Sequencing of

5 independent PCR products revealed an open reading frame of 1251 bp that is predicted to encode a protein of 417 amino acids (Figures 22A-C and 23A-B, respectively). In addition, several potential allelic variations were identified and verified by sequencing additional genomic DNA PCR products. The allelic variations are at the following nucleotide positions (relative to Figures 22A-C): position 913 can be either G or A, position 949 can be either C or T, position 955 can be either C or T, and position 1151 can be either C or T. None of these variants alter the predicted amino acid sequence. One construct, whose nucleotide sequence is shown in Figures 22A-C was renamed pcDNA3.1-rNPFF2-f.

Hydrophobicity (Kyte-Doolittle) analysis of the amino acid sequence of the full-length clone indicates the presence of seven hydrophobic regions, which is consistent with the seven transmembrane domains of a G protein-coupled receptor. The seven expected transmembrane domains are indicated in Figures 23A-B. A comparison of nucleotide and peptide sequences of rat rNPFF2 with sequences contained in the Genbank, EMBL and SwissProtPlus databases reveals that the nucleotide sequence of this clone is 81% identical to an orphan GPCR NPGPR (GenBank accession number AF119815), and the amino acid sequence of this clone is most related to orexin-1 and orexin-2 (34% amino acid identities), NPY2 (32% amino acid identity) and GIR (31% amino acid identity). There were no sequences in the Genbank databases (Genembl, STS, EST, GSS, or SwissProt) that were identical to rat NPFF2. The rat and human NPFF2 receptors share 81% nucleotide and 78% amino acid identities (Figure 24). The rat NPFF2 and rat NPFF1 receptors share 55% nucleotide and 50% amino acid identities (Figure 25).

Rat NPFF2 has five potential N-linked glycosylation sites, at asparagines 8, 20 and 31 in the amino-terminal tail, at asparagine 198 in the second extracellular loop and at asparagine 324 in the seventh transmembrane domain. It also has three potential protein kinase C (PKC) phosphorylation motifs at threonine 156 in the second intracellular loop, and at threonine 254 and serine 265 in the third intracellular loop. NPFF2 also has two potential casein kinase II phosphorylation sites at threonine 102 in the second transmembrane domain and at serine 403 in the carboxy-terminal tail.

Electrophysiology

NPFF1

Oocytes injected with both SNORF2 and chimeric $G\alpha_{q/z}$ synthetic RNAs generated robust inward currents in response to NPFF and the related peptide A-18-F-amide at 1 μ M (Figures 15A,B). Control oocytes receiving only G-protein synthetic RNA were unresponsive to these peptides. Responses to NPFF were concentration-dependent with a threshold for activation of inward current at 30 nM. The C-terminal tetrapeptide PQRFF-amide also elicited responses at a concentration of 10 μ M (Figure 15C). Analogs of NPFF containing a tyrosine residue at the N-terminus or internally including Y-8-F-amide, [tyr⁹]A-18-F-amide and Y-18-F-amide also displayed activity at 1 μ M. Unrelated neuropeptides and other neurotransmitters including melanin concentrating hormone, orexin B, PYY, 5-HT, nociceptin, galanin and CCK failed to activate oocytes injected with the SNORF2 synthetic RNA. The functional responsiveness to NPFF and related peptides strongly suggests that SNORF2 encodes a receptor for neuropeptide FF (NPFF); therefore SNORF2 was renamed NPFF1. Similarly, SNORF2-like was renamed NPFF-like.

Oocytes injected with NPFF1 and not the chimeric G-protein synthetic RNA failed to generated responses to NPFF. This observation supports the hypothesis that NPFF1 couples to G-proteins of the $G\alpha_i/G\alpha_o/G\alpha_z$ class, and by virtue of the N-terminal portion of $G\alpha_{q/z}$, subsequently activates phospholipase C. In oocytes expressing both NPFF1 and $G\alpha_{q/z}$, Cl^- currents were abolished by prior injection of 10 mM EGTA, demonstrating the Ca^{++} dependence of these currents.

NPFF2

Oocytes injected with both the NPFF-like PCR product and chimeric $G\alpha_{q/z}$ synthetic RNAs generated large inward currents in response to 1 μM NPFF (Figure 16A). A-18-F-amide and PGRF-amide also at 1 μM activated similar inward currents, although the magnitude of currents generated by PGRF-amide were smaller. No activity was observed using FMRF-amide at 1 μM . The unrelated neuropeptides orexin A, NPY, galanin, and neurokinin A at 1 μM also failed to activate responses in oocytes injected with NPFF-like mRNA (Figure 16B). Oocytes injected with both the NPFF-like plasmid (BO89) and chimeric $G\alpha_{q/z}$ synthetic RNAs also produced robust currents in response to NPFF (Figure 16C). Based on these results, NPFF-like was renamed NPFF2. Oocytes injected with NPFF2 and not chimeric G-protein mRNA failed to generate responses to NPFF. This observation supports the hypothesis that NPFF2 couples to G-proteins of the $G\alpha_i/G\alpha_o/G\alpha_z$ class, and by virtue of the N-terminal portion of $G\alpha_{q/z}$, subsequently activates phospholipase C.

Microphysiology

CHO cells transiently expressing either NPFF1 alone or NPFF1 accompanied by the chimeric protein Gq/Gz produced robust increases in metabolism when exposed to either NPFF or the related peptide A-18-F-amide as

evidenced by increased rates of extracellular acidification when measured by the microphysiometric technique (Figures 17A and 17B). Whereas control cells, not expressing NPFF1, produced no increase in acidification rates to either NPFF or A-18-F-amide. In all cases the NPFF1 mediated responses were dose-dependent. CHO cells transfected with NPFF1 alone produced an EC50 value of 19.3 nM for NPFF while cells transfected NPFF1 and the chimeric Gz/Gq produced an EC50 of 27.7 nM for NPFF. Challenges with A-18-F-amide were conducted only on cells that had been transfected with NPFF1 alone. These cells produced an EC50 value of 150nM for A-18-F-amide. The functional responsiveness to NPFF and A-18-F-amide supports the notion that NPFF1 encodes a receptor for neuropeptide FF (NPFF).

Radioligand binding assays

Cos-7 cells transiently expressing the gene encoding the novel rat NPFF1 receptor were used for pharmacological evaluation. Membranes harvested from transiently transfected Cos-7 cells exhibited high affinity, saturable [125 I]D-Tyr-NPFF ([D-Tyr¹(NMe)Phe³]NPFF) binding. Nonlinear analysis of [125 I]D-Tyr-NPFF saturation data yielded an equilibrium dissociation constant (K_d) of 0.335 ± 0.045 nM and a binding site density (B_{max}) of 180 ± 11 fmol/mg protein. Specific [125 I]D-Tyr-NPFF binding was about 50% of total binding at a radioligand concentration equal to the K_d value. Mock-transfected host cells did not display specific [125 I]D-Tyr-NPFF binding.

To further assess the pharmacological identity of the newly isolated NPFF1 receptor gene, detailed binding properties of cloned NPFF1 receptor were determined from nonlinear analysis of competition of high affinity [125 I]D-Tyr-NPFF binding. The rank order of affinity of

compounds to displace specific [125 I]D-Tyr-NPFF binding is shown in Table 1.

5 The binding profile of rat NPFF1 was compared to that of rat spinal cord membranes. Interestingly some differences were observed in the pharmacological profile between the two preparations. (See * Table 2). Notably, fPP did not displace the binding on the NPFF1 receptor up to 1 μ M whereas it displayed a high
10 affinity at the rat spinal cord. Furthermore, several compounds displayed significantly different affinities between NPFF1 receptor and the spinal cord membranes. These compounds are highlighted in Table 1 and are ([125 I]D-Tyr-NPFF, A18Famide, Y8Famide, [Y⁹]A18Famide, Dynorphin A 1-13, Neuropeptide F and Met-Enk-NH₂.
15 These data indicate the presence of additional NPFF receptor subtypes on the rat spinal cord.

Additional pharmacological evaluation was done using
20 293 human embryonic kidney cells (HEK-293 cells) transiently expressing the genes encoding the human NPFF1, NPFF2, and rat NPFF1 receptors, as well as Cos-7 cells expressing the rat NPFF2 receptors. Nonlinear analysis of [125 I]D-Tyr-NPFF saturation binding data
25 yielded equilibrium dissociation constants (K_d) of 0.46 ± 0.10 and 0.17 ± 0.04 nM for the human NPFF1 and NPFF2, and of 0.65 ± 0.22 and 0.17 ± 0.02 nM for the rat NPFF1 and NPFF2 receptors, respectively. The binding affinities (pK_i) of various NPFF-related
30 peptides were derived from competition binding assay using [125 I]D-Tyr-NPFF as a ligand. In agreement with the data shown in Table 1, fPP showed 31- and 77-fold greater affinity for the rat and human NPFF2 receptors, respectively, when compared to the NPFF1 receptors (see
35 Table 3). The other peptides studied showed overall similar binding affinities for both the rat and human NPFF1 and NPFF2 receptors. NPFF receptors displayed

high affinity for FMRF amide and lower binding affinity for the D-Met analog, suggesting the existence of stereoselectivity for this peptide.

5 The ability of NPFF1 receptors to functionally couple to PI was tested using intact Cos-7 cells transiently expressing NPFF1. Full dose-response curves were determined for NPFF-mediated total IP release (Figure 18A). NPFF stimulated total IP release with an EC50 of 23 nM and an Emax of approximately 200% basal. This weak stimulation was most probably mediated by NPFF1 coupling to a Gi/Go G-protein via $\beta\gamma$ -induced PI turnover, since the response was abolished by pretreatment with pertussis toxin but not cholera toxin. In contrast, a robust stimulation of total IP release was observed following NPFF in Cos-7 cells transfected with both the NPFF1 receptor and the Gq/Gz chimera (Figure 18B). NPFF stimulated total IP release with an EC50 of 2.95 nM, and an Emax of approximately 1500% basal. As anticipated, neither PTX nor CTX attenuated this response. Similar to what was observed in oocytes, this suggests a coupling in Cos-7 cells to G-proteins of the G α i/G α o/G α z class.

25 The coupling of human NPFF1 and NPFF2 receptors to the activation of intracellular second messenger pathways was studied further in COS-7 cells co-transfected with the Gq/Gz chimera. In such cells, NPFF elicited an increase in intracellular calcium when either the human NPFF1 or NPFF2 were transfected, and no response was observed in cells that were only transfected with the Gq/Gz chimera. As shown in Table 4, PQRF amide was a full agonist in cells expressing either the NPFF1 or NPFF2 receptors. However, only cells expressing the human NPFF2 responded with an intracellular calcium response to fPP, no response was observed in cells expressing the human NPFF1 receptor, suggesting that

fPP is an NPFF2-selective agonist.

Table 1

pKi for cloned rat NPFF1 receptor binding in COS-7 cells

	COMPOUND	MEAN	SEM	n
5	NPFF (F-8-Fa)	8.535	0.02	2
	(D-Tyr ¹ - (NMe) Phe ³) NPFF	8.549	0.13	4
	A18Fa	7.495	0.11	2
	PQRFa	8.182	0.03	2
	FMRFa	8.481	0.05	2
10	YFa	8.382	0.22	2
	[Y ⁹]A18Fa	7.558	0.12	2
	hPP	5	0	2
	fPP	5.5	0.35	2
	substance P	5	0	2
15	Dynorphin A1-13	6.838	0.29	2
	(3D) Y8Fa	8.623	0.44	4
	(2D) Y8Fa	8.33	0.15	4
	CCK8	5	0	2
	galanin	5	0	2
20	dopamine	5	0	2
	naloxone	5	0	2
	CGRP	5	0	2
	AF-1	6.634	0.13	2
	AF-2	7.023	0.41	2
25	SchistFLRF	5.96	0.68	2
	Met5-Arg6-Phe7-Enk-NH ₂	7.35	0.22	4
	Met5-Arg6-Phe7-Enk-OH	5	0	2
	Neuropeptide F	6.11	0.06	4
30	desamino-nor-Y8Ra	7.27	0.1	3
	(2DME) Y8Fa	9.2	0.01	3
	L-arginine	5	0	1

5	D-arginine	5	0	1
	desipramine	5	0	1
	fenfluramine	5	0	1
	harmine	5	0	1
	levocabastine	5	0	1
10	ibogaine	5	0	1
	ritanserine	5	0	1
	a-MSH	5	0	1
	Tyr-MIF-1	5	0	1
	nociceptin	5	0	1
15	nocistatin	5	0	1
	PMRFa	8.55	0.06	2
	FTRF	7.87	0.1	2
	FFRF	8	0	2

Table 2

pKi for rat spinal cord membrane receptor binding

5	COMPOUND	MEAN	SEM	n
	NPFF (F-8-fa)	9.055	0.08	2
	(D-Tyr ¹ - (NMe) Phe ³) NPFF	*9.724	0.25	4
	A18Fa	*9.000	0.21	2
	PQRFa	8.541	0.07	2
10	FMRFa	8.493	0.23	2
	Y8Fa	*9.189	0.06	2
	[Y ⁹]A18Fa	*8.502	0.01	2
	hPP	5	0	3
	fPP	*9.118	0.06	3
15	substance P	5	0	1
	Dynorphin A1-13	*5.700	0.5	2
	(3D)Y8Fa	9.123	0.12	4
	(2D)Y8Fa	*9.212	0.23	4
	CCK8	5	0	2
20	galanin	5	0	2
	dopamine	5	0	2
	naloxone	5	0	2
	CGRP	5	0	2
	AF-1	*7.563	0.47	2
25	AF-2	*7.965	0.24	2
	SchistFLRF	6.39	0.23	2
	Met-Enk-NH2	*8.400	0.08	4
	Met-Enk-OH	5	0	2
	Neuropeptide F	*8.100	0.1	3
30	desamino-nor-Y8Ra	7.51	0.07	3
	(2DME)Y8Fa	9.57	0.3	4
	L-arginine	5	0	1

5	D-arginine	5	0	1
	desipiramine	5	0	1
	fenfluramine	5	0	1
	harmine	5	0	1
	levocabastine	5	0	1
10	ibogaine	5	0	1
	ritanserine	5	0	1
	α -MSH	5	0	1
	Tyr-MIF-1	5	0	1
	nociceptin	5	0	1
15	nocistatin	5	0	1
	PMRFa	9.37	0.11	2
	FTRF	8.16	0.16	2
	FFRF	8.98	0.001	2

AF-1 = FMRF-like peptide

H₂N-Lys-Asn-Gln-Phe-Ile-Arg-Phe-NH₂

AF-2 H-Lys-His-Gln-Tyr-Leu-Arg-Phe-NH₂

Schisto (FLRFNH₂) =

20 Pro-Asp-Val-Asp-His-Val-Phe-Leu-Arg-Phe-amide

Met⁵, Arg⁶, Phe⁷- NH₂ = enhephalinamide

Met⁵, Arg⁶, Phe⁷- OH = enhephalin

Table 3

pKi of NPFF-related peptides at cloned human and rat NPFF receptors in 293 human embryonic kidney cells (HEK-293 cells)

	human		rat	
	NPFF1	NPFF2	NPFF1	NPFF2
	pKi ± SEM			
(D-Tyr ¹ - (NMe) Phe ³) NPFF	8.1 ±0.06	8.5 ±0.08	8.8 ±0.005	8.7 ±0.16
fPP	5.9 ±0.09	7.4 ±0.13	5.4 ±0.10	7.3 ±0.02
FMRF amide	9.1 ±0.19	8.4 ±0.02	8.7 ±0.01	8.0 ±0.02
D-Met-FMRF amide	6.6 ±0.24	6.4 ±0.03	6.2 ±0.09	6.2 ±0.03
A18Fa	7.2 ±0.11	8.9 ±0.13	7.5 ±0.14	8.2 ±0.007
PQRFa	7.4 ±0.45	7.6 ±0.05	7.6 ±0.05	7.6 ±0.004
BIBP 3226	6.9 ±0.04	5.9 ±0.04	7.6 ±0.04	5.8 ±0.02

Table 4

Activation of intracellular calcium mobilization by
COS-7 cells expressing human NPFF receptors and Gq/Gz
chimera.

Compound	NPFF1		NPFF2	
	pEC50	% of NPFF Response	pEC50	% of NPFF Response
NPFF	7.8 ± 0.10	100	8.7 ± 0.02	100
fPP	< 5.0	0	6.7 ± 0.07	78
PQRF amide	6.7 ± 0.02	93	7.0 ± 0.04	94

Localization

Detection of mRNA coding for rat NPFF1 receptors: mRNA was isolated from multiple tissues (Table 3) and assayed as described. The distribution of mRNA encoding rat NPFF1 receptors is widespread throughout the central nervous system, and structures associated with the nervous system (Table 3, Figures 19, 20). The highest levels of rNPFF1 mRNA are found in the hypothalamus and the pituitary gland. The protected segment seen with mRNA isolated from the pituitary, adrenal gland and ovary is considerably shorter than that seen in other tissue (Figure 20) and indicates the possibility of splice variants of this receptor. Peripheral organs contain little or no mRNA encoding rNPFF1 with the exception of the testes, ovary, the adrenal medulla and the adrenal cortex. There is good correlation between the distribution determined by RT-PCR and RPA (Table 3, Figures 19, 20). RT-PCR detected rat NPFF1 in more areas than RPA as it is a more sensitive technique.

High levels of mRNA encoding NPFF receptors in the hypothalamus and pituitary, with relatively low expression in most of the other regions assayed implicates this receptor in neuroendocrine control, as well as the control of feeding and metabolic regulation. Its presence in other areas, including the spinal cord, medulla and dorsal root ganglia implicate NPFF receptors as a potential modulator of pain and/or sensory transmission. Low levels in the hippocampal formation indicate a possible role in learning and memory.

Table 5

Summary of distribution of mRNA coding for rat NPFF1
receptors

Tissue	RT-PCR	Ribonuclease protection assay (RPA)	Potential applications
adrenal cortex	+	+	regulation of steroid hormones
adrenal medulla	+	++	regulation of epinephrine release
urinary bladder	-	-	urinary incontinence
duodenum	+/-	-	gastrointestinal disorders
heart	+/-	-	cardiovascular indications
kidney	+	-	electrolyte balance, hypertension
liver	+/-	-	diabetes
lung	+/-	-	respiratory disorders, asthma
ovary	+	+	reproductive function
pancreas	+/-	NA	diabetes, endocrine disorders
spleen	+/-	-	immune disorders

5

10

15

stomach	+/-	-	gastrointestinal disorders
striated muscle	+/-	-	musculoskeletal disorders
testicle	+/-	+	reproductive function
uterus	+/-	-	reproductive function
vas deferens	-	-	reproductive function
whole brain	+++		
spinal cord	++	++	analgesia, sensory modulation and transmission
amygdala	+++	+/-	
caudate/putamen	++	-	modulation of dopaminergic function
cerebellum	+++	+	motor coordination
cerebral cortex	++	+	Sensory and motor integration, cognition
DRG	+	+	sensory transmission
hippocampus	+++	+	cognition/memory
hypothalamus	+++	+++	appetite/obesity, neuroendocrine regulation
medulla	++	++	analgesia, motor coordination

olfactory bulb	++	NA	olfaction
pituitary	+++	+++	Endocrine/neuro-endocrine regulation
substantia nigra	+++	++	Modulation of dopaminergic function
superior cervical ganglion	+	-	modulation of sympathetic innervation

NA = not assayed

5

10

Localization of mRNA coding for hNPFF2 receptors using
RT-PCR

Detection of mRNA coding for hNPFF2 receptors

5 mRNA was isolated from multiple tissues (Table 4) and
assayed as described. The distribution of mRNA
encoding hNPFF2 receptors is widespread throughout all
regions assayed. (Table 4, Figure 21).

Table 6

Distribution of mRNA coding for hNPFF2 receptors

5	Region	hNPFF2	Potential Implications
	liver	++	Diabetes
	kidney	++	Hypertension, electrolyte balance
	Lung	++	Respiratory disorders, asthma
	heart	++	Cardiovascular indications
10	stomach	++	Gastrointestinal disorders
	small intestine	++	Gastrointestinal disorders
	spleen	++	Immune function
	pancreas	++	Diabetes, endocrine disorders
	striated muscle	++	Musculoskeletal disorders
15	pituitary	++	Endocrine/neuroendocrine regulation
	whole brain	++	
	amygdala	++	Depression, anxiety, mood disorders
	hippocampus	++	Cognition/memory
	spinal cord	++	Analgesia, sensory modulation and transmission
20	cerebellum	++	Motor coordination
	thalamus	++	sensory integration

substantia nigra	++	Modulation of dopaminergic function and motor coordination
caudate	++	Modulation of dopaminergic function
fetal brain	++	Developmental disorders
fetal lung	++	Developmental disorders
fetal kidney	++	Developmental disorders
fetal liver	++	Developmental disorders
HEK-293 cells	+	
HeLa cells	-	
Jurkat cells	-	

5

10

Localization of mRNA coding for human and rat NPFF.

Results

mRNA was isolated from multiple tissues (listed in Table 7) and assayed as described.

5

Human NPFF1

Quantitative RT-PCR using a fluorogenic probe demonstrated mRNA encoding human NPFF1 RNA to be localized in highest abundance in CNS tissue. All CNS tissues assayed demonstrate moderate levels of NPFF1 RNA. The broad distribution of NPFF1 mRNA implies a modulatory role in multiple systems within the CNS. Highest levels are found in the spinal cord, hippocampus, amygdala, thalamus and hypothalamus. High levels in the spinal cord and thalamus imply an important role in sensory transmission or modulation (including nociception). The hippocampal formation and amygdala also contain high levels of NPFF1 mRNA. Localization to these structures support the hypothesis that NPFF is involved in the modulation of learning and memory as well as having a role in the regulation of fear, mood, and may provide a target for the treatment of depression, anxiety, phobias and mood disorders.

25

NPFF1 mRNA is also expressed in the hypothalamus in moderate amounts. This suggests a role in neuroendocrine regulation, regulation of circadian rhythms, regulation of appetite/feeding behavior and other functions that are modulated by the hypothalamus. NPFF1 mRNA is also expressed, although at somewhat lower levels, in the basal ganglia. The caudate-putamen, and substantia nigra both express moderate levels of NPFF1 mRNA. Localization to these regions implies a role in regulation of dopaminergic systems, and may provide a therapeutic target for

35

treatment of movement disorders such as Parkinsons disease or tardive dyskinesia. The cerebellum also contains substantial amounts of NPFF1 mRNA indicating a role in the control of movement.

5

Fetal brain, although expressing NPFF1 mRNA, does so in much lower levels than that found in the adult. There is a five-fold difference in mRNA levels between fetal and adult brain. It is not known at this time if the developmental regulation is global within the CNS or restricted to selected regions. The time course of this increase has not been examined and would be important in understanding the function of this receptor.

15

In peripheral tissue, all tissues assayed expressed measurable NPFF1 mRNA levels. However, levels in peripheral tissue are much lower than those found in the CNS. The peripheral tissues expressing the highest levels of NPFF1 mRNA are spleen, lung and fetal lung. Levels in these tissues are more than 10 fold lower than that detected in the highest CNS regions. Others tissues assayed contain low levels of NPFF1 mRNA as indicated in Table 7.

25

In summary, the distribution of human NPFF1 mRNA implies broad regulatory function in the CNS, most notably in sensory transmission, modulation of the limbic system, modulation of feeding/circadian rhythms, and modulation of extrapyramidal motor systems. Its presence, albeit at low levels in peripheral tissues implies of broad regulatory role in multiple organ systems.

35

Human NPFF2

5 Unlike the distribution of human NPFF1 mRNA, which is
expressed primarily in the CNS, the highest levels of
NPFF2 RNA are found in the placenta. Expression in the
placenta is four-fold higher than any other tissue
assayed (Table 7). Presence of high levels NPFF2
receptor mRNA in the placenta indicates a role in
gestational regulation and possible gestational
10 abnormalities. It is not known at this time, whether
NPFF2 mRNA is present at all stages of development, or
which cells in the placenta express these receptors.
Other tissues expressing NPFF2 mRNA include the small
intestine, pituitary and spleen. RNA levels in the
15 placenta are 20 fold higher than in these organs.

Within the CNS, highest levels of NPFF2 mRNA expression
are found in the amygdala, caudate-putamen, and the
hippocampal formation. These regions also express high
20 levels of NPFF1 mRNA. As with NPFF1, localization to
limbic structures supports the hypothesis that NPFF is
involved in the modulation of learning and memory as
well as having a role in the regulation of fear, mood,
and may provide a target for the treatment of
25 depression, anxiety, phobias and mood disorders.
Localization to the caudate/putamen implies regulation
of dopaminergic systems and a role in the regulation of
extrapyramidal motor systems. Other areas assayed are
listed in Table 7.

30 In summary, human NPFF2 mRNA is broadly distributed in
both CNS and peripheral tissue. This implies broad
regulatory functions in multiple organ systems. High
levels in the placenta indicate a significant role in
35 gestational physiology. Within the CNS, its implied
function is modulation of the limbic system and
extrapyramidal motor systems. Its presence, albeit at

low levels in multiple tissues implies a broad modulatory role involving multiple physiological modalities.

5 Rat NPFF1

As with the human NPFF1 receptor mRNA, highest levels of rat NPFF1 RNA are found in central nervous system structures. Highest levels are found in the hypothalamus, amygdala, and the substantia nigra. All
10 CNS structures assayed express rNPFF1 RNA (Table 8).

The high levels of NPFF1 mRNA expressed in the hypothalamus indicate a role in neuroendocrine regulation, regulation of circadian rhythms, regulation
15 of appetite and other functions that are modulated by the hypothalamus. High levels in the amygdala and other limbic (or limbic related) structures suggest a role in modulation of mood, fear, phobia, anxiety and may provide a therapeutic target for the treatment of
20 depression and other neuropsychiatric disorders.

The presence of lower levels of NPFF1 RNA in other areas such as the hippocampal formation, spinal cord, medulla, caudate-putamen, cerebral cortex, cerebellum
25 and other areas suggests diverse functions as suggested in Table 8.

The tissue showing the highest levels of NPFF1 mRNA outside the CNS is the testes. Levels in the testes
30 are more than approximately half of the levels found in the hypothalamus, and containing approximately the same levels as those found in the amygdala, substantia nigra, and olfactory bulb (see Table 8). This strongly suggests a role in endocrine regulation or reproductive
35 function. Other peripheral tissues showing moderate amounts of NPFF1 mRNA are listed in Table 8.

Rat NPFF2

As with rat NPFF1, high levels of rat NPFF2 mRNA are found in CNS structures. Highest levels are found in the spinal cord and medulla. Localization to these structures as well as moderate levels in the dorsal root and trigeminal ganglia, strongly suggest a role in sensory transmission (or modulation) including nociceptive stimuli. In addition to the above, there are also moderate levels of NPFF2 RNA localized to the retina. This suggests a role in modulation of visual stimuli or circadian rhythms.

Other CNS regions expressing high levels of NPFF2 RNA include the hypothalamus, substantia nigra and amygdala. The high levels of NPFF2 mRNA expressed in the hypothalamus indicate a role in neuroendocrine regulation, regulation of circadian rhythms, regulation of appetite and other functions that are modulated by the hypothalamus. High levels in the amygdala suggests a role in modulation of mood, fear, phobia, anxiety and may provide a therapeutic target for the treatment of depression and other neuropsychiatric disorders.

The tissue expressing the highest levels of NPFF2 mRNA outside the CNS is the heart. NPFF2 RNA levels in the heart are comparable to those found in many CNS structures. The heart expresses similar levels of NPFF2 RNA as the spinal cord, medulla, hypothalamus, or substantia nigra. Another tissue expressing moderate levels of NPFF2 mRNA is the aorta. This distribution strongly implies regulation of cardiovascular function, perhaps by innervation from brain stem autonomic centers. It is not known if the NPFF2 mRNA is localized to myocytes within the heart or if they are localized on the conductance fibers, smooth muscle, or endothelial cells.

5

10

Table 7

Distribution of mRNA coding for human NPFF receptors using qRT-PCR

(mRNA encoding NPFF is expressed as % of highest expressing tissue: spinal cord for NPFF 1 and placenta for NPFF2 + SEM)

Region	h-NPFF1	h-NPFF2	Potential applications
heart	0.21 +0.03	0.39 +0.21	Cardiovascular indications
kidney	0.67 +0.11	0.83 +0.13	Hypertension, electrolyte balance
liver	0.35 +0.07	0.21 +0.04	Diabetes
lung	6.96 +0.56	0.71 +0.09	Respiratory disorders, asthma
pancreas	0.23 +0.06	0.53 +0.09	Diabetes, endocrine disorders
pituitary	2.46 +0.32	4.65 +0.47	Endocrine/neuroendocrine regulation
placenta	0.23 +0.03	100 +13.20	Gestational abnormalities
small intestine	2.74 +0.10	4.39 +0.17	Gastrointestinal disorders
spleen	8.08 +0.55	3.81 +0.28	Immune disorders
stomach	0.55 +0.06	.095 +0.14	Gastrointestinal disorders
striated muscle	1.22 +0.16	0.78 +0.12	Musculoskeletal disorders
amygdala	43.52 +4.35	27.24 +1.78	Depression, phobias, anxiety, mood disorders
caudate-putamen	19.04 +0.75	9.30 +1.12	Modulation of dopaminergic function
cerebellum	20.48 +2.14	trace	Motor coordination

5

10

hippocampus	44.56 +5.55	7.39 +0.75	Cognition/memory
hypothalamus	20.65 +0.97	1.58 +0.02	appetite/obesity, neuroendocrine regulation
spinal cord	100 +4.97	1.32 +0.07	Analgesia, sensory modulation and transmission
substantia nigra	13.36 +0.81	0.57 +0.06	Modulation of dopaminergic function. Modulation of motor coordination.
thalamus	29.84 +3.75	2.24 +0.27	Sensory integration disorders
whole brain	21.28 +1.00	7.89 +1.12	
fetal brain	4.24 +0.33	0.69 +0.08	Developmental disorders
fetal lung	6.01 +0.89	0.37 +0.08	Developmental disorders
fetal kidney	1.89 0.23	2.86 +0.31	Developmental disorders
fetal liver	trace	0.54 +0.06	Developmental disorders

Table 8

Summary of distribution of mRNA coding for rat NPFF receptors

(mRNA encoding NPFF is expressed as % of highest expressing tissue: hypothalamus for NPFF 1 and placenta for NPFF2 + SEM)

5

10

15

20

Tissue	rNPFF1	rNPFF2	Potential applications
adipose	2.56 +0.24	11.72 +3.17	metabolic disorders
adrenal cortex	2.98 +0.35	4.70 +0.44	regulation of steroid hormones
adrenal medulla	16.84 +1.23	trace	regulation of epinephrine release
amygdala	57.09 +10.25	41.65 +5.31	depression, phobias, anxiety, mood disorders
aorta	1.23 +0.24	23.83 +3.70	cardiovascular indications
celiac plexus	3.60 +0.14	12.15 +1.25	modulation of autonomic function
cerebellum	17.33 +1.69	10.41 +1.51	motor coordination
cerebral cortex	21.72 +0.78	10.99 +2.29	Sensory and motor integration, cognition
choroid plexus	24.82 +1.10	29.54 +6.92	regulation of cerebrospinal fluid
colon	trace	8.38 +2.72	gastrointestinal disorders
dorsal root ganglia	2.77 +0.46	38.26 +3.47	sensory transmission
duodenum	trace	5.28 +0.37	gastrointestinal disorders
heart	3.19 +0.30	82.32 +7.97	cardiovascular indications
hippocampus	20.27 +1.63	8.28 +2.41	cognition/memory
hypothalamus	100 +6.15	84.26 +11.01	appetite/obesity, neuroendocrine regulation

5	kidney	1.03 +0.23	20.44 +1.36	electrolyte balance, hypertension
	liver	1.82 +0.31	3.20 +0.42	diabetes
	lung	3.72 +0.29	15.88 +4.35	respiratory disorders, asthma
	medulla	22.44 +2.21	92.01 +6.49	analgesia, motor coordination
	nucleus accumbens	34.75 +0.78	10.85 +1.60	regulation of dopaminergic function, drug addiction, neuropsychiatric disorders
10	olfactory bulb	40.96 +4.01	9.83 +4.53	olfaction
	ovary	13.74 +1.85	12.35 +2.59	reproductive function
	pancreas	trace	trace	diabetes, endocrine disorders
	pineal	trace	4.12 +0.95	regulation of melatonin release
	pituitary	23.58 +1.81	33.90 +1.94	endocrine/neuroen docrine regulation
15	retina	14.15 +0.97	40.19 +2.48	visual disorders
	salivary gland	trace	32.93 +7.48	
	spinal cord	24.00 +1.41	100 +5.91	analgesia, sensory modulation and transmission
	spleen	trace	trace	immune disorders
	stomach	trace	13.90 +0.69	gastrointestinal disorders
20	striated muscle	trace	trace	musculoskeletal disorders
	striatum	17.33 +1.69	16.37 +4.59	modulation of dopaminergic function, motor disorders
	substantia nigra	48.82 +5.54	66.83 +8.45	modulation of dopaminergic function, modulation of motor coordination

10

testes	42.61 +4.71	4.31 +0.68	reproductive function
thalamus	3.14 +0.25	14.92 +1.92	sensory integration disorders
thymus	trace	11.53 +2.92	immune disorders
trigeminal ganglia	16.09 +0.14	56.82 +2.33	sensory transmission
urinary bladder	trace	15.79 +1.39	urinary incontinence
uterus	trace	trace	reproductive disorders
vas deferens	trace	trace	reproductive function
whole brain	21.49 +1.88	23.83 +2.97	

Localization of NPFF Receptor Subtypes in the rat CNS

Telencephalon

The cerebral cortex and the amygdala displayed
5 [125I] [D-Tyr¹- (NMe)Phe³]NPFF binding just above
background for both the NPFF1 and NPFF2 receptors.

In the basal ganglia the globus pallidus was devoid of
any specific binding. [125I] [D-Tyr¹- (NMe)Phe³]NPFF
10 binding related to the NPFF2 receptor was discretely
located in the dorsolateral caudate-putamen and was
completely displaced by frog PP. NPFF1 binding sites
were evident above background in the accumbens nucleus.
Within the septum there was a rostrocaudal gradient in
15 binding sites related to NPFF1. The greatest density
of binding was observed in the more caudal laterodorsal
and the intermediate lateral septal nuclei, while
rostrally a moderate density was observed.
Additionally, moderate NPFF1 binding was detected in
20 the medial septum. See Table 9.

Diencephalon

In the thalamus the majority of
[125I] [D-Tyr¹- (NMe)Phe³]NPFF binding was related to the
25 NPFF2 receptor subtype. NPFF2 receptors were detected
in the paraventricular and paratenial nuclei, as well
as in the reticular, laterodorsal, anterior pretectal,
and parafascicular thalamic nuclei. A significant
density of NPFF1 binding sites were detected in the
30 anterodorsal thalamic nucleus with lower expression in
the paraventricular, central medial and ventral nuclei.
In the epithalamus, NPFF2 receptors were present in the
lateral habenula. See Table 9.

35 In the hypothalamus, a rostrocaudal gradient of
[125I] [D-Tyr¹- (NMe)Phe³]NPFF binding to the NPFF2

receptor was observed in the lateral hypothalamus with the highest density of binding rostrally. The medial mammillary nucleus also contained considerable NPFF2 receptor binding while moderate binding was seen in the lateral anterior hypothalamus. A lower expression of NPFF2 binding sites was observed in the lateroanterior hypothalamus. NPFF1 binding sites were difficult to determine in the hypothalamus due to high background levels and the possible underestimation of NPFF1 binding densities (see Discussion), however, NPFF1 receptor binding sites were detectable in the tuber cinereum. See Table 9.

The hippocampal formation did not exhibit any specific [¹²⁵I] [D-Tyr¹- (NMe)Phe³]NPFF binding in Ammon's horn, although, a moderate number of NPFF1 binding sites were observed in the ventral dentate gyrus. In other related limbic structures, NPFF1 receptor binding sites were detected in the bed nucleus of the stria terminalis and the pre/parasubiculum appeared to contain both NPFF1 and NPFF2 receptors. See Table 9.

Mesencephalon

[¹²⁵I] [D-Tyr¹- (NMe)Phe³]NPFF binding to NPFF2 receptors was identified in the anterior pretectal nucleus and displayed a dorsal to ventral gradient with the highest density dorsally. NPFF2-receptor binding was also observed in the medial pretectal nucleus, posterior intralaminar thalamic nucleus, interstitial nucleus of mlf, substantia nigra, compact part, interpeduncular nucleus, rostral and caudal linear nuclei of raphe, dorsal and median raphe nuclei, retrorubral field, B9 5-hydroxytryptamine cells, medial and lateral parabrachial nuclei, and the microcellular tegmental nucleus. Moderate [¹²⁵I] [D-Tyr¹- (NMe)Phe³]NPFF binding to the NPFF2 receptor was visible in the dorsal and ventral periaqueductal gray and there was a very weak

signal in the ventral periaqueductal gray related to the NPFF1 receptor. The superior colliculus, pontine nuclei, and the caudal linear raphe nucleus contained NPFF1 receptor binding sites, while the parabrachial nucleus exhibited NPFF1 binding sites just above background. See Table 9.

Rhombencephalon (Pons/Medulla)

NPFF2 receptor binding sites were evident in the medial vestibular, spinal trigeminal, gigantocellular reticular, Barrington's and ventral cochlear nuclei, in addition to the nucleus of the solitary tract. The highest density of NPFF2 binding sites in the rhombencephalon was seen in the region of the facial nerve in the vicinity of the A5 noradrenaline cells. Throughout the pons and medulla there was a low homogeneous ligand binding just above background which appeared to be related to the NPFF2 receptor. NPFF1 binding sites were detectable in Barrington's nucleus, the nucleus of the solitary tract, principal trigeminal nucleus and throughout the reticular formation. See Table 9.

Spinal cord

The dorsal horn displayed the greatest number of [125 I] [D-Tyr¹-(NMe)Phe³]NPFF binding sites in the spinal cord. Ligand binding in the substantia gelatinosa and lamina X was attributed to the NPFF2 receptor. NPFF1 binding sites were evident in the spinal cord ventral horn. See Table 9.

Table 9

Distribution of NPFF1 and NPFF2 receptors in the rat CNS

5

10

15

20

Region	rNPFF1	rNPFF2	Potential Application
Telencephalon			
cerebral cortex	+	+	Cognition, sensory and motor integration
amygdala	+	+	Emotion and memory, social behaviors, modulation of autonomic and neuroendocrine systems
vertical diagonal band	+	-	Memory, modulation of cholinergic transmission
horizontal diagonal band	+	-	Memory, modulation of cholinergic transmission
globus pallidus	-	-	
caudate-putamen	-	+	Sensory/motor integration
accumbens n.	+	-	Modulation of dopaminergic function
lateral septal n., dorsal	+	+	Modulation of higher cognitive functions, emotions, and autonomic regulation
medial septal n.	+	-	Cognitive enhancement via cholinergic system

	Diencephalon			
	para-ventricular thal. n.	+	+	
5	central medial thalamic n.	+	+	
	paratenial thalamic n.	-	+	Modulation of information to the medial prefrontal cortex
10	anterodorsal thalamic n.	+	+	Modulation of motor information to the cerebral cortex/Eye movement
	reticular thalamic n.	-	+	Alertness/sedation
15	laterodorsal thalamic n.	-	+	Emotional expression
	para-fascicular thal. n.	-	+	Motor and behavioral responses to pain
20	latero-anterior hypothal.	-	+	
	lateral hypothalamus	-	+	Ingestive behavior, modulation of pain
25	tuber cinereum	+	+	
	supra-chiasmatic n.	-	+	Circadian rhythm

5	medial mammillary n.	-	+	Integration of autonomic or limbic-related functions with movement
	lateral habenular n.	-	+	
	Hippocampal formation			
	Ammon's horn	-	-	
10	ventral dentate gyrus	+	-	Cognition/Memory
	bed n. stria terminalis	+	+	Central autonomic system
	pre/para- subiculum	+	+	Modulation of memory aquisition
	Mesencephalon			
15	anterior pretectal n.	-	+	Mediate visual reflexes/nociception
	medial pretectal n.	-	+	
	post. intra- laminar n.	-	+	
20	interstitial n. of mlf	-	+	
	superior colliculus	+	-	Modulation of visual information/spatial localization
	peri- aqueductal gray	+	+	Analgesia

5	substantia nigra, compact part	-	+	Modulation of DA function/Motor coordination
	substantia nigra, reticular part	-	-	
	inter-peduncular n.	+	+	Analgesia
10	rostral linear n. raphe	-	+	
15	caudal linear n. raphe	+	+	
	red n.	-	-	
	microcellular tegmental n.	-	+	
20	dorsal raphe n.	-	+	Analgesia
	median raphe n.	-	+	
	locus coeruleus	-	-	
25	Barrington's n.	+	+	Pontine micturition center-urinary bladder function
	A5 noradrenergic cell group	-	+	Control of autonomic functions,modulating the perception of pain;blood pressure

	Rhomb- encephalon (Pons/ Medulla)			
5	medial vestibular n.	-	+	Maintenance of balance and equilibrium, Modulating auditory information
	n. of solitary tract	+	+	Modulation of gustatory and somatosensory information
10	parabrachial n.	+	+	Modulation of visceral sensory information
	spinal trigeminal n.	-	+	Nociception
	cerebellum	-	-	
15	giganto- cellular reticular n.	+	+	Nociception/Analgesia
	ventral cochlear n.	-	+	Modulation of auditory information
20	Spinal cord			
	dorsal horn	-	+	Nociception/Analgesia
	ventral horn	+	-	
	lamina X	-	+	Nociception, sensory-visceral reflex arc

Chromosomal Localization

5 The human NPFF1 gene maps to SHGC-30283 which is localized to chromosome 10q21. The human NPFF2 receptor maps to SHGC-24728, which is localized to chromosome 4q13.2-q13.3. There are minor positional discrepancies reported in localization between the G3 and the GH4 radiation hybrid panels.

Discussion

5 The anatomical distribution of the NPFF1 and NPFF2
receptors in the rat CNS was determined by receptor
autoradiography using [125 I] [D-Tyr¹- (NMe)Phe³]NPFF at
0.05 nM and making use of subtype selective displacers
to directly visualize the individual receptors, NPFF1
and NPFF2. The radioligand exhibits a somewhat higher
affinity for the rat NPFF2 subtype (K_d = 0.22 nM)
10 relative to the rat NPFF1 subtype (K_d = 0.65 nM). Thus
the data may reflect an approximately threefold
underestimate of the NPFF1 receptor density relative to
that for the NPFF2 subtype. [125 I] [D-Tyr¹- (NMe)Phe³]NPFF
binding to the NPFF1 receptor was defined as the frog
15 PP-insensitive binding, as this compound is highly
selective for NPFF2 [pK_i = 7.3 ± 0.02 at rat NPFF2 and
 5.4 ± 0.010 at rat NPFF1 (Table 3)]. Binding to the
NPFF2 receptor was defined as the BIBP 3226-insensitive
binding, as BIBP 3226 is highly selective for the NPFF1
20 receptor [pK_i = 7.6 ± 0.04 at rat NPFF1 and 5.8 ± 0.02
at rat NPFF2] (Table 3). The results suggest that while
both NPFF1 and NPFF2 receptors are present in the rat
CNS, the NPFF2 receptor appears to be the predominantly
expressed receptor. NPFF1 and NPFF2 receptors are
25 discretely localized in a number of brain nuclei.

NPFF1 receptors were observed to be in cholinergic
forebrain regions, namely the nucleus of the diagonal
band, the medial and lateral septal nuclei, and the
30 ventral dentate gyrus. NPFF1 binding sites were also
detected in the superior colliculus and the spinal cord
ventral horn. NPFF2 receptors were found to be present
in numerous nuclei in the diencephalon, namely the
reticular and laterodorsal thalamic nuclei, the
35 suprachiasmatic, lateroanterior, lateral, and medial
mammillary hypothalamic nuclei. Caudally, NPFF2
receptors were found in the compact part of the

substantia nigra, periaqueductal gray and various raphe nuclei. In all levels of the spinal cord, the dorsal horn and lamina X contained NPFF2 receptor binding sites.

5

NPFF-like immunoreactivity (NPFF-LI) has been described in the rat brain (74, 21). The distribution of NPFF-LI in the rat CNS is very limited, the highest levels of immunoreactivity were observed in the hypothalamus and the spinal cord. NPFF-LI neurons were identified in the medial hypothalamus and nucleus of the solitary tract, while immunoreactive fibers were evident in the lateral septal nucleus, amygdala, the lateral hypothalamus, median eminence, bed nucleus of the stria terminalis, nucleus of the diagonal band, nucleus of the solitary tract, the ventral medulla and the trigeminal complex. NPFF-LI cells and terminals, as well as the mRNA for both NPFF1 and NPFF2 (Table 8), have been reported to be present in the substantia gelatinosa and lamina X at all levels of the spinal cord of rats (75, 21). The distribution of the NPFF1 and NPFF2 receptor binding sites correlates well with the distribution of the NPFF-LI neurons and terminals. Additionally, the distribution of the NPFF1 and NPFF2 receptors is concordant with previous reports of the anatomical distribution of NPFF binding sites obtained using [125 I][D-Tyr¹-(NMe)Phe³]NPFF (35) and [125 I]Y8Fa (76).

30

Potential Application

NPFF-like peptides have been associated with pain mechanisms, opioid tolerance, autonomic functions, memory and neuroendocrine regulation.

35

The anatomical distribution of NPFF-LI, NPFF2 mRNA and NPFF2 receptor binding sites supports the idea of a role for the NPFF2 receptor in the regulation of pain

and analgesia, perhaps by modulating the effects of the endogenous opioid peptides. NPFF has been shown to attenuate the analgesic effects of morphine after intrathecal and intraventricular injection (77) and the localization suggests that this effect be mediated by the NPFF2 receptor. NPFF-LI in the spinal cord is thought to be mostly of intrinsic origin and NPFF-LI cells in rostral regions of the brain do not send descending fibers to the spinal cord (75). Additionally, no NPFF-LI is found in the dorsal root ganglia, and dorsal rhizotomy does not affect NPFF-LI in the dorsal spinal cord (27, 21). NPFF2 mRNA has been identified in DRGs, and this localization might imply that NPFF2 receptors are located on the primary afferent terminals, possibly mediating neurotransmitter release. NPFF-LI is concentrated in lamina I/II, the projection site for primary afferent terminals, a region that contains the highest density of NPFF2 binding sites. In the substantia gelatinosa primary afferents also make contact with large NPFF-LI nociceptive neurons which in turn project rostrally to the mesencephalon and thalamus, possibly playing a role in the autonomic and affective responses to pain. NPFF2 mRNA has been identified in the spinal cord supporting a role for this receptor in the ascending pain pathway. In lamina X there are NPFF-LI fibers possibly related to descending projections from cells originating around the central canal. Thus, the NPFF2 receptor may also be involved in sensory-visceral reflex arcs.

To further strengthen the concept that the NPFF2 receptor may be involved in nociceptive processing, NPFF2 binding sites were localized in a variety of brain regions known to be involved in nociception and pain modulation, namely the spinal trigeminal nucleus, parabrachial nucleus, gigantocellular reticular

nucleus, A5 noradrenergic cell group, dorsal raphe nucleus, periaqueductal gray, lateral hypothalamus, and the parafascicular thalamic nucleus. Injection of an anterograde trace (PHA-L) into the intermediomedial hypothalamus, a site of NPFF-ir cell bodies, supports the concordance between the NPFF2 binding site distribution and NPFF-ir terminals in many of these regions (80). Furthermore, NPFF2 mRNA has been identified in the hypothalamus and medulla. NPFF2 mRNA was also detected in the trigeminal ganglion which is most likely one of the sources of NPFF2 receptors found in the spinal trigeminal nucleus (Table 8).

There is some discordance between the localization of NPFF1 mRNA and NPFF1 binding sites in the spinal cord.

While there is no autoradiographic evidence for NPFF1 binding sites in the dorsal horn, NPFF1 mRNA has been identified in the spinal cord and DRG (Table 8). This discrepancy might be explained by the expression of the NPFF1 receptor on the peripheral terminal projections of the DRG cells or on the projections of spinal cord neurons to the ventral horn or more rostrally in the brainstem and thalamus. The localization of NPFF1 mRNA in both spinal cord and DRG and with NPFF1 receptor binding sites in the ventral horn is consistent with a potential role for the NPFF1 receptor in the processing of nociceptive information.

NPFF-LI fibers are present in several limbic system-related structures, namely the hippocampus, lateral septal nucleus, accumbens nucleus, nucleus of the diagonal band, and bed nucleus of the stria terminalis. The NPFF1 receptor is expressed in these regions. Furthermore, NPFF1 mRNA has been detected in the accumbens nucleus, amygdala, and hippocampal formation. On the basis of this localization, a role for the NPFF1 receptor may be to regulate learning and

memory and the emotional states of fear and anxiety (78). Kavaliers and Colwell (79) have shown that mice receiving icv injections of IgG from NPFF antiserum acquire spatial tasks more slowly and perform more poorly, while icv NPFF resulted in better acquisition of memory. The effect may be associated with the hypothalamo-limbic connections containing NPFF (80).

A role for NPFF receptors in regulating sensory information might be indicated by their presence in the relay nuclei of several sensory pathways. It appears that both of the receptors may participate in the modulation of the visual system. NPFF1 receptor binding sites were observed in the superior colliculus while NPFF2 receptor binding sites were detected in the suprachiasmatic nucleus. Both of these regions receive afferents from the retina that contains mRNA for NPFF1 and NPFF2. The possibility that the NPFF2 receptor might play a modulatory role in circadian rhythms is supported by the localization of NPFF2 binding sites in the suprachiasmatic nucleus. The suprachiasmatic nucleus receives direct input from the retina and is thought to be responsible for the maintenance of circadian rhythms. In the auditory system the NPFF2 receptor appears to be a possible modulator. The NPFF2 receptor is present in the cochlear and medial vestibular nuclei.

The identification of NPFF receptor binding sites and mRNA for NPFF1 and NPFF2 in various components of the basal ganglia, namely, the accumbens nucleus, the substantia nigra, compact part, and the caudate-putamen, suggests that NPFF receptors may be involved in regulation of the dopaminergic system, although they are not found on dopaminergic neurons (81). Ibotenic acid lesion studies have shown that NPFF receptors in the substantia nigra, compact part

are on afferent fibers, and thus may indirectly influence the mesocorticolimbic system. NPFF2 receptors were identified in the dorsolateral caudate-putamen, an region which represents the target area for the somatosensory cortex and may be involved in sensorimotor integration.

Some of the highest NPFF-LI in the brain was observed in the hypothalamus, one of the main loci for NPFF-LI cell bodies (74). The lateral hypothalamus is involved in catecholaminergic and serotonergic feeding systems and plays a role in circadian feeding and spontaneous activity. The localization of NPFF2 receptor binding sites and mRNA in this region suggests that the NPFF2 receptor may be involved in the regulation of ingestive behavior. Some of the NPFF2 receptor binding sites in the hypothalamus may be located presynaptically on projections from the amygdala since NPFF2 mRNA has been detected in the amygdala (Table 8). In addition, NPFF1 mRNA was detected in the amygdala and hypothalamus (Table 8), suggesting that NPFF1 receptors may also be involved in the regulation of ingestive behaviors. While NPFF1 binding sites were not evident in the hypothalamus, there was a low density of NPFF1 binding sites seen in the amygdala. The lateral parabrachial and nucleus of the solitary tract are two other brain regions involved in the regulation of feeding that contain NPFF1 and NPFF2 receptor binding sites. The origin of dense immunoreactive terminals in these regions is thought to be from the hypothalamus where NPFF1 and NPFF2 mRNA have been found, further supporting a potential role for both receptors in ingestive behaviors.

Effects of NPFF on Blood Pressure in Normotensive Rats Results

NPFF (1.0mg/kg) produced a transient increase in MAP.

A similar increase in blood pressure was evoked by fPP (0.1 mg/kg).

5 To test whether the response to fPP was mediated by an
action at NPFF receptors or NPY-Y₁ receptors, we first
determined a dose of BIBP 3226 (NPY-Y₁ antagonist which
has relatively high affinity for the rat NPFF1
10 receptor; see Table 9) which was just sufficient to
block the pressor response to pLeu,Pro-NPY. We then
tested this same dose of BIBP 3226 against fPP and
NPFF. When administered 1 minute before the agonists,
the NPY-Y₁ receptor antagonist BIBP 3226 (0.3 mg/kg)
15 completely blocked the pressor responses to
pLeu,Pro-NPY and fPP, and reduced the response to NPFF
by ca 50%.

Discussion

The pharmacological differentiation of NPFF₁ receptor
20 *versus* the NPFF2 receptor may be accomplished by
evaluating the effects of NPFF (non-selective
NPFF1/NPFF2 receptor agonist) and fPP (agonist at NPFF-
2; inactive at NPFF1). When using fPP as such a tool,
however, it must be borne in mind that it also
25 activates NPY receptors. In these experiments, the
pressor effect of fPP was blocked completely by the
NPY-Y₁ receptor antagonist BIBP 3226, at a dose of BIBP
3226 which was just sufficient to completely block the
response to pLeu,Pro-NPY. Since the only receptor
30 which is both (1) activated by fPP and (2) blocked by
BIBP 3226 is the NPY-Y₁ receptor, we conclude that fPP
elevates blood pressure *via* activation of NPY-Y₁
receptors, not NPFF receptors. In addition, the
pressor response to NPFF was also diminished by ca 50%
35 by BIBP 3226, reflecting the higher affinity of BIBP
3226 for the NPFF1 receptor relative to the NPFF2
subtype.

Thus, the receptor subtype which mediates the pressor response to intravenously administered NPFF exhibits the following characteristics: (1) insensitive to activation by fPP, and (2) sensitive to blockade by BIBP 3226. This indicates that the pressor response to intravenously administered NPFF is predominately via activation of the NPFF1 subtype.

Effects of NPFF on the Micturition Reflex in Anesthetized Rats.

Results

We found, unexpectedly, that distension-induced rhythmic contractions of the rat bladder were inhibited by NPFF (Fig 26). The disappearance time was dose-dependently increased between 0.3 to 3.0 mg/kg, i.v. (Fig 27). Contractions were also inhibited by fPP (0.1 mg/kg; Fig 28). To test whether the response to fPP was via an action at NPFF receptors or NPY-Y₁ receptors, fPP was re-tested in the presence of BIBP 3226 (0.3 mg/kg, i.v.). In the presence of a concentration of BIBP 3226 sufficient to block fPP's pressor effect (see above), the inhibitory effect of fPP on micturition was not blocked. Furthermore, BIBP 3226 did not block the inhibitory response to NPFF.

Discussion

These results represent the first description of the inhibitory effect of NPFF on the micturition reflex. The effect was dose-dependent, consistent with an interaction between agonist and receptor. Micturition was also inhibited by fPP, which has been shown to be an agonist at the NPFF2 receptor, but devoid of agonist activity at the NPFF1 subtype (see Table 9). The failure of BIBP 3226 to block the effect of fPP on micturition, in contrast to its actions on blood pressure (see above), indicates that fPP inhibits

micturition via activation of NPFF receptors and not NPY-Y₁ receptors. Therefore, the receptor which mediates inhibition of the of the micturition reflex by intravenously administered NPFF is one which is activated by both NPFF and fPP, indicating that it is the NPFF2 subtype.

Effects of NPFF on Food Intake in Rats

The intracerebroventricular (ICV) administration of NPFF to rats was found to decrease food intake, suggesting a role for NPFF receptors in the regulation of feeding behavior (Murase et al, 1996). Interestingly, BIBP3226, a selective NPY Y₁ receptor antagonist (Doods, et al, 1996), blocks NPY induced feeding via a mechanism that is not related to NPY Y₁ receptors (Morgan et al, 1998). This notion was based on the observation that the S-enantiomer of BIBP3226, BIBP3435 is also able to block NPY induced feeding in spite of the fact that it binds with very low affinity (>10,000 nM) to the human and rat NPY Y₁ receptors. Similar findings were reported in a recent study in mice, after NPY-induced feeding was inhibited by BIBP3226, but not by another NPY Y₁ antagonist GR231118 (Iyengar et al. 1999). This evidence supports the conclusion that the inhibition of NPY induced feeding by both BIBP3226 and BIBP3435 could be better accounted for by the interaction of these two compounds at a binding site other than the NPY Y₁ receptor. As shown in Table 10, BIBP3226, and BIBP3435, bind with high affinity to the cloned NPFF1 receptors, and with lower affinity to NPFF2 receptors. Moreover, as shown in Table 11, both BIBP3226, and BIBP3435 are agonists at the cloned rat NPFF2 receptor, with no agonist activity at the cloned rat NPFF1 receptor. Interestingly, both BIBP3226 and BIBP3435 have functional potencies at the

rat NPFF2 (EC₅₀) that differ only by 10-fold, in agreement with the difference in potency of these two compounds to inhibit NPY-induced feeding (Morgan et al, 1998). Given the fact that the administration of the endogenous agonist NPFF inhibits food intake in rats, it is not unexpected that the two synthetic NPFF2 receptor agonists BIBP3226 and BIBP3435 also inhibit food intake.

The selective agonist activity of BIBP3226 and BIBP3435 at the cloned rat NPFF2 receptor together with the preferential expression of the mRNA of NPFF2 in rat hypothalamus (see Table 9), a key structure of the central nervous system involved in the regulation of feeding behavior, strongly suggest that the actions of NPFF agonists on feeding behavior are mediated by the NPFF2 subtype. Altogether these observations predict that NPFF2 receptor agonists could be used as anorectic agents for the treatment of obesity and eating disorders.

Table 10

pKi of NPFF and other synthetic peptides at cloned human and rat NPFF receptors in 293 human embryonic kidney cells (HEK-293 cells)

Compound	human		rat	
	NPFF1	NPFF2	NPFF1	NPFF2
	pKi " SEM			
NPFF	8.5 " 0.05	8.6 " 0.03	8.5 " 0.03	8.2 " 0.02
BIBP3226	6.9 " 0.04	5.9 " 0.04	7.6 " 0.04	5.8 " 0.02
BIBP3435	6.9 " 0.03	6.3 " 0.05	6.9 " 0.03	6.2 " 0.07

Table 11

Functional activity of NPFF and other synthetic peptides at cloned rat NPFF receptors in COS-7 cells

Compound	rat NPFF1		rat NPFF2	
	EC50 (nM)	Maximum Effect (% NPFF)	EC50 (nM)	Maximum Effect (% NPFF)
NPFF	9.3	100	2.3	100
BIBP3226	>10,000	0	944	67
BIBP3435	>10,000	0	5415	71

The cloning of the gene encoding NPFF receptors has provided the means to explore their physiological roles by pharmacological characterization, and by Northern and *in situ* mapping of its mRNA distribution. Further, the availability of the DNA encoding the NPFF receptors will facilitate the development of antibodies and antisense technologies useful in defining the functions of the gene products *in vivo*. Antisense oligonucleotides which target mRNA molecules to selectively block translation of the gene products *in vivo* have been used successfully to relate the expression of a single gene with its functional sequelae. Thus, the cloning of these receptor genes provides the means to explore their physiological roles in the nervous system and elsewhere, and may thereby help to elucidate structure/function relationships within the GPCR superfamily.

REFERENCES

1. Yang, H.Y., Fratta, W., Majane, E.A., and Costa, E.
Isolation, sequencing, synthesis, and
5 pharmacological characterization of two brain
neuropeptides that modulate the action of morphine.
Proc.Natl.Acad.Sci.U.S.A. 82(22):7757-7761, 1985.
2. Vilim, E.S., Ziff, E. Cloning of the neuropeptide
10 NPFF and NPAF precursor form bovine, rat, mouse,
and human. *Soc. Neurosci.* 21:760 (1995).
3. Panula, P., Aarnisalo, A.A., and Wasowicz, K.
Neuropeptide FF, a mammalian neuropeptide with
15 multiple functions [published erratum appears in
Prog. Neurobiol. 1996 Jun; 49(3):285]. *Prog.*
Neurobiol. 48(4-5):461-487, 1996.
4. Roumy, M. and Zajac, J.M. Neuropeptide FF, pain and
20 analgesia. *Eur.J.Pharmacol.* 345(1):1-11, 1998.
5. Payza, K., Akar, C.A., and Yang, H.Y. Neuropeptide
FF receptors: structure-activity relationship and
effect of morphine. *J.Pharmacol.Exp.Ther.*
25 267(1):88-94, 1993.
6. Raffa, R.B., Kim, A., Rice, K.C., de Costa, B.R.,
Codd, E.E., and Rothman, R.B. Low affinity of
FMRFamide and four FaRPs (FMRFamide-related
30 peptides), including the mammalian-derived FaRPs
F-8-Famide (NPFF) and A-18-Famide, for opioid mu,
delta, kappa 1, kappa 2a, or kappa 2b receptors.
Peptides 15(3):401-404, 1994.
7. Malin, D.H., Lake, J.R., Arcangeli, K.R., Deshotel,
35 K.D., Hausam, D.D., Witherspoon, W.E., Carter,

V.A., Yang, H.Y., Pal, B., and Burgess, K. Subcutaneous injection of an analog of neuropeptide FF precipitates morphine abstinence syndrome. *Life Sci.* 53(17):PL261-6, 1993.

5

8. Malin, D.H., Lake, J.R., Fowler, D.E., Hammond, M.V., Brown, S.L., Leyva, J.E., Prasco, P.E., and Dougherty, T.M. FMRF-NH₂-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. *Peptides* 11(2):277-280, 1990.

10

9. Malin, D.H., Lake, J.R., Leyva, J.E., Hammond, M.V., Rogillio, R.B., Arcangeli, K.R., Ludgate, K., Moore, G.M., and Payza, K. Analog of neuropeptide FF attenuates morphine abstinence syndrome. *Peptides* 12(5):1011-1014, 1991.

15

10. Lake, J.R., Hebert, K.M., Payza, K., Deshotel, K.D., Hausam, D.D., Witherspoon, W.E., Arcangeli, K.A., and Malin, D.H. Analog of neuropeptide FF attenuates morphine tolerance. *Neurosci.Lett.* 146(2):203-206, 1992.

20

11. Lake, J.R., Hammond, M.V., Shaddox, R.C., Hunsicker, L.M., Yang, H.Y., and Malin, D.H. IgG from neuropeptide FF antiserum reverses morphine tolerance in the rat. *Neurosci.Lett.* 132(1):29-32, 1991.

25

12. Malin, D.H., Lake, J.R., Smith, D.A., Jones, J.A., Morel, J., Claunch, A.E., Stevens, P.A., Payza, K., Ho, K.K., and Liu, J. Subcutaneous injection of an analog of neuropeptide FF prevents naloxone-precipitated morphine abstinence syndrome. *Drug Alcohol Depend.* 40(1):37-42, 1995.

30

35

13. Altier, N. and Stewart, J. Neuropeptide FF in the VTA blocks the analgesic effects of both intra-VTA morphine and exposure to stress. *Brain Res.* 758(1-2):250-254, 1997.
- 5 14. Oberling, P., Stinus, L., Le Moal, M., and Simonnet, G. Biphasic effect on nociception and antiopiate activity of the neuropeptide FF (FLFQPQRFamide) in the rat. *Peptides* 14(5):919-924, 10 1993.
- 15 15. Kavaliers, M. Inhibitory influences of mammalian FMRFamide (Phe-Met-Arg-Phe-amide)-related peptides on nociception and morphine- and stress-induced analgesia in mice. *Neurosci.Lett.* 115(2-3):307-312, 1990.
- 20 16. Kavaliers, M. and Yang, H.Y. IgG from antiserum against endogenous mammalian FMRF-NH2-related peptides augments morphine- and stress-induced analgesia in mice. *Peptides* 10(4):741-745, 1989.
- 25 17. Kavaliers, M. Innes, D. Sex differences in the effects of neuropeptide FF and IgG from neuropeptide FF on morphine- and stress-induced analgesia. *Peptides* 13(3):603-607, 1992.
- 30 18. Gicquel, S., Mazarguil, H., Allard, M., Simonnet, G., and Zajac, J.M. Analogues of F8Famide resistant to degradation, with high affinity and in vivo effects. *Eur.J.Pharmacol.* 222(1):61-67, 1992.
- 35 19. Gouarderes, C., Sutak, M., Zajac, J.M., and Jhamandas, K. Antinociceptive effects of intrathecally administered F8Famide and FMRFamide in the rat. *Eur.J.Pharmacol.* 237(1):73-81, 1993.

20. Gouarderes, C., Jhamandas, K., Sutak, M., and Zajac, J.M. Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues. *Br.J.Pharmacol.* 117(3):493-501, 1996.
- 5
21. Lee, C.H., Wasowicz, K., Brown, R., Majane, E.A., Yang, H.T., and Panula, P. Distribution and characterization of neuropeptide FF-like immunoreactivity in the rat nervous system with a monoclonal antibody. *Eur.J.Neurosci.* 5(10):1339-1348, 1993.
- 10
22. Kivipelto, L. Ultrastructural localization of neuropeptide FF, a new neuropeptide in the brain and pituitary of rats. *Regul.Pept.* 34(3):211-224, 1991.
- 15
23. Kivipelto, L. and Panula, P. Central neuronal pathways containing FLFQPQRFamide-like (morphine-modulating) peptides in the rat brain. *Neuroscience* 41(1):137-148, 1991.
- 20
24. Allard, M., Labrousche, S., Nosjean, A., and Laguzzi, R. Mechanisms underlying the cardiovascular responses to peripheral administration of NPPF in the rat. *J.Pharmacol.Exp.Ther.* 274(1):577-583, 1995.
- 25
25. Laguzzi, R., Nosjean, A., Mazarguil, H., and Allard, M. Cardiovascular effects induced by the stimulation of neuropeptide FF receptors in the dorsal vagal complex: An autoradiographic and pharmacological study in the rat. *Brain Res.* 711(1-2):193-202, 1996.
- 30
26. Kivipelto, L., Aarnisalo, A., and Panula, P.
- 35

Neuropeptide FF is colocalized with catecholamine-synthesizing enzymes in neurons of the nucleus of the solitary tract. *Neurosci.Lett.* 143(1-2):190-194, 1992.

5

27. Panula, P., Kivipelto, L., Nieminen, O., Majane, E.A., and Yang, H.Y. Neuroanatomy of morphine-modulating peptides. *Med.Biol.* 65(2-3):127-135, 1987.

10

28. Allard, M., Geoffre, S., Legendre, P., Vincent, J.D., and Simonnet, G. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: a binding study. *Brain Res.* 500(1-2):169-176, 1989.

15

29. Allard, M., Zajac, J.M., and Simonnet, G. Autoradiographic distribution of receptors to FLFQPQRFamide, a morphine-modulating peptide, in rat central nervous system. *Neuroscience* 49(1):101-116, 1992.

20

30. Gouarderes, C., Tafani, J.A.M., and Zajac, J.M. Affinity of neuropeptide FF analogs to opioid receptors in the rat spinal cord. *Peptides* 19(4):727-730, 1998.

25

31. Payza, K. and Yang, H.Y. Modulation of neuropeptide FF receptors by guanine nucleotides and cations in membranes of rat brain and spinal cord. *J.Neurochem.* 60(5):1894-1899, 1993.

30

32. Devillers, J.P., Mazarguil, H., Allard, M., Dickenson, A.H., Zajac, J.M., and Simonnet, G. Characterization of a potent agonist for NPFF receptors: binding study on rat spinal cord

35

membranes. *Neuropharmacology* 33(5):661-669, 1994.

- 5 33. Gicquel, S., Mazarguil, H., Desprat, C., Allard, M., Devillers, J.P., Simonnet, G., and Zajac, J.M. Structure-activity study of neuropeptide FF: contribution of N-terminal regions to affinity and activity. *J.Med.Chem.* 37(21):3477-3481, 1994.
- 10 34. Dupouy, V. and Zajac, J.M. Neuropeptide FF receptors in rat brain: A quantitative light-microscopic autoradiographic study using [125I] [D.Tyr1, (NMe)Phe3]NPFF. *Synapse* 24(3):282-296, 1996.
- 15 35. Gouarderes, C., Tafani, J.A.M., Mazarguil, H., and Zajac, J.M. Autoradiographic characterization of rat spinal neuropeptide FF receptors by using [125I] [D.Tyr1, (NMe)Phe3]NPFF. *Brain Res.Bull.* 42(3):231-238, 1997.
- 20 36. Gherardi, N. and Zajac, J.M. Neuropeptide FF receptors of mouse olfactory bulb: Binding properties and stimulation of adenylate cyclase activity. *Peptides* 18(4):577-583, 1997.
- 25 37. Kontinen, V.K., Aarnisalo, A.A., Idaenpaeaen-Heikkilae, J.J., Panula, P., and Kalso, E. Neuropeptide FF in the rat spinal cord during carrageenan inflammation. *Peptides* 18(2):287-292, 1997.
- 30 38. Wei, H., Panula, P., and Pertovaara, A. A differential modulation of allodynia, hyperalgesia and nociception by neuropeptide FF in the periaqueductal gray of neuropathic rats: Interactions with morphine and naloxone.
- 35

Neuroscience 86(1):311-319, 1998.

39. Robert, J.J., Orosco, M., Rouch, C., Jacquot, C.,
5 and Cohen, Y. Unexpected responses of the obese
"cafeteria" rat to the peptide FMRF-amide.
Pharmacol.Biochem.Behav. 34(2):341-344, 1989.
40. Murase, T., Arima, H., Kondo, K., and Oiso, Y.
10 Neuropeptide FF reduces food intake in rats.
Peptides 17(2):353-354, 1996.
41. Kavaliers, M., Hirst, M., and Mathers, A.
15 Inhibitory influences of FMRFamide on morphine- and
deprivation-induced feeding. *Neuroendocrinology*.
40(6):533-535, 1985.
42. Muthal, A.V., Mandhane, S.N., and Chopde, C.T.
20 Central administration of FMRFamide produces
antipsychotic-like effects in rodents.
Neuropeptides 31(4):319-322, 1997.
43. Malin, D.H., Lake, J.R., Short, P.E., Blossman,
25 J.B., Lawless, B.A., Schopen, C.K., Sailer, E.E.,
Burgess, K., and Wilson, O.B. Nicotine abstinence
syndrome precipitated by an analog of neuropeptide
FF. *Pharmacol.Biochem.Behav.* 54(3):581-585, 1996.
44. U. S. Patent No. 5,602,024 (Gerald et al. Feb. 11,
30 1997).
45. Coleman, A. (1984) Transcription and Translation:
A Practical Approach (B.D. Hanes, S.J. Higgins,
eds., pp 271-302, IRL Press, Oxford, 1984)
46. Dascal, N., Schreibmayer, W., Lim, N. F., Wang, W.,
35 Chavkin, C., DiMagno, L., Labarca, C., Kieffer,

B.L., Gaveriaux-Ruff, C., Trollinger, D., Lester, H. A., Davidson, N. (1993) Proc. Natl. Acad. Sci. USA 90:10235-10239.

- 5 47. Fargin, A.; Raymond, J. R.; Lohse, M. J.; Kobilka, B. K.; Caron, M. G.; Lefkowitz, R. J. Nature 335:358-360 (1988).
- 10 48. Fong, T.M.; Huang, R.C.; Yu, H.; Swain, C.J.; Underwood, D.; Cascieri, M.A.; Strader, C.D. Can. J. Physiol. Pharmacol. 73(7):860-865 (Jul 1995).
- 15 49. Graziano, M.P.; Hey, P.J.; Strader, C.D. Receptors Channels 4(1):9-17 (1996).
- 20 50. Guam, X.M.; Amend, A.; Strader, C.D.; Mol. Pharmacol. 48(3):492-498 (Sep 1995).
- 25 51. Krapivinsky, G., Gordon, E. A., Wickman B., Velimirovic, B., Krapivinsky, L., Clapham, D. E. (1995) Nature 374:135-141.
- 30 52. Krapivinsky, G., Krapivinsky, L., Velimirovic, B., Wickman, K., Navarro, B., Clapham, D. E., (1995b) J. Biol. Chem. 270:28777-28779.
- 35 53. Kubo, Y., Reuveny, E., Slesinger, P. A., Jan, Y. N., Jan, L.Y. (1993) Nature 364:802-806.
54. Masu, Y. et al. (1994) Nature 329:21583-21586.
55. Miller, J., Germain, R.N., Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J.Exp.Med. 164:1478-1489 (1986).
56. Sambrook, J., Fritsch, E. F., and Maniatis, T., In:

Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.), 1989.

- 5 57. Sanger, F., Nicklen, S. and Coulsen, A. R. Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977).
58. Southern, E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 98:503-517 (1975).
10
59. Spurney, R.F.; Coffman, T.M. J. Pharmacol. Exp. Ther. 283(1):207-215 (Oct. 1997).
- 15 60. Weinshank, R. L.; Zgombick, J. M.; Macchi, M. J.; Branchek, T. A.; Hartig, P. R. Proc. Natl. Acad. Sci. U.S.A. 89(8):3630-3634 (1992).
61. Quick, M.W., Lester, H.A. Methods for expression of excitability proteins in *Xenopus* oocytes. Meth. Neurosci. 19:261-279 (1994).
20
62. Smith, K.E., Forray, C., Walker, M.W., Jones, K.A., Tamm, J.A., Bard, J., Branchek, T.A., Linemeyer, D.L., Gerald, C. Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J. Biol. Chem. 272:24612-24616 (1997).
25
63. Salon, J.A. and Owicki, J.A. Real-time measurements of receptor activity: Application of microphysiometric techniques to receptor biology. Methods in Neuroscience 25. Receptor Molecular Biology Ed. S.C. Sealson, Academic Press, pp. 201-224 (1996).
30
64. Berridge, M.J., Downes, C.P., Hanley, M.R., Lithium
35

amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. *Biochem. J.* 206: 587-595 (1982).

- 5 65. Cullen, B., "Use of eukaryotic expression technology in the functional analysis of cloned genes", *Methods Enzymol.* 152: 685-704 (1987).
- 10 66. Bush, et al., "Nerve growth factor potentiates bradykinin-induced calcium influx and release in PC12 cells", *J. Neurochem.* 57: 562-574 (1991).
- 15 67. Gundersen, C.B., et al., "Serotonin receptors induced by exogenous messenger RNA in *Xenopus* oocytes" *Proc. R. Soc. Lond. B. Biol. Sci.* 219(1214): 103-109 (1983).
- 20 68. Lazareno, S. and Birdsall, N.J.M., "Pharmacological characterization of acetylcholine stimulated [35S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies", *Br. J. Pharmacology* 109: 1120-1127 (1993).
- 25 69. Takahashi, T., et al., "Rat brain serotonin receptors in *Xenopus* oocytes are coupled by intracellular calcium to endogenous channels." *Proc. Natl. Acad. Sci. USA* 84(14): 5063-5067 (1987).
- 30 70. Tian, W., et al., "Determinants of alpha-Adrenergic Receptor Activation of G protein: Evidence for a Precoupled Receptor/G protein State." *Molecular Pharmacology* 45: 524-553 (1994).
- 35 71. Allard, M, Labrousche, S, Nosjean, A and Laguzzi, R. Mechanisms underlying the cardiovascular responses

to peripheral administration of NPFF in the rat.
J Pharmacol Exp Ther 274: 577-583, 1995.

- 5 72. Maggi, CA, Furio, M, Santicioli, P, Conte, B and
Meli, A. Spinal and supraspinal components of
GABAergic inhibition of the micturition reflex in
rats. *J Pharmacol Exp Ther* 240: 998-1005, 1987.
- 10 73. Morikawa, K, Hashimoto, S, Yamauchi, T, Kato, H,
Ito and Y, Gomi, Y. Inhibitory effect of
inaperisone hydrochloride (inaperisone), a new
centrally acting muscle relaxant, on the
micturition reflex. *Eur J Pharmacol* 213: 409-415,
1992.
- 15 74. Kivipelto, L., and Panula, P. Immunohistochemical
distribution and partial characterization of
FLFQPQRFamide-like peptides in the central nervous
system of rats. *J. Comp. Neurol.* 28:269-287, 1989.
- 20 75. Kivipelto, L., and Panula, P. Origin and
distribution of Neuropeptide-FF-like
immunoreactivity in the spinal cord of rats. *J.*
Comp. Neurol. 307:107-119, 1991.
- 25 76. Allard, M., Zajac, J.-M., Simonnet, G.
Autoradiographic distribution of receptors to
FLFQPQRFamide, a morphine-modulating peptide, in
rat central nervous system. *Neurosci.*
30 49(1):101-116, 1992.
- 35 77. Tang, J., Yang, H.-Y., Costa, E. Inhibition of
spontaneous and opiate-modified nociception by an
endogenous neuropeptide with
phe-met-arg-phe-NH₂-like immunoreactivity. *Proc.*
Natl. Acad. Sci. USA. 81:5002-5005, 1984.

78. Herman, J.P., Cullinan, W.E. Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. *Trends in Neurosci.* 78:3351-3358, 1997.
- 5
79. Kavaliers, M., Colwell, D.D. Neuropeptide FF (FLFQPQRFamide) and IgG from neuropeptide FF antiserum affect spatial learning in mice. *Neurosci. Lett.* 157:75-78, 1993.
- 10
80. Aarnisalo, A.A. and Panula, P. Neuropeptide FF-containing efferent projections from the medial hypothalamus of rat: a Phaseolus vulgaris leucoagglutinin study. *Neuroscience* 5:175-192, 1995.
- 15
81. Marco, N., Stinus, L., Allard, M., Le Moal, M., Simonnet, G. Neuropeptide FLFQPQRFamide receptors within the ventral mesencephalon and dopaminergic terminal areas: localization and functional antiopioid involvement. *Neuroscience* 4(4): 1035-1044, 1995.
- 20
82. Burns, C.M., et al. (1996) *Neuroscience Abstracts* 385.9.
- 25
83. Chu, H., et al. (1996) *Neuroscience Abstracts* 385.10.
- 30
84. Underwood, D.J., et al. (1994) "Structural Model of Antagonist and Agonist Binding To The Angiotensin II, AT1 Subtype, G protein Coupled Receptor", *Chem. Biol.* 1(4): 211-21.
- 35
85. Muthal, A.V. and Chopde, C.T. Anxiolytic effect of neuropeptide FMRamide in rats. *Neuropeptides.* 27: 105-108, 1994.

- 5 86. Arima, H., Takashi, M., Kondo, K., Iwasaki, Y. and Oiso, Y. Centrally administered neuropeptide FF inhibits arginine vasopressin release in conscious rats. *Endocrinology*. 137 (5): 1523-1529, 1996.
- 10 87. Labrousche, S., Laulin, J.-P., LeMoal, M., Tranu, G. and Simonnet, G. Neuropeptide FF in the rat adrenal gland: presence, distribution and pharmacological effects. *J. Neuroendocrinology*. 10: 559-565, 1998.
- 15 88. Fehmann, H.C., McGregor, G., Weber, V., Eissele, R., Goke, R., Doke, B. and Arnold, R. The effects of two FMRFamide related peptides (A-18-F-amide and F-8-F-amide; 'morphine modulating peptides') on the endocrine and exocrine rat pancreas. *Neuropeptides*. 17: 87-92, 1990.
- 20 89. Gicquel, S., Fioramonti, J., Bueno, L. and Zajac, J.-M. Effects of F8Famide analogs on intestinal transit in mice. *Peptides*. 14: 749-753, 1993.
- 25 90. Demichel, P., Rodrigues, J.C., Roquebert, J. and Simonnet, G. NPFF, a FMRF-NH₂-like peptide, blocks opiate effects on ileum contractions. *Peptides*. 14: 1005-1009, 1993.
- 30 91. Raffa, R.B. and Jacoby, H.I. FMRFamide enhances acetylcholine-induced contractions of guinea pig ileum. *Peptides*. 10: 693-695, 1989.
- 35 92. Murase, T., et al., "Neuropeptide FF reduces food intake in rats", *Peptides* **17**: 353-354 (1996).
93. Doods, H.N., et al., "BIBP 3226, The First

Selective Neuropeptide Y1 Receptor Antagonist: A Review of Its Pharmacological Properties", *Regulatory Peptides* 65: 71-77 (1996).

- 5 94. Morgan, D.G., et al., "The NPY Y1 Receptor Antagonist BIBP 3226 Blocks NPY Induced Feeding via a Non-specific Mechanism", *Regulatory Peptides* 75-76: 377-382 (1998).
- 10 95. Iyengar, S., et al., "Characterization of Neuropeptide Y-induced Feeding in Mice: Do Y1-Y6 Receptor Subtypes Mediate Feeding? *Journal of Pharmacology and Experimental Therapeutics* 289: 1031-1040 (1999).
- 15 96. McKusick, V.A., Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore: Johns Hopkins University Press, 1998 (12th Edition).

What is claimed is:

1. An isolated nucleic acid encoding a mammalian NPFF receptor.
2. The nucleic acid of claim 1, wherein the nucleic acid is DNA.
3. The DNA of claim 2, wherein the DNA is cDNA.
4. The DNA of claim 2, wherein the DNA is genomic DNA.
5. The nucleic acid of claim 1, wherein the nucleic acid is RNA.
6. The nucleic acid of claim 1, wherein the mammalian NPFF receptor is a NPFF1 receptor.
7. The nucleic acid of claim 6, wherein the mammalian NPFF1 receptor is a rat NPFF1 receptor.
8. The nucleic acid of claim 6, wherein the mammalian NPFF1 receptor is a human NPFF1 receptor.
9. The nucleic acid of claim 1, wherein the mammalian NPFF receptor is a NPFF2 receptor.
10. The nucleic acid of claim 9, wherein the mammalian NPFF2 receptor is a human NPFF2 receptor.
11. The nucleic acid of claim 9, wherein the mammalian NPFF2 receptor is a rat NPFF2 receptor.
12. The nucleic acid of claim 7, wherein the rat NPFF1 receptor has an amino acid sequence identical to that encoded by the plasmid pEXJ-rNPFF1 (ATCC Accession No. 203184).

13. The nucleic acid of claim 7, wherein the rat NPFF1 receptor has an amino acid sequence identical to the amino acid sequence shown in Figure 2 (SEQ ID NO: 2).
14. The nucleic acid of claim 8, wherein the human NPFF1 receptor has an amino acid sequence identical to that encoded by plasmid pWE15-hNPFF1 (ATCC Accession No. 203183).
15. The nucleic acid of claim 8, wherein the human NPFF1 receptor has an amino acid sequence identical to the amino acid sequence shown in Figure 5 SEQ ID NO: 4).
16. The nucleic acid of claim 8, wherein the human NPFF1 receptor has an amino acid sequence identical to that encoded by plasmid pCDNA3.1-hNPFF1 (ATCC Accession No. 203605).
17. The nucleic acid of claim 8, wherein the human NPFF1 receptor has an amino acid sequence identical to the amino acid sequence shown in Figure 12 (SEQ ID NO: 8).
18. The nucleic acid of claim 10, wherein the human NPFF2 receptor has an amino acid sequence identical to that encoded by plasmid pCDNA3.1-hNPFF2b (ATCC Accession No. 203255).
19. The nucleic acid of claim 10, wherein the human NPFF2 receptor has an amino acid sequence identical to the amino acid sequence shown in Figure 8 (SEQ ID NO: 6).
20. The nucleic acid of claim 11, wherein the rat NPFF2 receptor has an amino acid sequence identical to

that encoded by plasmid pcDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).

- 5 21. The nucleic acid of claim 11, wherein the rat NPFF2 receptor has an amino acid sequence identical to the amino acid sequence shown in Figures 23A-B (SEQ ID NO: 44).
- 10 22. The nucleic acid of claim 1, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 1 (SEQ ID NO: 1) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence of its complement.
- 15 23. The nucleic acid of claim 1, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 4 (SEQ ID NO: 3) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.
- 20 24. The nucleic acid of claim 1, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 7 (SEQ ID NO: 5) under low stringency conditions or a sequence complementary thereto and (b) id further
- 25 30 35

- 5 characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.
- 10 25. The nucleic acid of claim 1, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figure 11 (SEQ ID NO: 7) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.
- 15 26. The nucleic acid of claim 1, wherein the nucleic acid (a) hybridizes to a nucleic acid having the defined sequence shown in Figures 22A-C (SEQ ID NO: 43) under low stringency conditions or a sequence complementary thereto and (b) is further characterized by its ability to cause a change in the pH of a culture of CHO cells when a NPFF peptide is added to the culture and the CHO cells express the nucleic acid which hybridized to the nucleic acid having the defined sequence or its complement.
- 20 27. A purified mammalian NPFF receptor protein.
- 25 28. The purified mammalian NPFF receptor protein of claim 27, wherein the NPFF receptor protein is a NPFF1 receptor protein.
- 30
- 35

29. The purified mammalian NPFF receptor protein of claim 27, wherein the NPFF receptor protein is a NPFF2 receptor protein.
- 5 30. The purified mammalian NPFF1 receptor protein of claim 28, wherein the NPFF1 receptor protein is a rat NPFF1 receptor protein.
- 10 31. The purified mammalian NPFF1 receptor protein of claim 28, wherein the NPFF1 receptor protein is a human NPFF1 receptor protein.
- 15 32. The purified mammalian NPFF2 receptor protein of claim 29, wherein the NPFF2 receptor protein is a human NPFF2 receptor protein.
- 20 33. The purified mammalian NPFF2 receptor protein of claim 29, wherein the NPFF2 receptor protein is a rat NPFF2 receptor protein.
34. A vector comprising the nucleic acid of claim 1.
35. A vector comprising the nucleic acid of claim 6.
- 25 36. A vector comprising the nucleic acid of claim 9.
37. A vector comprising the nucleic acid of any of claims 22, 23, 24, or 25.
- 30 38. A vector of any of claims 22, 23, 24, 25, 34, 35, or 36 adapted for expression in a cell which comprises the regulatory elements necessary for expression of the nucleic acid in the cell operatively linked to the nucleic acid encoding the
- 35 receptor so as to permit expression thereof, wherein the cell is a bacterial, amphibian, yeast, insect or mammalian cell.

39. The vector of claim 38, wherein the vector is a baculovirus.
- 5 40. The vector of claim 34, wherein the vector is a plasmid.
41. The plasmid of claim 40 designated pEXJ-rNPFF1 (ATCC Accession No. 203184).
- 10 42. The plasmid of claim 40 designated pWE15-hNPFF1 (ATCC Accession No. 203183).
43. The plasmid of claim 40 designated pCDNA3.1-hNPFF2b (ATCC Accession No. 203255).
- 15 44. The plasmid of claim 40 designated pCDNA3.1-hNPFF1 (ATCC Accession No. 203605).
45. The plasmid of claim 40 designated pCDNA3.1-rNPFF2-f (Patent Deposit Designation No. PTA-535).
- 20 46. A cell comprising the vector of claim 38.
47. A cell of claim 46, wherein the cell is a non-mammalian cell.
- 25 48. A cell of claim 47, wherein the non-mammalian cell is a *Xenopus* oocyte cell or a *Xenopus* melanophore cell.
- 30 49. A cell of claim 46, wherein the cell is a mammalian cell.
- 35 50. A mammalian cell of claim 49, wherein the cell is a COS-7 cell, a 293 human embryonic kidney cell, a NIH-3T3 cell, a LM(tk-) cell, a mouse Y1 cell, or a CHO cell.

51. An insect cell comprising the vector of claim 38.
52. An insect cell of claim 51, wherein the insect cell
5 is an Sf9 cell, an Sf21 cell or a Trichoplusia ni
5B1-4 cell.
53. A membrane preparation isolated from the cell of
any of claims 46, 47, 49, 50, 51 or 52.
- 10 54. A nucleic acid probe comprising at least 15
nucleotides, which probe specifically hybridizes
with a nucleic acid encoding a mammalian NPFF
receptor, wherein the probe has a unique sequence
15 corresponding to a sequence present within one of
the two strands of the nucleic acid encoding the
mammalian NPFF1 receptor and contained in plasmid
pEXJ-rNPFF1 (ATCC Accession No. 203184), plasmid
pWE15-hNPFF1 (ATCC Accession No. 203183), plasmid
20 pCDNA3.1-hNPFF2b (ATCC Accession No. 203255),
plasmid pCDNA3.1-hNPFF1 (ATCC Accession No.
203605), or pCDNA3.1-rNPFF2-f (Patent Deposit
Designation No. PTA-535).
- 25 55. A nucleic acid probe comprising at least 15
nucleotides, which probe specifically hybridizes
with a nucleic acid encoding a mammalian NPFF
receptor, wherein the probe has a unique sequence
30 corresponding to a sequence present within (a) the
nucleic acid sequence shown in Figure 1 (SEQ ID NO:
1) or (b) the reverse complement thereto.
- 35 56. A nucleic acid probe comprising at least 15
nucleotides, which probe specifically hybridizes
with a nucleic acid encoding a mammalian NPFF
receptor, wherein the probe has a unique sequence
corresponding to a sequence present within (a) the
nucleic acid sequence shown in Figure 4 (SEQ ID NO:

3) or (b) the reverse complement thereto.

57. A nucleic acid probe comprising at least 15
nucleotides, which probe specifically hybridizes
with a nucleic acid encoding a mammalian NPFF
receptor, wherein the probe has a unique sequence
corresponding to a sequence present within (a) the
nucleic acid sequence shown in Figure 7 (SEQ ID NO:
5) or (b) the reverse complement thereto.

58. A nucleic acid probe comprising at least 15
nucleotides, which probe specifically hybridizes
with a nucleic acid encoding a mammalian NPFF
receptor, wherein the probe has a unique sequence
corresponding to a sequence present within (a) the
nucleic acid sequence shown in Figure 11 (SEQ ID
NO: 7) or (b) the reverse complement thereto.

59. A nucleic acid probe comprising at least 15
nucleotides, which probe specifically hybridizes
with a nucleic acid encoding a mammalian NPFF
receptor, wherein the probe has a unique sequence
corresponding to a sequence present within (a) the
nucleic acid sequence shown in Figures 22A-C (SEQ
ID NO: 43) or (b) the reverse complement thereto.

60. The nucleic acid probe of claim 55, 56, 57, or 58,
wherein the nucleic acid is DNA.

61. The nucleic acid probe of claim 55, 56, 57, or 58,
wherein the nucleic acid is RNA.

62. An antisense oligonucleotide having a sequence
capable of specifically hybridizing to the RNA of
claim 5, so as to prevent translation of the RNA.

63. An antisense oligonucleotide having a sequence

capable of specifically hybridizing to the genomic DNA of claim 4, so as to prevent transcription of the genomic DNA.

- 5 64. An antisense oligonucleotide of claim 62 or 63,
 wherein the oligonucleotide comprises chemically
 modified nucleotides or nucleotide analogues.
- 10 65. An antibody capable of binding to a mammalian NPFF
 receptor encoded by the nucleic acid of claim 1.
66. An antibody of claim 65, wherein the mammalian NPFF
 receptor is a human NPFF1 receptor.
- 15 67. An antibody of claim 65, wherein the mammalian NPFF
 receptor is a rat NPFF1 receptor.
68. An antibody of claim 65, wherein the mammalian NPFF
 receptor is a human NPFF2 receptor.
- 20 69. An antibody of claim 65, wherein the mammalian NPFF
 receptor is a rat NPFF2 receptor.
70. An agent capable of competitively inhibiting the
25 binding of the antibody of claim 65 to a mammalian
 NPFF receptor.
71. An antibody of claim 65, wherein the antibody is a
30 monoclonal antibody or antisera.
72. A pharmaceutical composition comprising (a) an
 amount of the oligonucleotide of claim 62 capable
 of passing through a cell membrane and effective to
35 reduce expression of a mammalian NPFF receptor and
 (b) a pharmaceutically acceptable carrier capable
 of passing through the cell membrane.

73. A pharmaceutical composition of claim 72, wherein the oligonucleotide is coupled to a substance which inactivates mRNA.

5 74. A pharmaceutical composition of claim 73, wherein the substance which inactivates mRNA is a ribozyme.

10 75. A pharmaceutical composition of claim 73, wherein the pharmaceutically acceptable carrier comprises a structure which binds to a mammalian NPFF receptor on a cell capable of being taken up by the cells after binding to the structure.

15 76. A pharmaceutical composition of claim 75, wherein the pharmaceutically acceptable carrier is capable of binding to a mammalian NPFF receptor which is specific for a selected cell type.

20 77. A pharmaceutical composition which comprises an amount of the antibody of claim 65 effective to block binding of a ligand to a human NPFF receptor and a pharmaceutically acceptable carrier.

25 78. A transgenic, nonhuman mammal expressing DNA encoding a mammalian NPFF receptor of claim 1.

30 79. A transgenic, nonhuman mammal comprising a homologous recombination knockout of the native mammalian NPFF receptor.

35 80. A transgenic, nonhuman mammal whose genome comprises antisense DNA complementary to the DNA encoding a mammalian NPFF receptor of claim 1 so placed within the genome as to be transcribed into antisense mRNA which is complementary to mRNA encoding the mammalian NPFF receptor and which hybridizes to mRNA encoding the mammalian NPFF

receptor, thereby reducing its translation.

- 5 81. The transgenic, nonhuman mammal of claim 78 or 79, wherein the DNA encoding the mammalian NPFF receptor additionally comprises an inducible promoter.
- 10 82. The transgenic, nonhuman mammal of claim 78 or 79, wherein the DNA encoding the mammalian NPFF receptor additionally comprises tissue specific regulatory elements.
- 15 83. A transgenic, nonhuman mammal of claim 78, 79, or 80, wherein the transgenic, nonhuman mammal is a mouse.
- 20 84. A process for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises contacting cells containing DNA encoding and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian NPFF receptor.
- 25 85. A process for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises contacting a membrane preparation from cells containing DNA encoding and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian NPFF receptor.
- 30 35

86. The process of claim 84 or 85, wherein the mammalian NPFF receptor is a human NPFF1 receptor.
- 5 87. The process of claim 84 or 85, wherein the mammalian NPFF receptor is a human NPFF2 receptor.
- 10 88. The process of claim 84 or 85, wherein the mammalian NPFF receptor has substantially the same amino acid sequence as the human NPFF1 receptor encoded by plasmid pWE15-hNPFF1 (ATCC Accession No. 203183).
- 15 89. The process of claim 84 or 85, wherein the mammalian NPFF receptor has substantially the same amino acid sequence as the human NPFF1 receptor encoded by plasmid pCDNA3.1-hNPFF1 (ATCC Accession No. 203605).
- 20 90. The process of claim 84 or 85, wherein the mammalian NPFF receptor has substantially the same amino acid sequence as the human NPFF2 receptor encoded by plasmid pCDNA3.1-hNPFF2b (ATCC Accession No. 203255).
- 25 91. The process of claim 84 or 85, wherein the mammalian NPFF receptor has substantially the same amino acid sequence as that shown in Figure 5 (SEQ ID NO: 4).
- 30 92. The process of claim 84 or 85, wherein the mammalian NPFF receptor has the amino acid sequence shown in Figure 5 (SEQ ID NO: 4).
- 35 93. The process of claim 84 or 85, wherein the mammalian NPFF receptor has substantially the same amino acid sequence as that shown in Figure 8 (SEQ ID NO: 6).

94. The process of claim 84 or 85, wherein the mammalian NPFF receptor has the same amino acid sequence shown in Figure 8 (SEQ ID NO: 6).
- 5 95. The process of claim 84 or 85, wherein the mammalian NPFF receptor has substantially the same amino acid sequence as that shown in Figure 12 (SEQ ID NO: 8).
- 10 96. The process of claim 84 or 85, wherein the mammalian NPFF receptor has the same amino acid sequence shown in Figure 12 (SEQ ID NO: 8).
- 15 97. The process of claim 84 or 85, wherein the compound is not previously known to bind to a mammalian NPFF receptor.
98. A compound identified by the process of claim 97.
- 20 99. A process of claim 84 or 85, wherein the cell is an insect cell.
100. The process of claim 84 or 85, wherein the cell is a mammalian cell.
- 25 101. The process of claim 100, wherein the cell is nonneuronal in origin.
- 30 102. The process of claim 101, wherein the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell.
- 35 103. A process of claim 100, wherein the compound is a compound not previously known to bind to a mammalian NPFF receptor.

104. A compound identified by the process of claim 103.

5 105. A process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises separately contacting cells expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not
10 normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding
15 of both compounds, and detecting specific binding of the chemical compound to the mammalian NPFF receptor, a decrease in the binding of the second chemical compound to the mammalian NPFF receptor in the presence of the
20 chemical compound indicating that the chemical compound binds to the mammalian NPFF receptor.

25 106. A process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian NPFF receptor which comprises separately contacting a membrane preparation from cells expressing on
30 their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the
35 second chemical compound, under conditions suitable for binding of both compounds, and detecting specific binding of the chemical compound to the mammalian NPFF receptor, a decrease in the binding of the second chemical

compound to the mammalian NPFF receptor in the presence of the chemical compound indicating that the chemical compound binds to the mammalian NPFF receptor.

5

107. A process of claim 105 or 106, wherein the mammalian NPFF receptor is a human NPFF1 receptor.

10

108. A process of claim 105 or 106, wherein the mammalian NPFF receptor is a human NPFF2 receptor.

15

109. The process of claim 105 or 106, wherein the cell is an insect cell.

110. The process of claim 105 or 106, wherein the cell is a mammalian cell.

20

111. The process of claim 110, wherein the cell is nonneuronal in origin.

25

112. The process of claim 111, wherein the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk-) cell.

30

113. The process of claim 112, wherein the compound is not previously known to bind to a mammalian NPFF receptor.

114. A compound identified by the process of claim 113.

35

115. A method of screening a plurality of chemical compounds not known to bind to a mammalian NPFF receptor to identify a compound which

specifically binds to the mammalian NPFF receptor, which comprises

- 5 (a) contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with a compound known to bind specifically to the mammalian NPFF receptor;
- 10 (b) contacting the preparation of step (a) with the plurality of compounds not known to bind specifically to the mammalian NPFF receptor, under conditions permitting binding of compounds known to bind to the
15 mammalian NPFF receptor;
- (c) determining whether the binding of the compound known to bind to the mammalian NPFF receptor is reduced in the presence
20 of any compound within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
- 25 (d) separately determining the binding to the mammalian NPFF receptor of compounds included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the mammalian NPFF
30 receptor.

116. A method of screening a plurality of chemical compounds not known to bind to a mammalian NPFF receptor to identify a compound which
35 specifically binds to the mammalian NPFF receptor, which comprises

- 5 (a) contacting a membrane preparation from cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the plurality of compounds not known to bind specifically to the mammalian NPFF receptor under conditions permitting binding of compounds known to bind to the mammalian NPFF receptor;
- 10 (b) determining whether the binding of a compound known to bind to the mammalian NPFF receptor is reduced in the presence of any compound within the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
- 15 (c) separately determining the binding to the mammalian NPFF receptor of compounds included in the plurality of compounds, so as to thereby identify the compound which specifically binds to the mammalian NPFF receptor.
- 20
- 25 117. A method of claim 115 or 116, wherein the mammalian NPFF receptor is a human NPFF1 receptor.
- 30 118. A method of claim 115 or 116, wherein the mammalian NPFF receptor is a human NPFF2 receptor.
- 35 119. A method of claim 115 or 116, wherein the cell is a mammalian cell.
120. A method of claim 119, wherein the mammalian cell is non-neuronal in origin.

121. The method of claim 120, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk-) cell, a CHO cell, a mouse Y1 cell, or an NIH-3T3 cell.

5

122. A method of detecting expression of a mammalian NPFF receptor by detecting the presence of mRNA coding for the mammalian NPFF receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe of any of claims 54, 55, 56, 57, or 58 under hybridizing conditions, detecting the presence of mRNA hybridizing to the probe, and thereby detecting the expression of the mammalian NPFF receptor by the cell.

10

15

123. A method of detecting the presence of a mammalian NPFF receptor on the surface of a cell which comprises contacting the cell with the antibody of claim 65 under conditions permitting binding of the antibody to the receptor, detecting the presence of the antibody bound to the cell, and thereby detecting the presence of the mammalian NPFF receptor on the surface of the cell.

20

25

124. A method of determining the physiological effects of varying levels of activity of mammalian NPFF receptors which comprises producing a transgenic, nonhuman mammal of claim 81 whose levels of mammalian NPFF receptor activity are varied by use of an inducible promoter which regulates mammalian NPFF receptor expression.

30

35

125. A method of determining the physiological effects of varying levels of activity of

mammalian NPFF receptors which comprises producing a panel of transgenic, nonhuman mammals of claim 81 each expressing a different amount of mammalian NPFF receptor.

5

126. A method for identifying an antagonist capable of alleviating an abnormality wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor comprising administering a compound to the transgenic, nonhuman mammal of claim 78, 81, 82, or 83, and determining whether the compound alleviates the physical and behavioral abnormalities displayed by the transgenic, nonhuman mammal as a result of overactivity of a mammalian NPFF receptor, the alleviation of the abnormality identifying the compound as an antagonist.

127. The method of claim 126, wherein the mammalian NPFF receptor is a human NPFF1 receptor.

128. The method of claim 126, wherein the mammalian NPFF receptor is a human NPFF2 receptor.

25

129. An antagonist identified by the method of claim 126.

130. A pharmaceutical composition comprising an antagonist of claim 129 and a pharmaceutically acceptable carrier.

30

131. A method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian NPFF receptor which comprises administering to the subject an effective amount of the

35

pharmaceutical composition of claim 130,
thereby treating the abnormality.

- 5 132. A method for identifying an agonist capable of
 alleviating an abnormality in a subject wherein
 the abnormality is alleviated by increasing the
 activity of a mammalian NPFF receptor
 comprising administering a compound to the
10 transgenic, nonhuman mammal of claim 78, 81,
 82, or 83, and determining whether the compound
 alleviates the physical and behavioral
 abnormalities displayed by the transgenic,
 nonhuman mammal, the alleviation of the
 abnormality identifying the compound as an
15 agonist.
133. The method of claim 132, wherein the mammalian
 NPFF receptor is a human NPFF1 receptor.
- 20 134. The method of claim 132, wherein the mammalian
 NPFF receptor is a human NPFF2 receptor.
135. An agonist identified by the method of claim
 132.
- 25 136. A pharmaceutical composition comprising an
 agonist identified by the method of claim 135
 and a pharmaceutically acceptable carrier.
- 30 137. A method of treating an abnormality in a
 subject wherein the abnormality is alleviated
 by increasing the activity of a mammalian NPFF
 receptor which comprises administering to the
 subject an effective amount of the
35 pharmaceutical composition of claim 136,
 thereby treating the abnormality.

138. A method for diagnosing a predisposition to a disorder associated with the activity of a specific mammalian allele which comprises:

- 5 (a) obtaining DNA of subjects suffering from the disorder;
- (b) performing a restriction digest of the DNA with a panel of restriction enzymes;
- 10 (c) electrophoretically separating the resulting DNA fragments on a sizing gel;
- (d) contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a mammalian NPFF receptor and labeled with a detectable marker;
- 15 (e) detecting labeled bands which have hybridized to the DNA encoding a mammalian NPFF1 receptor of claim 1 labeled with a detectable marker to create a unique band pattern specific to the DNA of subjects suffering from the disorder;
- 20 (f) preparing DNA obtained for diagnosis by steps (a)-(e); and
- 25 (g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step (e) and the DNA obtained for diagnosis from step (f) to determine whether the patterns are the same or different and to diagnose thereby
- 30
- 35

predisposition to the disorder if the patterns are the same.

5 139. The method of claim 138, wherein a disorder associated with the activity of a specific mammalian allele is diagnosed.

10 140. A method of preparing the purified mammalian NPFF receptor of claim 27 which comprises:

 (a) culturing cells which express the mammalian NPFF receptor;

15 (b) recovering the mammalian NPFF receptor from the cells; and

 (c) purifying the mammalian NPFF receptor so recovered.

20 141. A method of preparing the purified mammalian NPFF receptor of claim 27 which comprises:

 (a) inserting a nucleic acid encoding the mammalian NPFF receptor into a suitable vector;

25 (b) introducing the resulting vector into a suitable host cell;

30 (c) placing the resulting cell in suitable condition permitting the production of the mammalian NPFF receptor;

35 (d) recovering the mammalian NPFF receptor produced by the resulting cell; and

 (e) isolating and/or purifying the mammalian

NPFF receptor so recovered.

142. A process for determining whether a chemical compound is a mammalian NPFF receptor agonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the compound under conditions permitting the activation of the mammalian NPFF receptor, and detecting an increase in mammalian NPFF receptor activity, so as to thereby determine whether the compound is a mammalian NPFF receptor agonist.
143. A process for determining whether a chemical compound is a mammalian NPFF receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian NPFF receptor with the compound in the presence of a known mammalian NPFF receptor agonist, under conditions permitting the activation of the mammalian NPFF receptor, and detecting a decrease in mammalian NPFF receptor activity, so as to thereby determine whether the compound is a mammalian NPFF receptor antagonist.
144. A process of claim 142 or 143, wherein the mammalian NPFF receptor is a human NPFF1 receptor.
145. A process of claim 142 or 143, wherein the mammalian NPFF receptor is a human NPFF2 receptor.
146. A pharmaceutical composition which comprises an amount of a mammalian NPFF receptor agonist determined by the process of claim 142

effective to increase activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.

- 5 147. A pharmaceutical composition of claim 146,
 wherein the mammalian NPFF receptor agonist is
 not previously known.
- 10 148. A pharmaceutical composition which comprises an
 amount of a mammalian NPFF receptor antagonist
 determined by the process of claim 143
 effective to reduce activity of a mammalian
 NPFF receptor and a pharmaceutically acceptable
 carrier.
- 15 149. A pharmaceutical composition of claim 148,
 wherein the mammalian NPFF receptor antagonist
 is not previously known.
- 20 150. A process for determining whether a chemical
 compound specifically binds to and activates a
 mammalian NPFF receptor, which comprises
 contacting cells producing a second messenger
 response and expressing on their cell surface
25 the mammalian NPFF receptor, wherein such cells
 do not normally express the mammalian NPFF
 receptor, with the chemical compound under
 conditions suitable for activation of the
 mammalian NPFF receptor, and measuring the
30 second messenger response in the presence and
 in the absence of the chemical compound, a
 change in the second messenger response in the
 presence of the chemical compound indicating
 that the compound activates the mammalian NPFF
35 receptor.
151. The process of claim 150, wherein the second

messenger response comprises chloride channel activation and the change in second messenger is an increase in the level of inward chloride current.

5

152. A process for determining whether a chemical compound specifically binds to and inhibits activation of a mammalian NPFF receptor, which comprises separately contacting cells producing a second messenger response and expressing on their cell surface the mammalian NPFF receptor, wherein such cells do not normally express the mammalian NPFF receptor, with both the chemical compound and a second chemical compound known to activate the mammalian NPFF receptor, and with only the second chemical compound, under conditions suitable for activation of the mammalian NPFF receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the mammalian NPFF receptor.

10

15

20

25

30

153. The process of claim 152, wherein the second messenger response comprises chloride channel activation and the change in second messenger response is a smaller increase in the level of inward chloride current in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

35

154. A process of any of claims 150, 151, 152, or 153, wherein the mammalian NPFF receptor is a human NPFF1 receptor.
- 5 155. A process of any of claims 150, 151, 152, or 153, wherein the mammalian NPFF receptor is a human NPFF2 receptor.
- 10 156. The process of any of claims 150, 151, 152, or 153, wherein the cell is an insect cell.
157. The process of any of claims 150, 151, 152, or 153, wherein the cell is a mammalian cell.
- 15 158. The process of claim 157, wherein the mammalian cell is nonneuronal in origin.
159. The process of claim 158, wherein the nonneuronal cell is a COS-7 cell, CHO cell, 293 human embryonic kidney cell, NIH-3T3 cell or LM(tk-) cell.
- 20 160. The process of claim 150, 151, 152, or 153, wherein the compound is not previously known to bind to a mammalian NPFF receptor.
- 25 161. A compound determined by the process of claim 160.
- 30 162. A pharmaceutical composition which comprises an amount of a mammalian NPFF receptor agonist determined by the process of claim 150 or 151 effective to increase activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.
- 35 163. A pharmaceutical composition of claim 162,

wherein the mammalian NPFF receptor agonist is not previously known.

- 5 164. A pharmaceutical composition which comprises an amount of a mammalian NPFF receptor antagonist determined by the process of claim 152 or 153 effective to reduce activity of a mammalian NPFF receptor and a pharmaceutically acceptable carrier.
- 10 165. A pharmaceutical composition of claim 164, wherein the mammalian NPFF receptor antagonist is not previously known.
- 15 166. A method of screening a plurality of chemical compounds not known to activate a mammalian NPFF receptor to identify a compound which activates the mammalian NPFF receptor which comprises:
- 20 (a) contacting cells transfected with and expressing the mammalian NPFF receptor with the plurality of compounds not known to activate the mammalian NPFF receptor, under conditions permitting activation of the mammalian NPFF receptor;
- 25 (b) determining whether the activity of the mammalian NPFF receptor is increased in the presence of the compounds; and if so
- 30 (c) separately determining whether the activation of the mammalian NPFF receptor is increased by each compound included in the plurality of compounds, so as to thereby identify the compound which activates the mammalian NPFF receptor.
- 35

167. A method of claim 166, wherein the mammalian NPFF receptor is a human NPFF1 receptor.

168. A method of claim 166, wherein the mammalian NPFF receptor is a human NPFF2 receptor.

169. A method of screening a plurality of chemical compounds not known to inhibit the activation of a mammalian NPFF receptor to identify a compound which inhibits the activation of the mammalian NPFF receptor, which comprises:

(a) contacting cells transfected with and expressing the mammalian NPFF receptor with the plurality of compounds in the presence of a known mammalian NPFF receptor agonist, under conditions permitting activation of the mammalian NPFF receptor;

(b) determining whether the activation of the mammalian NPFF receptor is reduced in the presence of the plurality of compounds, relative to the activation of the mammalian NPFF receptor in the absence of the plurality of compounds; and if so

(c) separately determining the inhibition of activation of the mammalian NPFF receptor for each compound included in the plurality of compounds, so as to thereby identify the compound which inhibits the activation of the mammalian NPFF receptor.

170. A method of claim 169, wherein the mammalian NPFF receptor is a human NPFF1 receptor.

171. A method of claim 169, wherein the mammalian NPFF receptor is a human NPFF2 receptor.
- 5 172. A method of any of claims 166, 167, 168, 169, 162, or 163, wherein the cell is a mammalian cell.
173. A method of claim 172, wherein the mammalian cell is non-neuronal in origin.
- 10 174. The method of claim 173, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk-) cell or an NIH-3T3 cell.
- 15 175. A pharmaceutical composition comprising a compound identified by the method of claim 166 or 167 effective to increase mammalian NPFF receptor activity and a pharmaceutically acceptable carrier.
- 20 176. A pharmaceutical composition comprising a compound identified by the method of claim 169 or 170 effective to decrease mammalian NPFF receptor activity and a pharmaceutically acceptable carrier.
- 25 177. A method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian NPFF receptor which comprises administering to the subject an amount of a compound which is a mammalian NPFF receptor agonist effective to treat the abnormality.
- 30 178. A method of claim 177, wherein the abnormality is a lower urinary tract disorder, a regulation
- 35

of a steroid hormone disorder, an epinephrine
release disorder, a gastrointestinal disorder,
irritable bowel syndrome, a cardiovascular
disorder, an electrolyte balance disorder,
5 diuresis, hypertension, hypotension, diabetes,
hypoglycemia, a respiratory disorder, asthma,
a reproductive function disorder, an immune
disorder, an endocrine disorder, a
musculoskeletal disorder, a neuroendocrine
10 disorder, a cognitive disorder, a memory
disorder, a sensory modulation and transmission
disorder, a motor coordination disorder, a
sensory integration disorder, a motor
integration disorder, a dopaminergic function
15 disorder, a serotonergic function disorder, an
appetite disorder, obesity, a sensory
transmission disorder, an olfaction disorder,
a sympathetic innervation disorder, pain,
psychotic behavior, morphine tolerance,
20 nicotine addiction, opiate addiction, affective
disorder, or migraine.

179. A method of treating an abnormality in a
subject wherein the abnormality is alleviated
25 by decreasing the activity of a mammalian NPFF
receptor which comprises administering to the
subject an amount of a compound which is a
mammalian NPFF receptor antagonist effective to
treat the abnormality.

30 180. A method of claim 179, wherein the abnormality
is a lower urinary tract disorder, a regulation
of steroid hormone disorder, an epinephrine
release disorder, a gastrointestinal disorder,
35 irritable bowel syndrome, a cardiovascular
disorder, an electrolyte balance disorder,
diuresis, hypertension, hypotension, diabetes,

hypoglycemia, a respiratory disorder, asthma,
a reproductive function disorder, an immune
disorder, an endocrine disorder, a
musculoskeletal disorder, a neuroendocrine
disorder, a cognitive disorder, a memory
disorder, a sensory modulation and transmission
disorder, a motor coordination disorder, a
sensory integration disorder, a motor
integration disorder, a dopaminergic function
disorder, a serotonergic function disorder, an
appetite disorder, obesity, a sensory
transmission disorder, an olfaction disorder,
a sympathetic innervation disorder, pain,
psychotic behavior, morphine tolerance,
nicotine addiction, opiate addiction, affective
disorder, or migraine.

181. A process for making a composition of matter
which specifically binds to a mammalian NPFF
receptor which comprises identifying a chemical
compound using the process of any of claims 84,
85, 105, 106, 115, or 116 and then synthesizing
the chemical compound or a novel structural and
functional analog or homolog thereof.

182. A process for making a composition of matter
which specifically binds to a mammalian NPFF
receptor which comprises identifying a chemical
compound using the process of any of claims
134, 150, or 166 and then synthesizing the
chemical compound or a novel structural and
functional analog or homolog thereof.

183. A process for making a composition of matter
which specifically binds to a mammalian NPFF
receptor which comprises identifying a chemical
compound using the process of any of claims

143, 152, 169 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.

- 5 184. The process of any of claims 181, 182, or 183,
 wherein the mammalian NPFF receptor is a human
 NPFF1 receptor.
- 10 185. The process of any of claims 181, 182, or 183,
 wherein the mammalian NPFF receptor is a human
 NPFF2 receptor.
- 15 186. A process for preparing a pharmaceutical
 composition which comprises admixing a
 pharmaceutically acceptable carrier and a
 pharmaceutically acceptable amount of a
 chemical compound identified by the process of
 any of claims 84, 85, 105, 106, 115, or 116 or
 a novel structural and functional analog or
 homolog thereof.
- 20 187. A process for preparing a pharmaceutical
 composition which comprises admixing a
 pharmaceutically acceptable carrier and a
 pharmaceutically acceptable amount of a
 chemical compound identified by the process of
 any of claims 142, 150, or 166 or a novel
 structural and functional analog or homolog
 thereof.
- 30 188. A process for preparing a pharmaceutical
 composition which comprises admixing a
 pharmaceutically acceptable carrier and a
 pharmaceutically acceptable amount of a
 chemical compound identified by the process of
 any of claims 143, 152, or 169 or a novel
 structural and functional analog or homolog
- 35

thereof.

- 5 189. The process of any of claims 186, 187, or 188,
 wherein the mammalian NPFF receptor is a human
 NPFF1 receptor.
- 10 190. The process of any of claims 186, 187, or 188,
 wherein the mammalian NPFF receptor is a human
 NPFF2 receptor.
191. A method of claim 117, wherein the cell is a
 mammalian cell.
- 15 192. The method of claim 191, wherein the mammalian
 cell is non-neuronal in origin.
193. The method of claim 192, wherein the
 non-neuronal cell is a COS-7 cell, a 293 human
 embryonic kidney cell, a LM(tk-) cell, a CHO
20 cell, a mouse Y1 cell, or an NIH-3T3 cell.
194. A method of claim 118, wherein the cell is a
 mammalian cell.
- 25 195. The method of claim 194, wherein the mammalian
 cell is non-neuronal in origin.
196. The method of claim 195, wherein the
 non-neuronal cell is a COS-7 cell, a 293 human
30 embryonic kidney cell, a LM(tk-) cell, a CHO
 cell, a mouse Y1 cell, or an NIH-3T3 cell.
197. A method of claim 178 or 180, wherein the lower
 urinary tract disorder is urinary incontinence
35 or interstitial cystitis.
198. The method of claim 197, wherein the urinary

incontinence is urge incontinence.

199. The method of claim 197, wherein the urinary incontinence is stress incontinence.

5

200. A method of treating urinary incontinence which comprises administering to a subject an amount of an antagonist of a human NPFF2 receptor effective to inhibit activation of the receptor and thereby treat incontinence.

10

201. The method of claim 200, wherein the urinary incontinence is urge incontinence.

15

202. A method of treating urinary retention which comprises administering to a subject an amount of an agonist of a human NPFF2 receptor effective to activate the receptor and thereby treat retention.

20

203. A method of treating hypertension which comprises administering to a subject an amount of an antagonist of a human NPFF1 receptor effective to inhibit activation of the receptor and thereby treat hypertension.

25

204. A method of treating hypotension which comprises administering to a subject an amount of an agonist of a human NPFF1 receptor effective to activate the receptor and thereby treat hypotension.

30

205. Use of a human NPFF2 receptor antagonist for the preparation of a pharmaceutical composition for treating urinary incontinence.

35

206. The use of claim 205, wherein the urinary

incontinence is urge incontinence.

- 5 207. Use of a human NPFF2 receptor agonist for the
 preparation of a pharmaceutical composition for
 treating urinary retention.
- 10 208. Use of a human NPFF1 receptor antagonist for
 the preparation of a pharmaceutical composition
 for treating hypertension.
209. Use of a human NPFF1 receptor agonist for the
 preparation of a pharmaceutical composition for
 treating hypotension.
- 15 210. A method of modifying the feeding behavior of
 a subject which comprises administering the
 subject an amount of a compound which is a
 NPFF2 receptor agonist effective to decrease
 the consumption of food by the subject so as to
20 thereby modify the feeding behavior of the
 subject.
211. The method of claim 210, wherein the subject is
 a vertebrate, a mammal, a human or a canine
25 subject.
212. A method of treating a feeding disorder in a
 subject which comprises administering to the
 subject an amount of a compound which is NPFF2
30 receptor agonist effective to activate the
 receptor and thereby treat the feeding
 disorder.
213. The method of claim 212, wherein the feeding
35 disorder is bulimia, bulimia nervosa or
 obesity.

214. The method of claim 212, wherein the subject is a vertebrate, a mammal, a human or a canine subject.

5 215. A method of inhibiting feeding which comprises administering to a subject an amount of an agonist of a human NPFF2 receptor effective to activate the receptor and thereby inhibit feeding.

10 216. Use of a human NPFF2 receptor agonist for the preparation of a pharmaceutical composition for inhibiting feeding.

15 217. Use of a human NPFF2 receptor agonist for the preparation of a pharmaceutical composition for treating a feeding disorder.

DNA ENCODING MAMMALIAN NEUROPEPTIDE FF RECEPTORS (NPFF)
AND USES THEREOF

5 **Abstract of the Disclosure**

10 This invention provides isolated nucleic acids encoding
mammalian NPFF receptors, purified mammalian NPFF
receptors, vectors comprising nucleic acid encoding
mammalian NPFF receptors, cells comprising such
vectors, antibodies directed to mammalian NPFF
receptors, nucleic acid probes useful for detecting
nucleic acid encoding mammalian NPFF receptors,
antisense oligonucleotides complementary to unique
15 sequences of nucleic acid encoding mammalian NPFF
receptors, transgenic, nonhuman animals which express
DNA encoding normal or mutant mammalian NPFF
receptors, methods of isolating mammalian NPFF
receptors, methods of treating an abnormality that is
20 linked to the activity of the mammalian NPFF receptors,
as well as methods of determining binding of compounds
to mammalian NPFF receptors, methods of identifying
agonists and antagonists of NPFF receptors, and
agonists and antagonists so identified.

25

Figure 1

```
1  ACCCTTCC TGGCCCCA GTCACCCG CTTGAAGG TGCCCGCC TCCTTTGG AGAGTGTCCC
61  GGAGCAGAC AGTATGGAG GCGGAGCC CTCAGCC CTCCTCC AACGGC AGCTGGCC CCGTGGGT
121  CAGAACGGG AGTGATGTG GAGACCAG CATGGCA ACCAGCC TCACCTT CTCTCCTA CTAC
181  CAACACTCC TCTCCGG TGCGAGCC ATGTTCA TCAGCGG CCTACGT GCTCATC TCTCCTCC TC
241  TGCATGGT GGGCAAC ACCCTGG TCTGCTT CATTTG TGTCAAG AACCCGGC ACATGCGCA CT
301  GTCACCAAC ATGTTTAT CCTCAAC CTGGCCG TCAGCGA CCTGCTG GTGGCATC TTCTGC
361  ATGCCACA AACCCTTG TGGACA ACCTTAT CACTGGT TGGCCTT TTGACAC GGCACATGC
421  AAGATGAG CGGCTTGG TGAGGGC ATGTCGT GTCTGCA TCGGTTT TCACACT GGTGGCC
481  ATCGCTGT GGAAGG TTCCGCT GCATCGT GCACCC CTTTCGG CGAGAA GCTGACCC TTCCG
541  AAGCGCTG TTCACCA TCAGCAT CGCGTG ATCTGGG CTTCTGG CGCTGCT CATCATG TGTCCCTCG
601  GCGGTCACT CTGACAG TCACCCG AGAGGAG CATCACT TCATG CTGGATG CTCTGTA ACCGC
661  TCCTACCC GCTCTA CTGCGC ACATCTA CCTGG TGAGG CCTGGCC CGAGAA GGCATG CGCAAGG TCTAC
721  ACCGCGTG CTCTTC GCGCAC ATCTAC CTGGT GCGCTG GCGCTCAT CCGTAGT GATGTAC
781  GTGCGCAT CGCGCA AGCTAT GCCAGG CCCCCTG GTCGCT GCGCTCAT CCGTAGT GATGTAC
841  GTGCCGAG GGTGGCC GCACTT CGCGCC GTAGG GCGCCG CTGTTG CACATG CTGGTCATG
901  GTGGCGCT CTCTTCA CGTTGT CCTGGC TGCCACT CTGGG TGCTGT GCTCATCG AC
961  TATGGGAG CTGAGCG AGCTGCA ACTGCA CTGCTG TCGGTCTAC GCTTCCCC TTGGCA
1021  CACTGGCT GGCTTCTT CACAGC AGCGCCA ACCCCAT CATCTAC GGTACTTCA ACGAG
1081  AACTTCGG CCGCGG CTTCAG GCTGCC TTCCGTG CACAGC TCTGTG GCTTCCCTGG GCC
1141  GCCACAAG CAAGCCTA CTCGAG CGGCCCC AACCGC CTCTG CGCAGG CGGTGGTGTG
1201  GACGTGCA ACCCAG CGACTCC GGCCTGCC ATCAGAG TCTGG CCCCAG CAGCGGGTCC CA
1261  GGGCCTGG CCGGCTGCC ACTGCG CAATGG GCGTGT GGCCTC ATCAGG ATGGCC CCGGGAA
1321  GGGCCAGG CTGCAACC ACATGCC CCTCAC CATCCG GCTGGA ACATTG AGGTGGTCCA
1381  GAGAGGGAG GGGCCAG TAGTCCT GTGGCCC
```


Figure 2

```

1  M E A E P S Q P P N G S W P L G Q N G S 20
21 D V E T S M A T S L T F S S Y Y Q H S S 40
41 P V A A M F I A A Y V L I F L L C M V G 60
61 N T L V C F I V L K N R H M R T V T N M 80
81 F I L N L A V S D L L V G I F C M P T T 100
101 L V D N L I T G W P F D N A T C K M S G 120
121 L V Q G M S V S A S V F T L V A I A V E 140
141 R F R C I V H P F R E K L T L R K A L F 160
161 T I A V I W A L A L L I M C P S A V T L 180
181 T V T R E E H H F M L D A R N R S Y P L 200
201 Y S C W E A W P E K G M R K V Y T A V L 220
221 F A H I Y L V P L A L I V V M Y V R I A 240
241 R K L C Q A P G P A R D T E E A V A E G 260
261 G R T S R R R A R V V H M L V M V A L F 280
281 F T L S W L P L W V L L L L I D Y G E L 300
301 S E L Q L H L L S V Y A F P L A H W L A 320
321 F F H S S A N P I I Y G Y F N E N F R R 340
341 G F Q A A F R A Q L C W P P W A A H K Q 360
361 A Y S E R P N R L L R R R V V V D V Q P 380
381 S D S G L P S E S G P S S G V P G P G R 400
401 L P L R N G R V A H Q D G P G E G P G C 420
421 N H M P L T I P A W N I 432

```

3/33

Figure 3

1	M E A E P S Q P P N G S W P L G Q N G S	20
21	D V E T S M A T S L T F S S Y Y Q H S S	40
	I	
41	<u>P V A A M F I A A Y V L I F L L C M V G</u>	60
61	<u>N T L V C F I V L K N R H M R T V T N M</u>	80
	II	
81	<u>F I L N L A V S D L L V G I F C M P T T</u>	100
101	<u>L V D N L I T G W P F D N A T C K M S G</u>	120
	III	
121	<u>L V O G M S V S A S V F T L V A I A V E</u>	140
141	R F R C I V H P F R E K L T L R K <u>A L F</u>	160
	IV	
161	<u>T I A V I W A L A L L I M C P S A V T L</u>	180
181	T V T R E E H H F M L D A R N R S Y P L	200
201	Y S C W E A W P E K G M R K V Y <u>T A V L</u>	220
	V	
221	<u>F A H I Y L V P L A L I V V M Y V R I A</u>	240
241	R K L C Q A P G P A R D T E E A V A E G	260
261	G R T S R R R A R V <u>V V H M L V M V A L F</u>	280
	VI	
281	<u>F T L S W L P L W V L L L L I D Y G E L</u>	300
	VII	
301	S E L Q L H L L S V Y A <u>F P L A H W L A</u>	320
321	<u>F F H S S A N P I I Y G Y F N E N F R R</u>	340
341	G F Q A A F R A Q L C W P P W A A H K Q	360
361	A Y S E R P N R L L R R R V V V D V Q P	380
381	S D S G L P S E S G P S S G V P G P G R	400
401	L P L R N G R V A H Q D G P G E G P G C	420
421	N H M P L T I P A W N I	432

Figure 4

```
1  GAGCCCTCCAGCCTCCCAACAGCAGTTGGCCCCCTAAGTCAGAATGGGACTAACACTGAG 60
61  GCCACCCCGGCTACAAACCTCACCTTCTCCTCCTACTATCAGCACACCTCCCCCTGTGGCG 120
121  GCCATGTTCAATTGTGGCCCTATGCGCTCATCTTCCCTGCTCTGCATGGTGGGCAACACCCCTG 180
181  GTCTGTTTCAATCGTGCTCAA 200
```

5/33

Figure 5

1	E P S Q P P N S S W P L S Q N G T N T E	20
21	A T P A T N L T F S S Y Y Q H T S P V A	40
41	A M F I V A Y A L I F L L C M V G N T L	60
61	V C F I V L	66

Figure 6

```
1 MEAEPSQPPNGSWPLGQNGSDVETSMATSLTFSSYYQHSSPVAAMFIAAY rNPFF1
  ||||| |||| |||| |||| | . ||. ||||| ||||. ||||| ||
1 ...EPSQPPNSSWPLSQNGTNTTEATPATNLTFSSYYQHTSPVAAMFIVAY hNPFF1

51 VLIFLLCMVGNTLVCFIVL rNPFF1
  ||||| ||||| ||||| |||||
48 ALIFLLCMVGNTLVCFIVL hNPFF1
```

Figure 7

1	GCCGACAGGGCTGCCCCGGAGAGGTTTCATCATGAATGAGAAATGGGACACAAACTCTTCA	60
61	GAAAACTGGCATCCCATCTGGAATGTCAATGACACAAAGCATCATCTGTACTCAGATATT	120
121	AATATTACCTATGTGAACCTACTATCTTCACCAGCCTCAAGTGGCAGCAATCTTCATTATT	180
181	TCCTACTTTCGTGATCTTCTTTTGTGCATGATGGGAAATACTGTGGTTTGCCTTATTGTA	240
241	ATGAGGAACAAACATATGCACACAGTCACATAATCTCTTCATCTTAAACCTGGCCATAAGT	300
301	GATTTACTAGTTGGCATATTCTGCATGCCATATAACACTGCTGGACAAATATTATAGCAGGA	360
361	TGGCCATTTGGAAACACGATGTGCAAGATCAGTGGATTGGTCCAGGGAATATCTGTCCGA	420
421	GCTTCAGTCTTTACGTTAGTTGCAATTGCTGTAGATAGGTTCCAGTGTGGTCTACCCCT	480
481	TTTAAACCAAAGCTCACTATCAAGACAGCGGTTTGTCAATTATTATGATCATCTGGGTCCTA	540
541	GCCATCACCATTAATGTCTCCATCTGCAGTAATGTTACATGTGCAAGAGAAAAATATTAC	600
601	CGAGTGAGACTCAACTCCCAGAAATAAACCCAGTCCAGTCTACTGGTGCCGGGAAGACTGG	660
661	CCAAATCAGGAAATGAGGAAAGATCTACCCACTGTGCTGTTTGCCAACATCTACCTGGCT	720
721	CCCCCTCTCCCTCATTTGTTCATCATGTATGGAAGGATTGGAATTTCACTCTTCAGGGCTGCA	780
781	GTTCCCTCACACAGGCAGGAAGAACCCAGAGCAGTGGCACGTGGTGTCCAGGAAGAAGCAG	840
841	AAGATCATTAAGATGCTCCTGATTGTGGCCCTGCTTTTATTCTCTCATGGCTGCCCCCTG	900
901	TGGACTCTAAATGATGCTCTCAGACTACGCTGACCTTTCTCCAAATGAACGTCAGATCATC	960
961	AACATCTACATCTACCCCTTTTGCACACTGGCTGGCATTCGGCAACAGCAGTGTCAATCCC	1020
1021	ATCATTTATGGTTTCTTCAACGAGAAATTCGCGCGTGGTTTCCAAGAAGCTTTCAGCTC	1080
1081	CAGCTCTGCCAAAAAAGAGCAAGCCCTATGGAAGCTTATGCCCTAAAGCTAAAGCCCAT	1140
1141	GTGCTCATAAACACATCTAATCAGCTTGTCCAGGAATCTACATTTCAAAACCCCTCATGGG	1200
1201	GAAACCTTGCTTTATAGGAAAAGTGCTGAAAAACCCCAACAGGAATTAGTGATGGAAGAA	1260
1261	TTAAAGAAACTACTACAGCAGTGAGATTTAA AAAGAGCTA	1302

Figure 8

1	M N E K W D T N S S E N W H P I W N V N	20
21	D T K H H L Y S D I N I T Y V N Y Y L H	40
41	Q P Q V A A I F I I S Y F L I F F L C M	60
61	M G N T V V C F I V M R N K H M H T V T	80
81	N L F I L N L A I S D L L V G I F C M P	100
101	I T L L D N I I A G W P F G N T M C K I	120
121	S G L V Q G I S V A A S V F T L V A I A	140
141	V D R F Q C V V Y P F K P K L T I K T A	160
161	F V I I M I I W V L A I T I M S P S A V	180
181	M L H V Q E E K Y Y R V R L N S Q N K T	200
201	S P V Y W C R E D W P N Q E M R K I Y T	220
221	T V L F A N I Y L A P L S L I V I M Y G	240
241	R I G I S L F R A A V P H T G R K N Q E	260
261	Q W H V V S R K K Q K I I K M L L I V A	280
281	L L F I L S W L P L W T L M M L S D Y A	300
301	D L S P N E L Q I I N I Y I Y P F A H W	320
321	L A F G N S S V N P I I Y G F F N E N F	340
341	R R G F Q E A F Q L Q L C Q K R A K P M	360
361	E A Y A L K A K S H V L I N T S N Q L V	380
381	Q E S T F Q N P H G E T L L Y R K S A E	400
401	K P Q Q E L V M E E L K E T T N S S E I	420

9/33

Figure 9

1 M N E K W D T N S S E N W H P I W N V N 20
21 D T K H H L Y S D I N I T Y V N Y Y L H 40
41 Q P Q V A A I F I I S Y F L I F F L C M 60
61 M G N T V V C F I V M R N K H M H T V T 80
81 N L F I L N L A I S D L L V G I F C M P 100
101 I T L L D N I I A G W P F G N T M C K I 120
121 S G L V O G I S V A A S V F T L V A I A 140
141 V D R F Q C V V Y P F K P K L T I K T A 160
161 F V I I M I I W V L A I T I M S P S A V 180
181 M L H V Q E E K Y Y R V R L N S Q N K T 200
201 S P V Y W C R E D W P N Q E M R K I Y T 220
221 T V L F A N I Y L A P L S L I V I M Y G 240
241 R I G I S L F R A A V P H T G R K N Q E 260
261 Q W H V V S R K K Q K I I K M L L I V A 280
281 L L F I L S W L P L W T L M M L S D Y A 300
301 D L S P N E L Q I I N I Y I Y P F A H W 320
321 L A F G N S S V N P I I Y G F F N E N F 340
341 R R G F Q E A F Q L Q L C Q K R A K P M 360
361 E A Y A L K A K S H V L I N T S N Q L V 380
381 Q E S T F Q N P H G E T L L Y R K S A E 400
401 K P Q Q E L V M E E L K E T T N S S E I 420

Figure 10

```

rNPFF1 MEAEPSQPPNGSWPLGQNGSDVETSMAT..SLTFSSYYQHSSPVAAMFIA 48
      | . . . | | . | . : . : : . | | | | |
hNPFF2 MNEKWDTNSSSENWHPiWNVNDTKHhLYSDINITYVNYYLHQpQVAaIFII 50

rNPFF1 AYVLIFLLCMVGNTLVCfIVLKNRHMRtVTNMfILNLAVSDLLVGIFcMP 98
      . | | | | | . | | | | | : : : | | | | : | | | | | | | |
hNPFF2 SYFLIFFLCMMGNTVVCfIVMRNKhMHTvTNLfILNLAIStDLLVGIFcMP 100

rNPFF1 TTLVDNLITGWPFdNATCKMSGLVQGMsVSASvFTLVaIAVERfRCIVhP 148
      | | . | | : | | | | | | | . | | | | | | | | : | | . | : : |
hNPFF2 ITLLDNIIAGWPFGNTMCKISGLVQGISvAASvFTLVaIAVDRfQCvVYP 150

rNPFF1 FREKLTLRKALFTIAVIWALALLIMCPSAVTLTVTREEHH.FMLDARNRS 197
      | : | | : : | | : | | : | | | | | | | | | : : | | . . | : .
hNPFF2 FKPKLTIKtAFVIIMiIWVLAITIMSPSAVMLhVQEEKYyRVRLNSQnKT 200

rNPFF1 YPLYSCWEAWPEKGMRKVYTAVLFAHIYLVPLALIVVMYVRIARKLCQAP 247
      | . | | | | | . | | : | | | | | . | | | | : | | | | | . |
hNPFF2 SPVYWCREdWPNQEMRKIYTTVLFANIYLAPLSLIVIMYGRIGISLFRAA 250

rNPFF1 GPaRDTEEEAVAEGGRtSRRRARVVHMLVMVALFFtLSWLPLWVLLLLIDY 297
      | . . : | | : : : | | . | | | | | | | | | | | : : | | |
hNPFF2 VPHTGRKNQ.EQWHVVSRRKKQKIiKMLLiVALLFiLSWLPLWTLMLLSdY 299

rNPFF1 GELSELQLHLLSVYAFPLAHWLAFFHSSANPIIYGyFNENFRRGfQAaFR 347
      : | | : | : : : | : | | | | | | . | | | | | : | | | | | | | |
hNPFF2 ADLSPNELQIINIYIYPFAHWLAFGNSSVNPIIYGfFNENFRRGfQEAFQ 349

rNPFF1 AQLCWPPWAAHKQAYSERPNRLLRRRVVDVQPSDGLP.SESGPSSGVP 396
      | | | . . . . | | | | | | | | .
hNPFF2 LQLCQKRAKPMEAYALKAKSHVLINTSNQLVQESTFQNPPhGETLLYRKSA 399

rNPFF1 GPGRlPLRNGRVAHQDGPGEgPGCNhMPLTIpAWNI 432
      . | . . |
hNPFF2 EKpQQELVMEELKETTNSSEI..... 420

```

Figure 11

1 ATGAGGGGAGCCCTCCAGCCTCCCAACAGCAGTTGGCCCTAAGTCAGAAATGGGACT 60
61 AACACTGAGGCCACCCGGCTACAAACCTCACCTTCTCCTCCTACTATCAGCACACCTCC 120
121 CCTGTGGCGGCCATGTTCAATTGTGGCCTATGCGCTCATCTTCTGTCTGTCATGTTGGC 180
181 AACACCCCTGGTCTGTTTCATCGTGTCTCAAGAACCGGCACATGCATACTGTACCAACAATG 240
241 TTCATCCTCAACCTGGCTGTGAGTGAACCTGCTGTGGGCATCTTCTGCATGCCACCAACC 300
301 CTTGTGGACAACCTCATCACTAGGTGGCCCTTCGACAATGCCACATGCAAGATGAGCGGC 360
361 TTGGTGCAAGGCATGTCGTGTGGCTTCCGTTTTTCACACTGGTGGCCATTGCTGTGGAA 420
421 AGGTTCCGCTGCATCGTGCACCCCTTCCGCGAGAAGCTGACCCCTGCGGAAGCGGCTCGTC 480
481 ACCATCGCCGTCATCTGGGCCCTGGCGCTGCTCATCATGTGTCCCTCGGCCGTCACGCTG 540
541 ACCGTACCCGTGAGGAGCACCACTTCATGGTGGACGCCCGCAACCGCTCCTACCCCTCTC 600
601 TACTCCTGCTGGAGGCCCTGGCCCCGAGAAGGGCATGCGCAGGGTCTACACCACTGTGCTC 660
661 TTCTCGCACATCTACCTGGGCGCTGGCGCTCATCGTGTCTATGACGCCCGCATCGCG 720
721 CGCAAGCTCTGCCAGGCCCGGGCCCCGGGGCGGAGAGGCTGCGGACCCCGGA 780
781 GCATCGGGCGCAGAGCGCGGTGGTGACATGCTGGTTCATGGTGGCGCTGTTCTTCACG 840
841 CTGTCTGGCTGCCGCTCTGGGCGCTGCTGCTCATCGACTACGGGCAGCTCAGCGCG 900
901 CCGCAGCTGCACCTGGTCACCGCTACGCCCTTCCCTTCGGGCACTGGCTGGCCCTCTTC 960
961 AACAGCAGCGCCAACCCATCATCTACGGCTACTTCAACGAGAACTTCCGCCCGGCTTC 1020
1021 CAGGCCGCTTCCGCGCCCGCTCTGCCCGGCCCGCTCGGGGAGCCACAAGGAGGCCTAC 1080
1081 TCCGAGCGGGCGGGGCTTCTGCACAGCGGGTCTTTCGTGGTGGTGGCGCCAGCGAC 1140
1141 TCCGGGCTGCCCTCTGAGTCGGGCCCCTAGCACTGGGGCCCCCAGGCCCGCCCTCCCG 1200
1201 CTGCGGAATGGCGGGTGGCTCACCAACGGCTGCCCAGGGAAGGGCCTGGCTGCTCCAC 1260
1261 CTGCCCCTCACCATTCAGCCTGGGATATCTGA 1293

12/33

Figure 12

```

1  M E G E P S Q P P N S S W P L S Q N G T 20
21 N T E A T P A T N L T F S S Y Y Q H T S 40
41 P V A A M F I V A Y A L I F L L C M V G 60
61 N T L V C F I V L K N R H M H T V T N M 80
81 F I L N L A V S D L L V G I F C M P T T 100
101 L V D N L I T G W P F D N A T C K M S G 120
121 L V Q G M S V S A S V F T L V A I A V E 140
141 R F R C I V H P F R E K L T L R K A L V 160
161 T I A V I W A L A L L I M C P S A V T L 180
181 T V T R E E H H F M V D A R N R S Y P L 200
201 Y S C W E A W P E K G M R R V Y T T V L 220
221 F S H I Y L A P L A L I V V M Y A R I A 240
241 R K L C Q A P G P A P G G E E A A D P R 260
261 A S R R R A R V V H M L V M V A L F F T 280
281 L S W L P L W A L L L L I D Y G Q L S A 300
301 P Q L H L V T V Y A F P F A H W L A F F 320
321 N S S A N P I I Y G Y F N E N F R R G F 340
341 Q A A F R A R L C P R P S G S H K E A Y 360
361 S E R P G G L L H R R V F V V V R P S D 380
381 S G L P S E S G P S S G A P R P G R L P 400
401 L R N G R V A H H G L P R E G P G C S H 420
421 L P L T I P A W D I 430

```

Figure 13

1 M E G E P S Q P P N S S W P L S Q N G T 20
 21 N T E A T P A T N L T F S S Y Y Q H T S 40
 41 P V A A M F I V A Y A L I F L L C M V G 60
 61 N T L V C F I V L K N R H M H T V T N M 80
 81 F I L N L A V S D L L V G I F C M P T T 100
 101 L V D N L I T G W P F D N A T C K M S G 120
 121 L V O G M S V S A S V F T L V A I A V E 140
 141 R F R C I V H P F R E K L T L R K A L V 160
 161 T I A V I W A L A L L I M C P S A V T L 180
 181 T V T R E E H H F M V D A R N R S Y P L 200
 201 Y S C W E A W P E K G M R R V Y T T V L 220
 221 F S H I Y L A P L A L I V V M Y A R I A 240
 241 R K L C Q A P G P A P G G E E A A D P R 260
 261 A S R R R A R V V H M L V M V A L F F T 280
 281 L S W L P L W A L L L L I D Y G Q L S A 300
 301 P Q L H L V T V Y A F P F A H W L A F F 320
 321 N S S A N P I I Y G Y F N E N E R R G F 340
 341 Q A A F R A R L C P R P S G S H K E A Y 360
 361 S E R P G G L L H R R V F V V V R P S D 380
 381 S G L P S E S G P S S G A P R P G R L P 400
 401 L R N G R V A H H G L P R E G P G C S H 420
 421 L P L T I P A W D I 430

Figure 14

hNPFF2 1 MNEKWDTNSSSENWHPIWNVNDTKHHLYSDINITYVNYYLHQPQVAAIFII 50
. : . | . | | | : : . | | | | . | :
hNPFF1 1 ..MEGEPSQPPNSSWPLSQNGTNTTEATPATNLTFSSYYQHTSPVAAMFIV 48
hNPFF2 51 SYFLIFFLCMMGNTVVCFIVMRNKHMTVTNLFILNLAISDLLVGIFCMP 100
. | | | | | | . | | | | | | : : | | | | | | : | | | | | | | |
hNPFF1 49 AYALIFLLCMVGNTLVCFIVLKNRHMHTVTNMFILNLAVSDLLVGIFCMP 98
hNPFF2 101 ITLLDNIIAGWPFGNTMCKISGLVQGISVAASVFTLVAVAVDRFQCVVYP 150
| | . | | : | | | | | | | | | | | | | | | | | | : | | . | : |
hNPFF1 99 TTLVDNLITGWPFDNATCKMSGLVQGMVSASVFTLVAVIAVERFRCIVHP 148
hNPFF2 151 FKPKLTIKTA FVIIMIIWVLAITIMSPSAVMLHVQEEKYYRVRLNSQNKT 200
| : | | | : : | | | : | | | | | | | | | | | | | | : | : .
hNPFF1 149 FREKLTLRKALVTIAVIWALALLIMCPSAVTLTVTREEHH.FMVDARNRS 197
hNPFF2 201 SPVYWCREDWPNQEMRKIYTTVLFANIYLAPLSLIVIMYGRIGISLFRAA 250
| . | | | | | . | : : | | | | | . | | | | | . | | : | | | | | . |
hNPFF1 198 YPLYSCWEAWPEKGMRRVYTTVLFSHIYLAPLALIVVMYARIARKLCQAP 247
hNPFF2 251 VPHTGRKNQEQWHVVSRRKQKIIKMLLIVALLFILSWLPLWTLMMLSDYA 300
| | . | | : : : | | . | | | | | | | | | | | | : : | | |
hNPFF1 248 GPAPGGEEAADPR.ASRRRARVVHMLVMVALFFTLWLPLWALLLLIDYG 296
hNPFF2 301 DLSPNELQIINIYIYPFAHWLAFGNSSVNPIIYGFFNENFRRGFQEAQFQL 350
| | : | : : : | : | | | | | | | | | | | | | | | | | | | | | |
hNPFF1 297 QLSAPQLHLVTVYAFPPFAHWLAFNSSANPIIYGYFNENFRRGFQAAQFRA 346
hNPFF2 351 QLCQKRAKPMEAYALKAKSHVLINTSNQLVQESTFQNPGETLLYRKSAE 400
. | | | | | | | : | : . | . | . | . | . | . | . | . | . | .
hNPFF1 347 RLC.PRPSGSHKEAYSERPGGLLHRRVFVVVRPSDSGLPSESGPSSGAPR 395
hNPFF2 401 KPQQELVMEELKETTSSEI*..... 420
. | . | . | . | . | . | . | . | . | . | . | . | . | . | . | .
hNPFF1 396 PGRLPLRNGRVAHHGLPREGPGCSHLPLTIPAWDI* 431

Figure 15A




Figure 15B




Figure 15C




Figure 16A




Figure 16B




Figure 16C




Figure 17A





Figure 17B



18/33

Figure 18A






Figure 18B




19/33

Figure 19



20/33

Figure 20



21/33

Figure 21




FIGURE 22A

1 AGCCTCTCCTTTGATAAGGTCACCATGGGCAAGAGATGGGACTCAAACCTCTTCAGGAAG 60

61 CTGGGATCACATCTGGAGTGGCAATGACACACAGCATCCTTGGTATTTCAGATATCAACAT 120

121 CACATACATGAACTACTATCTCCACCAGCCCCACGTGACAGCTGTCTTCATTAGCTCCTA 180

181 CTTCCCTGATCTTCTTCCCTGTGCAATGGTGGGAAACACTGTCGTTTGCTTTGTGTAATAAG 240

241 GAATAGGTACATGCACACGGTCACCTAAATTTCTTCATCTTCAACCTCGCAATAAGTGACTT 300

301 ACTGGTTGGAATATTCTGCATGCCCTATCACATTGCTGGACAACATCATAGCAGGATGGCC 360

361 GTTTGGAAAGCAGCATGTGCAAGATCAGCGGGCTGGTGCAAGGATATCGGTTGCCCGCTTC 420

421 TGTCTTTCACCTTGGTTGCCATAGCCGTAGACAGATTCCGGTGTGTGGTCTACCCCTTTAA 480

481 GCCCAAGCTCACTGTCAAGACAGCCCTTTGTCAATGATCGTGATCATCTGGGGCCTGGCCAT 540

541 CACCATTATGACCCCATCTGCAATCATGTTACATGTACAGGAAGAAAAATACTACCGTGT 600

601 GAGGCTCAGCTCCCAACAATAAAACCAGCACAGTCTACTGGTGTCTGGGAGGATTGGCCAAA 660

FIGURE 22B

661	CCAGGAAATGAGGAGGATCTACACCCGCTGCTCTTTGCCACTATCTACCTGGCTCCACT	720
721	CTCCCTCATTTGTTATCATGTATGCAAGGATTGGGGCTTCCCTCTTCAAGACCTCAGCACA	780
781	CAGCACAGGTAAGCAGCGCCTGGAGCAGTGGCATGTATCCAAGAAACAGAAAGGTCAT	840
841	CAAGATGCTGCTGACTGTGGCCCTCCTTTTCATCCTTTCCCTGGCTTCCCTGTGGACTCT	900
901	GATGATGCTCTCAGACTATGCTGACCTGTCACCTAACAACTACGTGTCATCAATATTA	960
961	TGTCFACCCCTTTTGCCCACTGGCTCGCCTTCTGCAATAGCAGTGTCAACCCCATCATTA	1020
1021	TGGTTTCTTTAATGAAAATTTTCGCAGTGGTTTCCAAGATGCTTTCCAGTTCTGCCAAA	1080
1081	GAAAGTCAAACCCAGGAAGCCTATGGCCTAAGAGCTAAACGCAACCTGGACATAAACAC	1140
1141	ATCTGGCCTGTTGGTCCATGAACCTGCATCTCAAAACCCCAAGTGGGAAAACCTTGGGATG	1200
1201	TAGAAAAAGTGCAGACAAATCCCACACAGGAATCCTTGATGGAGGAAACGGGAGAAGCTAC	1260
1261	CAACAGTACTGAGACTTAGAAAGATAGTATGCTATCCAATGTTATATAGCATACGAAGCC	1320

bioRxiv preprint doi: <https://doi.org/10.1101/2021.03.11.433333>; this version posted March 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

FIGURE 22C

1321 AACTCCGATGGCTG 1334

FIGURE 23A

1	M	G	K	R	W	D	S	N	S	S	G	S	W	D	H	I	W	S	G	N	20
21	D	T	Q	H	P	W	Y	S	D	I	N	I	T	Y	M	N	Y	Y	L	H	40
41	Q	P	H	V	T	A	V	F	I	S	S	Y	F	L	I	F	F	L	C	M	60
61	V	G	N	T	V	V	C	F	V	V	I	R	N	R	Y	M	H	T	V	T	80
81	N	F	F	I	F	N	L	A	I	S	D	L	L	V	G	I	F	C	M	P	100
101	I	T	L	L	D	N	I	I	A	G	W	P	F	G	S	S	M	C	K	I	120
121	S	G	L	V	O	G	I	S	V	A	A	S	V	F	T	L	V	A	I	A	140
141	V	D	R	F	R	C	V	V	Y	P	F	K	P	K	L	T	V	K	T	A	160
161	F	V	M	I	V	I	I	W	G	L	A	I	T	I	M	T	P	S	A	I	180
181	M	L	H	V	Q	E	E	K	Y	Y	R	V	R	L	S	S	H	N	K	T	200
201	S	T	V	Y	W	C	R	E	D	W	P	N	Q	E	M	R	R	I	Y	T	220
221	T	V	L	F	A	T	I	Y	L	A	P	L	S	L	I	V	I	M	Y	A	240
241	R	I	G	A	S	L	F	K	T	S	A	H	S	T	G	K	Q	R	L	E	260
261	Q	W	H	V	S	K	K	Q	K	V	I	K	M	L	L	T	V	A	L		280
281	L	F	I	L	S	W	L	P	L	W	T	L	M	M	L	S	D	Y	A	D	300

FIGURE 23B

301	L	S	P	N	K	L	R	V	I	N	I	Y	V	Y	P	F	A	H	W	L	320
321	A	F	C	N	S	S	V	N	P	I	I	Y	G	F	F	N	E	N	F	R	340
341	S	G	F	Q	D	A	F	Q	F	C	Q	K	K	V	K	P	Q	E	A	Y	360
361	G	L	R	A	K	R	N	L	D	I	N	T	S	G	L	L	V	H	E	P	380
381	A	S	Q	N	P	S	G	E	N	L	G	C	R	K	S	A	D	N	P	T	400
401	Q	E	S	L	M	E	E	T	G	E	A	T	N	S	T	E	T				417

FIGURE 24A

hNPFF2	1	MNEKWD	TNSSEN	WHPIWN	VNDTKH	HLYS	DINITY	VNYYL	HQPQ	VAAIFII	50
			.:								
rNPFF2	1	MGKRWD	SNSSGS	WDHIWS	GNDTQH	PHWYS	DINITY	MNYYL	HQPH	VTAVFIS	50
hNPFF2	51	SYFLIF	FLCMMG	NTVVC	FIVMRN	KHMH	TVTNL	FILNL	LAIS	DLLVGIF	100
rNPFF2	51	SYFLIF	FLCMMG	NTVVC	FIVMRN	KHMH	TVTNL	FILNL	LAIS	DLLVGIF	100
hNPFF2	101	ITLLDN	IILAGW	PFNG	NTMCKI	SGLV	QGIS	VAA	SFTL	VAIAVDR	150
rNPFF2	101	ITLLDN	IILAGW	PFNG	NTMCKI	SGLV	QGIS	VAA	SFTL	VAIAVDR	150
hNPFF2	151	EKPKLT	IKTAF	VIIMI	IWVL	AITM	SPSA	VMLH	VQEEK	YYRVRL	200
rNPFF2	151	EKPKLT	IKTAF	VIIMI	IWVL	AITM	SPSA	VMLH	VQEEK	YYRVRL	200
hNPFF2	201	SPVYWC	REDW	PNQEM	RKIY	TTVL	FANI	YLAP	LSLIV	IMYGRIGIS	250
rNPFF2	201	STVYWC	REDW	PNQEM	RRIY	TTVL	FATI	YLAP	LSLIV	IMYARIGAS	250

FIGURE 24B

hNPFF2	251	VPHTGRKNQEQWHVVSRRKKQIKIKMLLIVALLFILSWLPLWTLMMLSDYA	300
		:.. : :	
rNPFF2	251	AHSTGKQRLEQWH.VSKKKQKVIKMLLTVALLFILSWLPLWTLMMLSDYA	299
hNPFF2	301	DLSPNELQIINIYYPFAHWLAFGNSSVNPIIYGFFNENFRRGFQEAQQL	350
		. : : :	
rNPFF2	300	DLSPNKLRVINIYYPFAHWLAFCNSSFVNPIIYGFFNENFRSGFQDAF..	347
hNPFF2	351	QLCQKRAKPMEEAYALKAKSHVLINTSNQLVQESTFQNPNGETLLYRKSAE	400
		: : .. :	
rNPFF2	348	QFCQKKVKPQEAAYGLRAKRNLDINTSGLLVHEPASQNPNGENLGCRKSAD	397
hNPFF2	401	KPQQELVMEELKETNSSEI	420
		. .	
rNPFF2	398	NPTQESLMEETGEATNSTET	417

FIGURE 25A

```

rNPFF1 1 MEAEPSQPPNGSWPLGQNGSDVETSMAT..SLTFSSYYQHSSPVAAMFIA 48
      | .||| .|.| : . :||| | |.||.
rNPFF2 1 MGKRWDSNSSGSWDHIWSGNDTQHPWYSDINITYMNYYLHQPHVTAVFIS 50

rNPFF1 49 AYVLIFFLCMVGNLTLCFIVLKNRHMRTVTNMFILNLAUSDLLVGIFCMP 98
      .| ||| |||||.||||:|||| ||| || |||:|||||||
rNPFF2 51 SYFLIFFLCMVGNTVVCFVIRNRYMHTVTNFFIFNLAISDLLVGIFCMP 100

rNPFF1 99 TTLVDNLIITGWPFDNATCKMSGLVQGMVSASVFTLVAI AVERFCIVHP 148
      ||.||||| |||| .. ||.|||||.||.|||||||:||||:|
rNPFF2 101 ITLLDNIIAGWPFGSSMCKISGLVQGISVAASVFTLVAI ADRFCVVYP 150

rNPFF1 149 FREKLTLRKALFTIAVIWALALLIMCPSAVTLT VTREEHH.FMLDARNRS 197
      |: |||. : | :|| |||: || |||: | | |.: | . |:
rNPFF2 151 FKPKLTVKTA FVMIVIIWGLAITIMTPSAIMLHVQEEKYYRVR LSSHNKT 200

rNPFF1 198 YPLYSCWEAWPEKGMRKVYTAVLFAHIYLVPLALIVVMYVRIARKLCQAP 247
      .| | | | . ||: || |||| ||| ||.||||: || | .
rNPFF2 201 STVYWCREDWPNQEMRRIYTTVLFATIYLA PLSLIVIMYARIGASLFKT. 249

```

FIGURE 25B

```

rNPFF1 248 GPARDTEEAEAGGRTSRRRARVVHMLVMVALEFFTLWPLWVLLLLIDY 297
      | | . | |::: |: | | | | | | | | | | | | | | | |
rNPFF2 250 .SAHSTGKQRLEQWHVSKKKQKVIKMLLTVALLFILSWPLWTLMMLSDY 298


rNPFF1 298 GELSEQLHLLSVYAFPLAHWLAFFHSSANPIIYGYFNENFRRGFQAAFR 347
      : | | . | .::: | : | | | | | . | | | | | | | | | | | |
rNPFF2 299 ADLSPNKLRVINIYVYPFAHWLAFCNSSVNPPIIYGFFNENFRSGFQDAF. 347

rNPFF1 348 AQLCWPPWAAHKQAYSERPNRLRRRVVDVQPSDSL...PSESGPSS 393
      | | .::: | | | | | | | | | | | | | | | | | | | |
rNPFF2 348 .QFCQKK.VKPQEAYGLRAKRNL.....DI..NTSGLLVHEPASQNPSG 387

rNPFF1 394 GVPGPGRPLPLNRGRVAHQDGPGEGPCNHHMPLTIPAWN I 432
      | : . . . : | |
rNPFF2 388 ENLGCRKSADNPTQESLMEETGEATNSTET..... 417


```

Figure 26




32/33

Figure 27



33/33

Figure 28



SEQUENCE LISTING

<110> Gerald, Christophe P.G.

Jones, Kenneth A.

Bonini, James A.

Borowsky, Beth E.

Craig, Douglas A.

<120> DNA Encoding Mammalian Neuropeptide FF (NPFF) Receptors
And Uses Thereof

<130> 57155-D/JPW

<140>

<141>

<150> 09/405,558

<151> 1999-09-24

<150> 09/255,368

<151> 1999-02-22

<150> 09/161,113

<151> 1998-09-25

<160> 71

<170> PatentIn Ver. 2.1

<210> 1

<211> 1410

<212> DNA

<213> Rattus norvegicus

<400> 1

```

acccttcctg ggccccagtc taccgcttg aaggtgcccg cctcctttgg agagtgtccc 60
ggagcagaca gtatggaggc ggagccctcc cagcctccca acggcagctg gcccttgggt 120
cagaacggga gtgatgtgga gaccagcatg gcaaccagcc tcaccttctc ctctactac 180
caacactcct ctccggtggc agccatgttc atcgcgccct acgtgctcat ctctctctc 240
tgcatgggtg gcaacaccct ggtctgcttc attgtgctca agaaccggca catgcgcact 300
gtcaccaaca tgtttatcct caacctggcc gtcagcgacc tgctgggtgg catcttctgc 360
atgccacaaa cccttgtgga caaccttacc actggttggc cttttgacaa cgccacatgc 420
aagatgagcg gcttgggtgca gggcatgtcc gtgtctgcat cggttttcac actggtggcc 480
atcgctgtgg aaaggttccg ctgcatcgtg caccctttcc gcgagaagct gacccttcgg 540
aaggcgctgt tcaccatcgc ggtgatctgg gctctggcgc tgctcatcat gtgtccctcg 600
ggggtcactc tgacagtcac ccgagaggag catcacttca tgctggatgc tcgtaaccgc 660
tcttaccgcg tctactcgtg ctgggaggcc tggcccgaga agggcatgcg caaggtctac 720
accgcggtgc tcttcgcgca catctacctg gtgccgctgg cgctcatcgt agtgatgtac 780

```

gtgcgcacatg cgcgcaagct atgccaggcc cccggtcctg cgcgcgacac ggaggaggcg 840
 gtggccgagg gtggccgcac ttgcgcgcgt agggcccgcg tggcgcacat gctggcatg 900
 gtggcgctct tcttcacgtt gtctggctg ccaactctggg tgcctgctgct gctcatcgac 960
 tatggggagc tgagcgagct gcaactgcac ctgctgtcgg tctacgcctt ccccttgcca 1020
 cactggctgg ccttcttcca cagcagcgcc aaccccatca tctacggcta cttcaacgag 1080
 aacttcggcc gcggttcca ggctgccttc cgtgcacagc tctgctggcc tccctgggcc 1140
 gccacaagc aagcctactc ggagcggccc aaccgcctcc tgcgcaggcg ggtggtggtg 1200
 gacgtgcaac ccagcgactc cggcctgcc tcaagagtctg gcccagcag cggggtccca 1260
 gggcctggcc ggctgccact gcgcaatgg cgtgtggccc atcaggatgg cccgggggaa 1320
 gggccaggct gcaaccacat gccctcacc atcccgccct ggaacatttg aggtggtcca 1380
 gagaaggag ggccagtagt cctgtggccc 1410

<210> 2

<211> 432

<212> PRT

<213> Rattus norvegicus

<400> 2

Met	Glu	Ala	Glu	Pro	Ser	Gln	Pro	Pro	Asn	Gly	Ser	Trp	Pro	Leu	Gly
1				5					10					15	
Gln	Asn	Gly	Ser	Asp	Val	Glu	Thr	Ser	Met	Ala	Thr	Ser	Leu	Thr	Phe
			20					25					30		
Ser	Ser	Tyr	Tyr	Gln	His	Ser	Ser	Pro	Val	Ala	Ala	Met	Phe	Ile	Ala
		35					40					45			
Ala	Tyr	Val	Leu	Ile	Phe	Leu	Leu	Cys	Met	Val	Gly	Asn	Thr	Leu	Val
	50					55					60				
Cys	Phe	Ile	Val	Leu	Lys	Asn	Arg	His	Met	Arg	Thr	Val	Thr	Asn	Met
65				70					75					80	
Phe	Ile	Leu	Asn	Leu	Ala	Val	Ser	Asp	Leu	Leu	Val	Gly	Ile	Phe	Cys
			85						90					95	
Met	Pro	Thr	Thr	Leu	Val	Asp	Asn	Leu	Ile	Thr	Gly	Trp	Pro	Phe	Asp
		100						105					110		
Asn	Ala	Thr	Cys	Lys	Met	Ser	Gly	Leu	Val	Gln	Gly	Met	Ser	Val	Ser
		115					120					125			
Ala	Ser	Val	Phe	Thr	Leu	Val	Ala	Ile	Ala	Val	Glu	Arg	Phe	Arg	Cys
	130				135						140				
Ile	Val	His	Pro	Phe	Arg	Glu	Lys	Leu	Thr	Leu	Arg	Lys	Ala	Leu	Phe
145				150					155					160	

Thr Ile Ala Val Ile Trp Ala Leu Ala Leu Leu Ile Met Cys Pro Ser
 165 170 175

Ala Val Thr Leu Thr Val Thr Arg Glu Glu His His Phe Met Leu Asp
 180 185 190

Ala Arg Asn Arg Ser Tyr Pro Leu Tyr Ser Cys Trp Glu Ala Trp Pro
 195 200 205

Glu Lys Gly Met Arg Lys Val Tyr Thr Ala Val Leu Phe Ala His Ile
 210 215 220

Tyr Leu Val Pro Leu Ala Leu Ile Val Val Met Tyr Val Arg Ile Ala
 225 230 235 240

Arg Lys Leu Cys Gln Ala Pro Gly Pro Ala Arg Asp Thr Glu Glu Ala
 245 250 255

Val Ala Glu Gly Gly Arg Thr Ser Arg Arg Arg Ala Arg Val Val His
 260 265 270

Met Leu Val Met Val Ala Leu Phe Phe Thr Leu Ser Trp Leu Pro Leu
 275 280 285

Trp Val Leu Leu Leu Leu Ile Asp Tyr Gly Glu Leu Ser Glu Leu Gln
 290 295 300

Leu His Leu Leu Ser Val Tyr Ala Phe Pro Leu Ala His Trp Leu Ala
 305 310 315 320

Phe Phe His Ser Ser Ala Asn Pro Ile Ile Tyr Gly Tyr Phe Asn Glu
 325 330 335

Asn Phe Arg Arg Gly Phe Gln Ala Ala Phe Arg Ala Gln Leu Cys Trp
 340 345 350

Pro Pro Trp Ala Ala His Lys Gln Ala Tyr Ser Glu Arg Pro Asn Arg
 355 360 365

Leu Leu Arg Arg Arg Val Val Val Asp Val Gln Pro Ser Asp Ser Gly
 370 375 380

Leu Pro Ser Glu Ser Gly Pro Ser Ser Gly Val Pro Gly Pro Gly Arg
 385 390 395 400

Leu Pro Leu Arg Asn Gly Arg Val Ala His Gln Asp Gly Pro Gly Glu
 405 410 415

Gly Pro Gly Cys Asn His Met Pro Leu Thr Ile Pro Ala Trp Asn Ile
420 425 430

<210> 3
<211> 200
<212> DNA
<213> Homo sapiens

<400> 3
gagccctccc agcctcccaa cagcagttgg cccctaagtc agaatgggac taacactgag 60
gccaccccggt ctacaaacct caccctctcc tccctactatc agcacacctc cctgtggcg 120
gccatgttca ttgtggccta tgcgctcctc ttctgtctct gcatgggtggg caacaccctg 180
gtctgtttca tcgtgctcaa 200

<210> 4
<211> 66
<212> PRT
<213> Homo sapiens

<400> 4
Glu Pro Ser Gln Pro Pro Asn Ser Ser Trp Pro Leu Ser Gln Asn Gly
1 5 10 15
Thr Asn Thr Glu Ala Thr Pro Ala Thr Asn Leu Thr Phe Ser Ser Tyr
20 25 30
Tyr Gln His Thr Ser Pro Val Ala Ala Met Phe Ile Val Ala Tyr Ala
35 40 45
Leu Ile Phe Leu Leu Cys Met Val Gly Asn Thr Leu Val Cys Phe Ile
50 55 60
Val Leu
65

<210> 5
<211> 1302
<212> DNA
<213> Homo sapiens

<400> 5

```

gccgacaggg ctgcgcggga gaggttcate atgaatgaga aatgggacac aaactcttca 60
gaaaactggc atcccatctg gaatgtcaat gacacaaagc atcatctgta ctcatatatt 120
aatattacct atgtgaacta ctatcttcac cagcctcaag tggcagcaat cttcattatt 180
tctacttttc tgatcttctt tttgtgcatg atgggaaata ctgtggtttg ctttattgta 240
atgaggaaca aacatatgca cacagtcact aatctcttca tcttaaacct ggccataagt 300
gatttactag ttggcatatt ctgcatgcct ataactctgc tggacaatat tatagcagga 360
tggccatttg gaaacacgat gtgcaagatc agtggattgg tccagggaat atctgtcgca 420
gcttcagtct ttacgttagt tgcaattgct gtagataggt tccagtgtgt ggtctacct 480
tttaaaccac agctcactat caagacagcg tttgtcatta ttatgatcat ctgggtccta 540
gccatcacca ttatgtctcc atctgcagta atgttacatg tgcaagaaga aaaatattac 600
cgagtgcagc tcaactccca gaataaaacc agtccagtct actggtgccc ggaagactgg 660
ccaaatcagg aaatgaggaa gatctacacc actgtgctgt ttgccaacat ctacctggct 720
ccctctccc tcattgtcat catgtatgga aggattggaa tttcactctt cagggctgca 780
gttcctcaca caggcaggaa gaaccaggag cagtggcacg tgggtgtccag gaagaagcag 840
aagatcatta agatgctcct gattgtggcc ctgcttttta ttctctcatg gctgcccttg 900
tggactctaa tgatgctctc agactacgct gacctttctc caaatgaact gcagatcatc 960
aacatctaca tctacccttt tgcacactgg ctggcattcg gcaacagcag tgtcaatccc 1020
atcattttatg gtttcttcaa cgagaatttc cgccgtggtt tccaagaagc tttccagctc 1080
cagctctgcc aaaaaagagc aaagcctatg gaagcttatg ccctaaaagc taaaagccat 1140
gtgctcataa acacatctaa tcagcttgct caggaatcta catttcaaaa ccctcatggg 1200
gaaaccttgc tttataggaa aagtgtgtaa aaacccaac aggaattagt gatggaagaa 1260
ttaaagaaaa ctactaacag cagtgcagatt taaaagagc ta 1302

```

<210> 6

<211> 420

<212> PRT

<213> Homo sapiens

<400> 6

```

Met Asn Glu Lys Trp Asp Thr Asn Ser Ser Glu Asn Trp His Pro Ile
  1                      5                      10                      15

```

```

Trp Asn Val Asn Asp Thr Lys His His Leu Tyr Ser Asp Ile Asn Ile
          20                      25                      30

```

```

Thr Tyr Val Asn Tyr Tyr Leu His Gln Pro Gln Val Ala Ala Ile Phe
          35                      40                      45

```

```

Ile Ile Ser Tyr Phe Leu Ile Phe Phe Leu Cys Met Met Gly Asn Thr
          50                      55                      60

```

```

Val Val Cys Phe Ile Val Met Arg Asn Lys His Met His Thr Val Thr
          65                      70                      75                      80

```

```

Asn Leu Phe Ile Leu Asn Leu Ala Ile Ser Asp Leu Leu Val Gly Ile
          85                      90                      95

```

Phe Cys Met Pro Ile Thr Leu Leu Asp Asn Ile Ile Ala Gly Trp Pro
 100 105 110

Phe Gly Asn Thr Met Cys Lys Ile Ser Gly Leu Val Gln Gly Ile Ser
 115 120 125

Val Ala Ala Ser Val Phe Thr Leu Val Ala Ile Ala Val Asp Arg Phe
 130 135 140

Gln Cys Val Val Tyr Pro Phe Lys Pro Lys Leu Thr Ile Lys Thr Ala
 145 150 155 160

Phe Val Ile Ile Met Ile Ile Trp Val Leu Ala Ile Thr Ile Met Ser
 165 170 175

Pro Ser Ala Val Met Leu His Val Gln Glu Glu Lys Tyr Tyr Arg Val
 180 185 190

Arg Leu Asn Ser Gln Asn Lys Thr Ser Pro Val Tyr Trp Cys Arg Glu
 195 200 205

Asp Trp Pro Asn Gln Glu Met Arg Lys Ile Tyr Thr Thr Val Leu Phe
 210 215 220

Ala Asn Ile Tyr Leu Ala Pro Leu Ser Leu Ile Val Ile Met Tyr Gly
 225 230 235 240

Arg Ile Gly Ile Ser Leu Phe Arg Ala Ala Val Pro His Thr Gly Arg
 245 250 255

Lys Asn Gln Glu Gln Trp His Val Val Ser Arg Lys Lys Gln Lys Ile
 260 265 270

Ile Lys Met Leu Leu Ile Val Ala Leu Leu Phe Ile Leu Ser Trp Leu
 275 280 285

Pro Leu Trp Thr Leu Met Met Leu Ser Asp Tyr Ala Asp Leu Ser Pro
 290 295 300

Asn Glu Leu Gln Ile Ile Asn Ile Tyr Ile Tyr Pro Phe Ala His Trp
 305 310 315 320

Leu Ala Phe Gly Asn Ser Ser Val Asn Pro Ile Ile Tyr Gly Phe Phe
 325 330 335

Asn Glu Asn Phe Arg Arg Gly Phe Gln Glu Ala Phe Gln Leu Gln Leu
 340 345 350

Cys Gln Lys Arg Ala Lys Pro Met Glu Ala Tyr Ala Leu Lys Ala Lys
 355 360 365

Ser His Val Leu Ile Asn Thr Ser Asn Gln Leu Val Gln Glu Ser Thr
 370 375 380

Phe Gln Asn Pro His Gly Glu Thr Leu Leu Tyr Arg Lys Ser Ala Glu
 385 390 395 400

Lys Pro Gln Gln Glu Leu Val Met Glu Glu Leu Lys Glu Thr Thr Asn
 405 410 415

Ser Ser Glu Ile
 420

<210> 7

<211> 1293

<212> DNA

<213> Homo sapiens

<400> 7

```

atggaggggg agccctccca gcctcccaac agcagttggc ccctaagtca gaatgggact 60
aacactgagg ccaccccggc tacaaacctc accttctcct cctactatca gcacacctcc 120
cctgtggcgg ccattgttcat tgtggcctat gcgctcatct tcctgctctg catgggtggc 180
aacaccctgg tctgtttcat cgtgctcaag aaccggcaca tgcatactgt caccaacatg 240
ttcatcctca acctggtgtgt cagtgaacct ctggtgggca tcttctgcat gccaccacc 300
cttgtggaca acctcatcac tgggtggccc ttcgacaatg ccacatgcaa gatgagcggc 360
ttggtgcagg gcatgtctgt gtgggtttcc gttttcacac tgggtggccat tgctgtggaa 420
aggttccgct gcatcgtgca ccttttccgc gagaagctga cctgcgga ggcgctcgtc 480
accatcgccg tcatctgggc cctggcgctg ctcatcatgt gtccctcggc cgtcacgctg 540
accgtcaccg gtgaggagca ccacttcatg gtggacgccc gcaaccgctc ctaccctctc 600
tactcctgct gggaggcctg gccogagaag ggcattcgca gggcttacac cactgtgctc 660
ttctgcaca tctacctggc gccgctggcg ctcatcgtgg tcatgtacgc ccgcatcgcg 720
cgcaagctct gccaggcccc gggcccgccc cccgggggcg aggaggctgc ggaccgcga 780
gcatcgcggc gcagagcgcg cgtggtgcac atgctggtca tgggtggcgt gttcttcacg 840
ctgtcctggc tgcgctctg ggcgctgctg ctgctcatcg actacgggca gctcagcgcg 900
ccgcagctgc acctggtcac cgtctacgcc ttcccttcg cgcactggct ggctttcttc 960
aacagcagcg ccaaccccat catctacggc tacttcaacg agaacttccg ccgcggtctc 1020
caggccgcct tccgcgcccg cctctgcccg cgcccgctcg ggagccacaa ggaggcctac 1080
tccgagcggc ccggcgggct tctgcacagg cgggtcttcg tgggtggtgc gccagcgac 1140
tccgggctgc cctctgagtc gggccctagc agtggggccc ccaggcccgg ccgcctcccg 1200
ctgcggaatg ggcgggtggc tcaccacggc ttgccaggg aagggcctgg ctgctccac 1260
ctgcccctca ccattccagc ctgggatata tga 1293

```

<210> 8

<211> 430

<212> PRT

<213> Homo sapiens

<400> 8

Met	Glu	Gly	Glu	Pro	Ser	Gln	Pro	Pro	Asn	Ser	Ser	Trp	Pro	Leu	Ser	
1				5					10					15		
Gln	Asn	Gly	Thr	Asn	Thr	Glu	Ala	Thr	Pro	Ala	Thr	Asn	Leu	Thr	Phe	
			20					25					30			
Ser	Ser	Tyr	Tyr	Gln	His	Thr	Ser	Pro	Val	Ala	Ala	Met	Phe	Ile	Val	
		35					40					45				
Ala	Tyr	Ala	Leu	Ile	Phe	Leu	Leu	Cys	Met	Val	Gly	Asn	Thr	Leu	Val	
	50					55					60					
Cys	Phe	Ile	Val	Leu	Lys	Asn	Arg	His	Met	His	Thr	Val	Thr	Asn	Met	
65					70					75					80	
Phe	Ile	Leu	Asn	Leu	Ala	Val	Ser	Asp	Leu	Leu	Val	Gly	Ile	Phe	Cys	
			85						90					95		
Met	Pro	Thr	Thr	Leu	Val	Asp	Asn	Leu	Ile	Thr	Gly	Trp	Pro	Phe	Asp	
			100					105						110		
Asn	Ala	Thr	Cys	Lys	Met	Ser	Gly	Leu	Val	Gln	Gly	Met	Ser	Val	Ser	
		115					120					125				
Ala	Ser	Val	Phe	Thr	Leu	Val	Ala	Ile	Ala	Val	Glu	Arg	Phe	Arg	Cys	
	130					135					140					
Ile	Val	His	Pro	Phe	Arg	Glu	Lys	Leu	Thr	Leu	Arg	Lys	Ala	Leu	Val	
145					150					155					160	
Thr	Ile	Ala	Val	Ile	Trp	Ala	Leu	Ala	Leu	Leu	Ile	Met	Cys	Pro	Ser	
			165					170						175		
Ala	Val	Thr	Leu	Thr	Val	Thr	Arg	Glu	Glu	His	His	Phe	Met	Val	Asp	
			180					185					190			
Ala	Arg	Asn	Arg	Ser	Tyr	Pro	Leu	Tyr	Ser	Cys	Trp	Glu	Ala	Trp	Pro	
		195					200					205				
Glu	Lys	Gly	Met	Arg	Arg	Val	Tyr	Thr	Thr	Val	Leu	Phe	Ser	His	Ile	
	210					215					220					
Tyr	Leu	Ala	Pro	Leu	Ala	Leu	Ile	Val	Val	Met	Tyr	Ala	Arg	Ile	Ala	
225					230					235					240	

Arg Lys Leu Cys Gln Ala Pro Gly Pro Ala Pro Gly Gly Glu Glu Ala
 245 250 255
 Ala Asp Pro Arg Ala Ser Arg Arg Arg Ala Arg Val Val His Met Leu
 260 265 270
 Val Met Val Ala Leu Phe Phe Thr Leu Ser Trp Leu Pro Leu Trp Ala
 275 280 285
 Leu Leu Leu Leu Ile Asp Tyr Gly Gln Leu Ser Ala Pro Gln Leu His
 290 295 300
 Leu Val Thr Val Tyr Ala Phe Pro Phe Ala His Trp Leu Ala Phe Phe
 305 310 315 320
 Asn Ser Ser Ala Asn Pro Ile Ile Tyr Gly Tyr Phe Asn Glu Asn Phe
 325 330 335
 Arg Arg Gly Phe Gln Ala Ala Phe Arg Ala Arg Leu Cys Pro Arg Pro
 340 345 350
 Ser Gly Ser His Lys Glu Ala Tyr Ser Glu Arg Pro Gly Gly Leu Leu
 355 360 365
 His Arg Arg Val Phe Val Val Val Arg Pro Ser Asp Ser Gly Leu Pro
 370 375 380
 Ser Glu Ser Gly Pro Ser Ser Gly Ala Pro Arg Pro Gly Arg Leu Pro
 385 390 395 400
 Leu Arg Asn Gly Arg Val Ala His His Gly Leu Pro Arg Glu Gly Pro
 405 410 415
 Gly Cys Ser His Leu Pro Leu Thr Ile Pro Ala Trp Asp Ile
 420 425 430

<210> 9

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<220>

<223> n = a, c, t, or g

<400> 9
gyntwyrynn tnwsntgght ncc 23

<210> 10
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<220>
<223> n = a, c, t or g

<400> 10
avnadngbrw avannanngg rtt 23

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 11
ttatgcttcc ggctcgtatg ttgtg 25

<210> 12
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 12
atgtgctgca aggcgattaa gttggg 26

<210> 13
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer/probe

<400> 13
 ggtgctgctg ctgctcatcg actatg 26

<210> 14
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer/probe

<400> 14
 ttggcgctgc tgtggaagaa ggccag 26

<210> 15
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer/probe

<400> 15
 cggtgctctt cgcgcacatc tacc 24

<210> 16
 <211> 60
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer/probe

<400> 16
 tgccaagggg aaggcgtaga ccgacagcag gtgcagttgc agctcgatca gctccccata 60

<210> 17
 <211> 53
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 17

ccacccttgt ggacaacctc atcactgggt ggccttcga caatgccaca tgc 53

<210> 18

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 18

ctgctctgca tggtagggcaa cacc 24

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 19

gacggcgatg gtgacgagcg c 21

<210> 20

<211> 65

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 20

gtcaccaaca tgttcactct caacctggct gtcagtgacc tgctggtagg catcttctgc 60
atgcc 65

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 21

gcgagaagct gaccctgcgg aagg

24

<210> 22

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 22

tcgtcaccat cgccgtcatc tggg

24

<210> 23

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 23

cgtcacatctgg gccgagggac acag

24

<210> 24

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 24

tgacggcgat ggtgacgagc gcc

23

<210> 25

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 25

cagcctccca acagcagttg gcc

23

<210> 26

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 26

tagcaaggat ccgcatatgg aggggggagcc ctccc

35

<210> 27

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 27

cttcatgaat tcatcgctg catgtatctc gtgtcc

36

<210> 28

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 28

cgtgtacggt gggaggtcta tataagcaga g

31

<210> 29

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 29

ccatcctaatacgcactcactatagggc

27

<210> 30

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 30

actcactatagggctcgagcggc

23

<210> 31

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 31

tgatagtgagctttgggtttaaaagg

26

<210> 32

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 32

gaagatctacaccactgtgtctgtttg

26

<210> 33

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 33

aacatctacc tggctcccct ctccc

25

<210> 34

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 34

ttgtcatcat gtatggaagg attgg

25

<210> 35

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 35

gaccacacac tggaacctat ctac

24

<210> 36

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 36

gcaattgcaa ctaacgtaaa gactg

25

<210> 37

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 37

tagcaaggat ccgaggttca tcatgaatga gaaatgg

37

<210> 38

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 38

cttcatgaat tcgcgtagta gagttaggat tatcac

36

<210> 39

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 39

ctcctactac caacactcct ctcc

24

<210> 40

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 40

acgggttacg agcatccag

19

<210> 41

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 41

gatcagtgga ttggtccagg gaatatc

27

<210> 42

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 42

ccaggtagat gttggcaaac agcac

25

<210> 43

<211> 1334

<212> DNA

<213> Rattus norvegicus

<400> 43

agcctctoct ttgataaggt ccaccatggg caagagatgg gactcaaact cttcaggaag 60
ctgggatcac atctggagtg gcaatgacac acagcatcct tggatttcag atatcaacat 120
cacatacatg aactactatc tccaccagcc ccacgtgaca gctgtcttca ttagctccta 180
cttctctgatc ttcttctctgt gcatgggtgg aaacactgtc gtttgctttg ttgtaataag 240
gaataggtac atgcacacgg tctaataatt cttcatcttc aacctcgcaa taagtgaactt 300
actggttgga atattctgca tgcctatcac attgctggac aacatcatag caggatggcc 360
gtttggaagc agcatgtgca agatcagcgg gctgggtgcaa gggatatcgg ttgccgcttc 420
tgtcttcacc ttggttgcca tagccgtaga cagattccgg tgtgtggtct acccctttaa 480
gcccaagctc actgtcaaga cagcctttgt catgatcgtg atcatctggg gcctggccat 540
caccattatg accccatctg caatcatggt acatgtacag gaagaaaaat actaccgtgt 600
gaggctcagc tcccacaata aaaccagcac agtctactgg tgtcgggagg attggccaaa 660
ccaggaaatg aggaggatct acaccaccgt gctctttgcc actatctacc tggctccact 720
ctccctcatt gttatcatgt atgcaaggat tggggcttcc ctcttcaaga cctcagcaca 780
cagcacaggt aagcagcgcc tggagcagtg gcatgtatcc aagaagaaac agaaggtcat 840
caagatgctg ctgactgtgg cctcctttt catcctttcc tggcttcccc tgtggactct 900
gatgatgctc tcagactatg ctgacctgtc acctaacaaa ctacgtgtca tcaatattta 960
tgtctaccct tttgccact ggctcgctt ctgcaatagc agtgtcaacc ccatcattta 1020
tggtttcttt aatgaaaatt ttgcagtggt tttccaagat gctttccagt tctgccaaaa 1080
gaaagtcaaa cccaggaag cctatggcct aagagctaaa cgcaacctgg acataaacac 1140
atctggcctg ttggtccatg aacctgcac tcaaaacca agtggggaaa acttgggatg 1200
tagaaaaagt gcagacaatc ccacacagga atccttgatg gaggaaacgg gagaagctac 1260

caacagtact gagacttaga aagatagtagt gctatccaat gttatatagc atacgaagcc 1320
aactccgatg gctg 1334

<210> 44
<211> 417
<212> PRT
<213> Rattus norvegicus

<400> 44
Met Gly Lys Arg Trp Asp Ser Asn Ser Ser Gly Ser Trp Asp His Ile
1 5 10 15
Trp Ser Gly Asn Asp Thr Gln His Pro Trp Tyr Ser Asp Ile Asn Ile
20 25 30
Thr Tyr Met Asn Tyr Tyr Leu His Gln Pro His Val Thr Ala Val Phe
35 40 45
Ile Ser Ser Tyr Phe Leu Ile Phe Phe Leu Cys Met Val Gly Asn Thr
50 55 60
Val Val Cys Phe Val Val Ile Arg Asn Arg Tyr Met His Thr Val Thr
65 70 75 80
Asn Phe Phe Ile Phe Asn Leu Ala Ile Ser Asp Leu Leu Val Gly Ile
85 90 95
Phe Cys Met Pro Ile Thr Leu Leu Asp Asn Ile Ile Ala Gly Trp Pro
100 105 110
Phe Gly Ser Ser Met Cys Lys Ile Ser Gly Leu Val Gln Gly Ile Ser
115 120 125
Val Ala Ala Ser Val Phe Thr Leu Val Ala Ile Ala Val Asp Arg Phe
130 135 140
Arg Cys Val Val Tyr Pro Phe Lys Pro Lys Leu Thr Val Lys Thr Ala
145 150 155 160
Phe Val Met Ile Val Ile Ile Trp Gly Leu Ala Ile Thr Ile Met Thr
165 170 175
Pro Ser Ala Ile Met Leu His Val Gln Glu Glu Lys Tyr Tyr Arg Val
180 185 190
Arg Leu Ser Ser His Asn Lys Thr Ser Thr Val Tyr Trp Cys Arg Glu
195 200 205

Asp Trp Pro Asn Gln Glu Met Arg Arg Ile Tyr Thr Thr Val Leu Phe
 210 215 220
 Ala Thr Ile Tyr Leu Ala Pro Leu Ser Leu Ile Val Ile Met Tyr Ala
 225 230 235 240
 Arg Ile Gly Ala Ser Leu Phe Lys Thr Ser Ala His Ser Thr Gly Lys
 245 250 255
 Gln Arg Leu Glu Gln Trp His Val Ser Lys Lys Lys Gln Lys Val Ile
 260 265 270
 Lys Met Leu Leu Thr Val Ala Leu Leu Phe Ile Leu Ser Trp Leu Pro
 275 280 285
 Leu Trp Thr Leu Met Met Leu Ser Asp Tyr Ala Asp Leu Ser Pro Asn
 290 295 300
 Lys Leu Arg Val Ile Asn Ile Tyr Val Tyr Pro Phe Ala His Trp Leu
 305 310 315 320
 Ala Phe Cys Asn Ser Ser Val Asn Pro Ile Ile Tyr Gly Phe Phe Asn
 325 330 335
 Glu Asn Phe Arg Ser Gly Phe Gln Asp Ala Phe Gln Phe Cys Gln Lys
 340 345 350
 Lys Val Lys Pro Gln Glu Ala Tyr Gly Leu Arg Ala Lys Arg Asn Leu
 355 360 365
 Asp Ile Asn Thr Ser Gly Leu Leu Val His Glu Pro Ala Ser Gln Asn
 370 375 380
 Pro Ser Gly Glu Asn Leu Gly Cys Arg Lys Ser Ala Asp Asn Pro Thr
 385 390 395 400
 Gln Glu Ser Leu Met Glu Glu Thr Gly Glu Ala Thr Asn Ser Thr Glu
 405 410 415
 Thr

<210> 45
 <211> 8
 <212> PRT
 <213> Rattus norvegicus

<400> 45

Phe Leu Phe Gln Pro Gln Arg Phe

1 5

<210> 46

<211> 18

<212> PRT

<213> Rattus norvegicus

<400> 46

Ala Gly Glu Gly Leu Ser Ser Pro Phe Trp Ser Leu Ala Ala Pro Gln

1 5 10 15

Arg Phe

<210> 47

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 47

tttgtcatta ttatgatcat ctgg

24

<210> 48

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 48

aataaaaagc agggccacaa tcag

24

<210> 49

<211> 23

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 49
tcattatttc ctactttctg atc 23

<210> 50
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 50
ctcatttcct ggtttggcca atcc 24

<210> 51
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 51
tcttcaagac ctcagcacac agc 23

<210> 52
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 52
gagctggaaa gcttcttgga aacc 24

<210> 53
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 53
 ctggtgtcgg gaggattggc caaaccagga aatgaggagg atctacacc 49

 <210> 54
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 54
 gcagtgtcaa ccccatcatt tatgg 25

 <210> 55
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 55
 caaagcaaac gacagtgttt cccacc 26

 <210> 56
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 56
 agtgaccgtg tgcattgtacc tattcc 26

 <210> 57
 <211> 60
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 57
 ggtgggaaac actgtcgttt gctttgttgt aataaggaat aggtacatgc acacggtcac 60

 <210> 58
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 58
 gtcacggatc cagcctctcc ttgataagg tccacc 36

 <210> 59
 <211> 45
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 59
 gtcagccatc gagttggctt cgtatgctat ataacattgg atagc 45

 <210> 60
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer/probe

 <400> 60
 ctggtcaccg tctacgcctt 20

 <210> 61
 <211> 16
 <212> DNA
 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 61
ccgcggcgga agttct 16

<210> 62
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 62
acagcagcgc caaccccatc at 22

<210> 63
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 63
cctgattgtg gccctgct 18

<210> 64
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 64
catttgaga aaggtcagcg tag 23

<210> 65
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 65
ctcatggctg cccctgtgga ctcaat

26

<210> 66
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 66
gctgtggaaa gggtccgct

19

<210> 67
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 67
cgccctccga agggcca

17

<210> 68
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer/probe

<400> 68
atcgtgcacc ctttccgca gaa

23

<210> 69
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 69

gaggatctac accaccgtgc tatt

24

<210> 70

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 70

gaagccccaa tccttgcata c

21

<210> 71

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer/probe

<400> 71

tctacctggc tccactctcc ctcattgtt

29